[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8RSPaPiQiN6Y4uO0i6Qn3aegcfPi5gfsGcf-rp3NekQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Jonsson Comprehensive Cancer Center",[4],394,false,115,19,436993,85,142,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Prostate Cancer",30,{"name":18,"count":19},"Lymphoma",24,{"name":21,"count":22},"Breast Cancer",22,{"name":24,"count":25},"Lung Cancer",21,{"name":27,"count":28},"Leukemia",17,{"name":30,"count":31},"Brain and Central Nervous System Tumors",16,{"name":33,"count":31},"Unspecified Adult Solid Tumor, Protocol Specific",{"name":35,"count":36},"Prostate Adenocarcinoma",12,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03732950","Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer","2023-12-05","Pembrolizumab",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02881242","Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer","2024-01-31","Trametinib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03825796","CPX-351 Plus Enasidenib for Relapsed AML","2024-09-01","Enasidenib Mesylate",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT01990196","Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With\u002FWithout SRC or MEK Inhibition in Prostate Cancer","2024-09-23","degarelix",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04395079","Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies","2024-10-11","Durvalumab",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04459273","Prospective Exploratory Study of FAPi PET\u002FCT With Histopathology Validation in Patients With Various Cancers","2025-06-24","Gallium Ga 68 FAPi-46",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT03582475","Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell\u002FNeuroendocrine Cancers of Urothelium or Prostate","2025-12-01","Carboplatin",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03546361","CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","2026-01-11","Autologous Dendritic Cell-Adenovirus CCL21 Vaccine",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT02296229","Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer","2026-01-27","androgen deprivation therapy",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04299113","Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and\u002For Recurrent Rhabdomyosarcoma","2026-05-22","Vinorelbine",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,250,275,421,506,694,772,852,882,912,961,1012,1141,1189,1215,1241,1283,1318,1353,1392,1414,1448,1524,1586,1652,1678,1742,1780,1821,1847,1877,1917,1948,1978,1996,2014,2032,2050,2068,2086,2104,2133,2159,2177,2203,2221,2239,2264,2290,2308,2326,2344,2362,2380,2398,2416,2439,2457,2483,2513,2539,2557,2575,2593,2611,2636,2674,2718,2867,2910,2932,2954,2981,3010,3033,3051,3069,3087,3110,3128,3146,3164,3182,3210,3232,3254,3297,3346,3368,3394,3412,3437,3455,3473,3491,3513,3531,3549,3576,3601,3628,3646,3684,3734,3777,3822,3860,3900,3930,3956,3992,4027,4069,4091,4116,4138,4166,4194,4216,4238,4269,4298,4326,4348,4375,4397,4421,4439,4460,4478,4496,4514,4532,4550,4568,4586,4609,4627,4645,4663,4691,4709,4727,4745,4767,4795,4813,4831,4853,4871,4894,4915,4936,4954,4972,4990,5008,5030,5048,5071,5089,5112,5130,5154,5172,5190,5208,5229,5251,5273,5296,5318,5340,5358,5376,5394,5412,5430,5448,5470,5488,5512,5536,5561,5588,5616,5637,5659,5677,5701,5725,5748,5802,5824,5846,5873,5901,5937,5955,5973,5991,6013,6034,6057,6078,6096,6114,6132,6150,6171,6192,6213,6237,6255,6276,6294,6315,6333,6351,6372,6390,6408,6426,6447,6465,6483,6504,6525,6543,6570,6597,6619,6637,6655,6677,6705,6727,6745,6763,6789,6814,6832,6857,6879,6901,6924,6946,6970,6994,7015,7036,7060,7083,7105,7123,7152,7174,7199,7217,7240,7264,7289,7313],{"intervention":97,"totalTrials":98,"cells":99},"temozolomide",10,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":129,"PHASE3":232,"PHASE4":246,"NA":248},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105,119],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":116},"NCT02049593","PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors","COMPLETED",[90],"2019-10-07","2014-06-12",44,[114,115],"Metastatic Cancer","Unspecified Adult Solid Tumor",[117,97,118],"PARP inhibitor BMN-673","irinotecan hydrochloride",{"nctId":120,"briefTitle":121,"status":108,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":31,"conditions":125,"interventions":127},"NCT01005472","Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma",[90],"2018-01-17","2008-12-01",[126],"Metastatic Melanoma",[128,97],"sunitinib malate",{"trials":130,"activeCount":231,"soonestReadout":203},[131,144,166,179,199,212,222],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"start":137,"enrollment":102,"conditions":138,"interventions":139},"NCT00601289","Temozolomide in Treating Patients With Invasive Pituitary Tumors","WITHDRAWN",[91],"2010-10","2009-12",[30],[97,140,141,142,143],"DNA methylation analysis","microarray analysis","protein expression analysis","proteomic profiling",{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":162},"NCT03830918","Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy","ACTIVE_NOT_RECRUITING",[90,91],"2027-01-03","2019-03-06",59,[153,154,155,156,157,158,159,160,161],"Advanced Malignant Solid Neoplasm","Extensive Stage Lung Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[163,164,165],"Atezolizumab","Niraparib","Temozolomide",{"nctId":167,"briefTitle":168,"status":108,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":177},"NCT01149850","Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma",[91],"2023-12-08","2010-04-28",50,[174,175,176],"Giant Cell Glioblastoma","Glioblastoma","Gliosarcoma",[178,97,141,140],"bevacizumab",{"nctId":180,"briefTitle":181,"status":134,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":102,"conditions":185,"interventions":197},"NCT04603365","Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer",[91],"2023-05-07","2021-10-18",[186,187,188,189,190,191,192,193,194,195,196],"Clear Cell Papillary Renal Neoplasm","Collecting Duct Carcinoma","Hereditary Leiomyomatosis and Renal Cell Carcinoma","Hereditary Papillary Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Unclassified Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8","Stage IV Renal Cell Cancer AJCC v8","Tubulocystic Renal Cell Carcinoma","Unresectable Renal Cell Carcinoma",[198,165],"Pamiparib",{"nctId":200,"briefTitle":201,"status":147,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":210},"NCT03672773","Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer",[91],"2026-10-01","2027-10-01","2018-10-31",35,[208,209],"Recurrent Extensive Stage Small Cell Lung Carcinoma","Refractory Extensive Stage Small Cell Lung Carcinoma",[211,165],"Talazoparib",{"nctId":213,"briefTitle":214,"status":108,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":221},"NCT01013285","Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",[91],"2013-10","2015-08","2006-06",70,[30],[178,97],{"nctId":223,"briefTitle":224,"status":108,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},"NCT00012116","Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain",[91],"2002-04","2000-10",4,[114],[97],2,{"trials":233,"activeCount":245,"soonestReadout":239},[234],{"nctId":235,"briefTitle":236,"status":237,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},"NCT06448286","PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma","NOT_YET_RECRUITING",[92],"2029-06-01","2030-06-01","2026-12-01",60,[175],[165],1,{"trials":247,"activeCount":102},[],{"trials":249,"activeCount":102},[],{"intervention":251,"totalTrials":245,"cells":252},"Ferumoxytol",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":271,"NA":273},{"trials":254,"activeCount":102},[],{"trials":256,"activeCount":102},[],{"trials":258,"activeCount":102},[],{"trials":260,"activeCount":245,"soonestReadout":266},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT07461948","Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients","RECRUITING",[92],"2028-10-27","2025-10-27",15,[175],[251],{"trials":272,"activeCount":102},[],{"trials":274,"activeCount":102},[],{"intervention":42,"totalTrials":98,"cells":276},{"EARLY_PHASE1":277,"PHASE1":293,"PHASE2":341,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":278,"activeCount":102},[279],{"nctId":280,"briefTitle":281,"status":282,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":245,"conditions":286,"interventions":291},"NCT04777708","BO-112 and Pembrolizumab for the Treatment of PD-1\u002FPD-L1 Refractory Liver Cancer","TERMINATED",[89],"2023-03-13","2021-10-13",[287,288,289,290],"Advanced Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Refractory Hepatocellular Carcinoma",[292,42],"Nanoplexed Poly I:C BO-112",{"trials":294,"activeCount":340,"soonestReadout":71},[295,320,333],{"nctId":69,"briefTitle":70,"status":147,"phases":296,"primaryCompletion":71,"completion":241,"start":297,"enrollment":268,"conditions":298,"interventions":316},[90],"2019-01-11",[299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315],"Bladder Small Cell Neuroendocrine Carcinoma","Castration-Resistant Prostate Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Prostate Carcinoma Metastatic in the Bone","Prostate Neuroendocrine Neoplasm","Prostate Small Cell Carcinoma","Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8","Stage III Prostate Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8","Stage IVA Bladder Cancer AJCC v8","Stage IVB Bladder Cancer AJCC v8","Ureter Small Cell Carcinoma","Urothelial Carcinoma",[72,317,318,319,42],"Cisplatin","Docetaxel","Etoposide",{"nctId":321,"briefTitle":322,"status":147,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT04201873","Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",[90],"2026-08-01","2027-08-01","2020-01-08",40,[329],"Recurrent Glioblastoma",[331,42,332],"Dendritic Cell Tumor Cell Lysate Vaccine","Poly ICLC",{"nctId":74,"briefTitle":75,"status":147,"phases":334,"primaryCompletion":76,"completion":335,"start":336,"enrollment":19,"conditions":337,"interventions":339},[90],"2027-01-11","2019-07-08",[338,159,160,161],"Lung Non-Small Cell Carcinoma",[77,42],3,{"trials":342,"activeCount":359,"soonestReadout":41},[343,356,365,376,389,400],{"nctId":344,"briefTitle":345,"status":108,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":355},"NCT02879994","Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",[91],"2017-11-30","2019-01-03","2016-09-15",11,[352,353,354],"Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[42],{"nctId":39,"briefTitle":40,"status":147,"phases":357,"primaryCompletion":41,"completion":358,"start":150,"enrollment":359,"conditions":360,"interventions":364},[91],"2025-03-06",5,[361,362,363],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[42],{"nctId":366,"briefTitle":367,"status":264,"phases":368,"primaryCompletion":324,"completion":325,"start":369,"enrollment":370,"conditions":371,"interventions":375},"NCT03603223","Pembrolizumab in Treating Participants With Leukoplakia",[91],"2019-05-03",26,[372,373,374],"Erythroleukoplakia","Leukoplakia","Verrucous Oral Leukoplakia",[42],{"nctId":377,"briefTitle":378,"status":264,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":388},"NCT04712851","Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia",[91],"2027-01-31","2028-01-31","2021-06-30",25,[385,386,387],"Cervical Intraepithelial Neoplasia","Cervical Squamous Cell Carcinoma In Situ","Cervical Squamous Intraepithelial Neoplasia 2",[42],{"nctId":390,"briefTitle":391,"status":264,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":25,"conditions":396,"interventions":398},"NCT05775471","Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer",[91],"2027-12-01","2028-12-01","2024-06-26",[397],"Renal Pelvis and Ureter Urothelial Carcinoma",[399,42],"Enfortumab Vedotin",{"nctId":401,"briefTitle":402,"status":264,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":206,"conditions":407,"interventions":412},"NCT06543576","External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer",[90,91],"2031-01-31","2032-01-31","2025-07-29",[408,409,410,411],"Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma","Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8",[413,317,414,42],"Bevacizumab","Paclitaxel",{"trials":416,"activeCount":102},[],{"trials":418,"activeCount":102},[],{"trials":420,"activeCount":102},[],{"intervention":62,"totalTrials":359,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":452,"PHASE3":500,"PHASE4":502,"NA":504},{"trials":424,"activeCount":102},[],{"trials":426,"activeCount":245,"soonestReadout":431},[427],{"nctId":428,"briefTitle":429,"status":237,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":444},"NCT07619313","AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer",[90],"2027-06-01","2028-06-01","2026-06-01",46,[436,437,438,439,440,441,442,443],"Borderline Resectable Pancreatic Ductal Adenocarcinoma","Locally Advanced Cholangiocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","Metastatic Cholangiocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8",[317,62,445,446,447,448,449,450,451],"Fluorouracil","Gemcitabine","Irinotecan","Leucovorin","Ligritinib","Oxaliplatin","Zimberelimab",{"trials":453,"activeCount":340,"soonestReadout":61},[454,472,481,491],{"nctId":455,"briefTitle":456,"status":282,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":9,"conditions":460,"interventions":470},"NCT03618134","Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner",[90,91],"2023-06-30","2018-10-04",[461,462,463,464,465,466,467,468,469],"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Human Papillomavirus Positive","Oropharyngeal Squamous Cell Carcinoma","p16 Positive Neoplastic Cells Present","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",[62,471],"Tremelimumab",{"nctId":473,"briefTitle":474,"status":147,"phases":475,"primaryCompletion":433,"completion":431,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT03148327","Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I\u002FII Study of Stereotactic Body Radiotherapy",[90,91],"2017-10-11",18,[479],"Carcinoma, Non-Small-Cell Lung",[62],{"nctId":59,"briefTitle":60,"status":147,"phases":482,"primaryCompletion":61,"completion":241,"start":483,"enrollment":484,"conditions":485,"interventions":490},[91],"2020-08-07",9,[486,487,488,489],"Metastatic Malignant Female Reproductive System Neoplasm","Platinum-Resistant Malignant Female Reproductive System Neoplasm","Recurrent Malignant Female Reproductive System Neoplasm","Refractory Malignant Female Reproductive System Neoplasm",[62,471],{"nctId":492,"briefTitle":493,"status":147,"phases":494,"primaryCompletion":380,"completion":381,"start":495,"enrollment":496,"conditions":497,"interventions":499},"NCT03601455","Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer",[91],"2018-10-26",13,[498,309,312,313],"Bladder Urothelial Carcinoma",[62,471],{"trials":501,"activeCount":102},[],{"trials":503,"activeCount":102},[],{"trials":505,"activeCount":102},[],{"intervention":507,"totalTrials":496,"cells":508},"carboplatin",{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":528,"PHASE3":651,"PHASE4":673,"NA":675},{"trials":510,"activeCount":102},[],{"trials":512,"activeCount":245,"soonestReadout":71},[513,517],{"nctId":69,"briefTitle":70,"status":147,"phases":514,"primaryCompletion":71,"completion":241,"start":297,"enrollment":268,"conditions":515,"interventions":516},[90],[299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315],[72,317,318,319,42],{"nctId":518,"briefTitle":519,"status":108,"phases":520,"primaryCompletion":297,"completion":297,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT01664754","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",[90],"2012-09-07",8,[524],"Stage IV Non-small Cell Lung Cancer",[526,527,507],"exemestane","pemetrexed disodium",{"trials":529,"activeCount":231,"soonestReadout":592},[530,541,566,575,588,622,632,642],{"nctId":531,"briefTitle":532,"status":108,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":538},"NCT00068341","Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer",[91],"2013-11","2003-07",74,[21],[539,507,540,539],"trastuzumab","docetaxel",{"nctId":542,"briefTitle":543,"status":108,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":370,"conditions":547,"interventions":564},"NCT02048020","Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer",[91],"2017-01-09","2013-12-26",[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563],"Human Papilloma Virus Infection","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Verrucous Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Verrucous Carcinoma of the Larynx",[565,507],"paclitaxel",{"nctId":567,"briefTitle":568,"status":237,"phases":569,"primaryCompletion":239,"completion":240,"start":431,"enrollment":31,"conditions":570,"interventions":572},"NCT07229339","Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer",[91],[571],"Lung Non-Squamous Non-Small Cell Carcinoma",[72,573,574],"Pemetrexed","Zipalertinib",{"nctId":576,"briefTitle":577,"status":134,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":102,"conditions":582,"interventions":586},"NCT02756130","Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)",[90,91],"2020-02-01","2021-02-01","2018-08-01",[583,584,585,361,362,363],"High Grade Fallopian Tube Serous Adenocarcinoma","High Grade Ovarian Serous Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma",[587,72],"Birinapant",{"nctId":589,"briefTitle":590,"status":147,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":595,"interventions":616},"NCT05319873","Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",[90,91],"2027-04-01","2028-04-01","2022-04-07",[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],"Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Locally Advanced HER2-Positive Breast Carcinoma","Metastatic HER2-Positive Breast Carcinoma","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8",[72,318,617,618,619,620,621],"Fulvestrant","Pertuzumab","Ribociclib","Trastuzumab","Tucatinib",{"nctId":623,"briefTitle":624,"status":625,"phases":626,"start":627,"conditions":628,"interventions":630},"NCT00021385","Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer","UNKNOWN",[91],"2001-05",[629],"Ovarian Cancer",[507,631],"squalamine lactate",{"nctId":633,"briefTitle":634,"status":108,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":640},"NCT00062179","Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer",[91],"2006-11","2003-03",7,[24],[507,641,565],"celecoxib",{"nctId":643,"briefTitle":644,"status":108,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":650},"NCT00049257","Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[91],"2009-03","2002-10",58,[15],[507,565],{"trials":652,"activeCount":102},[653,662],{"nctId":654,"briefTitle":655,"status":625,"phases":656,"conditions":657,"interventions":658},"NCT00005024","Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease",[92],[33],[507,659,660,661],"cyclophosphamide","doxorubicin hydrochloride","granisetron hydrochloride",{"nctId":663,"briefTitle":664,"status":108,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":671},"NCT00047255","Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer",[92],"2006-01","2010-04","2002-05",263,[21],[539,507,540,672,318],"trastuxumab",{"trials":674,"activeCount":102},[],{"trials":676,"activeCount":245,"soonestReadout":380},[677],{"nctId":678,"briefTitle":679,"status":147,"phases":680,"primaryCompletion":380,"completion":381,"start":681,"enrollment":682,"conditions":683,"interventions":693},"NCT01345851","Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery",[94],"2011-03-23",29,[684,685,686,687,688,689,690,691,692],"Adenocarcinoma of the Lung","Adenosquamous Cell Lung Cancer","Large Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer","Squamous Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[507,565],{"intervention":695,"totalTrials":522,"cells":696},"cisplatin",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":717,"PHASE3":755,"PHASE4":768,"NA":770},{"trials":698,"activeCount":102},[],{"trials":700,"activeCount":231,"soonestReadout":71},[701,709,713],{"nctId":702,"briefTitle":703,"status":625,"phases":704,"conditions":705,"interventions":706},"NCT00005996","SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors",[90],[33],[695,707,708],"gemcitabine hydrochloride","semaxanib",{"nctId":69,"briefTitle":70,"status":147,"phases":710,"primaryCompletion":71,"completion":241,"start":297,"enrollment":268,"conditions":711,"interventions":712},[90],[299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315],[72,317,318,319,42],{"nctId":428,"briefTitle":429,"status":237,"phases":714,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":715,"interventions":716},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":718,"activeCount":245,"soonestReadout":404},[719,731,740,751],{"nctId":720,"briefTitle":721,"status":282,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":245,"conditions":725,"interventions":729},"NCT04106362","Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma",[91],"2023-05-23","2020-01-14",[463,726,727,469,728],"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","KRAS Protein Variant","Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",[730,317],"Cetuximab",{"nctId":732,"briefTitle":733,"status":108,"phases":734,"primaryCompletion":735,"start":736,"enrollment":245,"conditions":737,"interventions":738},"NCT00090909","Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",[91],"2005-03","2003-06",[18],[695,739,707],"dexamethasone",{"nctId":741,"briefTitle":742,"status":108,"phases":743,"primaryCompletion":744,"start":745,"conditions":746,"interventions":748},"NCT00004865","Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy",[91],"2002-01","1999-11",[747],"Head and Neck Cancer",[749,695,750,565],"cetuximab","fluorouracil",{"nctId":401,"briefTitle":402,"status":264,"phases":752,"primaryCompletion":404,"completion":405,"start":406,"enrollment":206,"conditions":753,"interventions":754},[90,91],[408,409,410,411],[413,317,414,42],{"trials":756,"activeCount":102},[757],{"nctId":758,"briefTitle":759,"status":108,"phases":760,"primaryCompletion":744,"completion":761,"start":762,"enrollment":522,"conditions":763,"interventions":766},"NCT00020787","Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer",[92],"2002-12","2001-07",[764,765],"Esophageal Cancer","Gastric Cancer",[767,695,750],"G17DT Immunogen",{"trials":769,"activeCount":102},[],{"trials":771,"activeCount":102},[],{"intervention":445,"totalTrials":638,"cells":773},{"EARLY_PHASE1":774,"PHASE1":790,"PHASE2":815,"PHASE3":832,"PHASE4":848,"NA":850},{"trials":775,"activeCount":102},[776],{"nctId":777,"briefTitle":778,"status":108,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":786},"NCT03970252","Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer",[89],"2024-05-25","2019-07-24",28,[784,785],"Borderline Resectable Pancreatic Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma",[445,447,787,448,788,789,450],"Irinotecan Hydrochloride","Leucovorin Calcium","Nivolumab",{"trials":791,"activeCount":231,"soonestReadout":203},[792,811],{"nctId":793,"briefTitle":794,"status":264,"phases":795,"primaryCompletion":203,"completion":796,"start":797,"enrollment":383,"conditions":798,"interventions":809},"NCT04703101","Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer",[90],"2027-10-15","2021-02-11",[799,800,801,802,803,804,805,806,807,808],"Locally Advanced Rectal Carcinoma","Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8","Stage IIA Rectal Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8",[810,445,448,450],"Capecitabine",{"nctId":428,"briefTitle":429,"status":237,"phases":812,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":813,"interventions":814},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":816,"activeCount":245,"soonestReadout":241},[817,828],{"nctId":818,"briefTitle":819,"status":264,"phases":820,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":826},"NCT05688215","Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma",[90,91],"2027-03-02","2023-03-07",56,[784,825],"Locally Advanced Pancreatic Ductal Adenocarcinoma",[445,447,448,788,450,827,451],"Quemliclustat",{"nctId":741,"briefTitle":742,"status":108,"phases":829,"primaryCompletion":744,"start":745,"conditions":830,"interventions":831},[91],[747],[749,695,750,565],{"trials":833,"activeCount":102},[834,844],{"nctId":835,"briefTitle":836,"status":625,"phases":837,"start":838,"conditions":839,"interventions":841},"NCT00021281","Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer",[92],"2000-12",[840],"Colorectal Cancer",[842,750,118,843,708],"FOLFIRI regimen","leucovorin calcium",{"nctId":758,"briefTitle":759,"status":108,"phases":845,"primaryCompletion":744,"completion":761,"start":762,"enrollment":522,"conditions":846,"interventions":847},[92],[764,765],[767,695,750],{"trials":849,"activeCount":102},[],{"trials":851,"activeCount":102},[],{"intervention":448,"totalTrials":228,"cells":853},{"EARLY_PHASE1":854,"PHASE1":860,"PHASE2":870,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":855,"activeCount":102},[856],{"nctId":777,"briefTitle":778,"status":108,"phases":857,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":858,"interventions":859},[89],[784,785],[445,447,787,448,788,789,450],{"trials":861,"activeCount":231,"soonestReadout":203},[862,866],{"nctId":793,"briefTitle":794,"status":264,"phases":863,"primaryCompletion":203,"completion":796,"start":797,"enrollment":383,"conditions":864,"interventions":865},[90],[799,800,801,802,803,804,805,806,807,808],[810,445,448,450],{"nctId":428,"briefTitle":429,"status":237,"phases":867,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":868,"interventions":869},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":871,"activeCount":245,"soonestReadout":241},[872],{"nctId":818,"briefTitle":819,"status":264,"phases":873,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":874,"interventions":875},[90,91],[784,825],[445,447,448,788,450,827,451],{"trials":877,"activeCount":102},[],{"trials":879,"activeCount":102},[],{"trials":881,"activeCount":102},[],{"intervention":450,"totalTrials":228,"cells":883},{"EARLY_PHASE1":884,"PHASE1":890,"PHASE2":900,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":885,"activeCount":102},[886],{"nctId":777,"briefTitle":778,"status":108,"phases":887,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":888,"interventions":889},[89],[784,785],[445,447,787,448,788,789,450],{"trials":891,"activeCount":231,"soonestReadout":203},[892,896],{"nctId":793,"briefTitle":794,"status":264,"phases":893,"primaryCompletion":203,"completion":796,"start":797,"enrollment":383,"conditions":894,"interventions":895},[90],[799,800,801,802,803,804,805,806,807,808],[810,445,448,450],{"nctId":428,"briefTitle":429,"status":237,"phases":897,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":898,"interventions":899},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":901,"activeCount":245,"soonestReadout":241},[902],{"nctId":818,"briefTitle":819,"status":264,"phases":903,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":904,"interventions":905},[90,91],[784,825],[445,447,448,788,450,827,451],{"trials":907,"activeCount":102},[],{"trials":909,"activeCount":102},[],{"trials":911,"activeCount":102},[],{"intervention":913,"totalTrials":340,"cells":914},"Lutetium Lu 177 Vipivotide Tetraxetan",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":916,"activeCount":102},[],{"trials":918,"activeCount":102},[],{"trials":920,"activeCount":340,"soonestReadout":950},[921,934,946],{"nctId":922,"briefTitle":923,"status":264,"phases":924,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":932},"NCT07150715","Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma",[91],"2030-10-31","2031-10-31","2025-12-12",107,[930,931],"Oligometastatic Prostate Adenocarcinoma","Recurrent Prostate Adenocarcinoma",[933,913],"Actinium Ac 225 Vipivotide Tetraxetan",{"nctId":935,"briefTitle":936,"status":264,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":945},"NCT06216249","Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)",[91],"2027-12-31","2028-12-31","2024-08-01",90,[943,944],"Prostate Carcinoma","Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8",[913],{"nctId":947,"briefTitle":948,"status":264,"phases":949,"primaryCompletion":950,"completion":951,"start":940,"enrollment":327,"conditions":952,"interventions":954},"NCT06288113","Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial",[91],"2027-01-27","2028-01-27",[300,953],"Stage IVB Prostate Cancer AJCC v8",[913],{"trials":956,"activeCount":102},[],{"trials":958,"activeCount":102},[],{"trials":960,"activeCount":102},[],{"intervention":540,"totalTrials":962,"cells":963},6,{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":983,"PHASE3":1002,"PHASE4":1008,"NA":1010},{"trials":965,"activeCount":102},[],{"trials":967,"activeCount":245,"soonestReadout":71},[968,972],{"nctId":69,"briefTitle":70,"status":147,"phases":969,"primaryCompletion":71,"completion":241,"start":297,"enrollment":268,"conditions":970,"interventions":971},[90],[299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315],[72,317,318,319,42],{"nctId":973,"briefTitle":974,"status":134,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":102,"conditions":979,"interventions":981},"NCT02451865","Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",[90],"2018-06","2019-06","2016-06",[980,354],"Recurrent Non-Small Cell Lung Carcinoma",[982,318],"Binimetinib",{"trials":984,"activeCount":245,"soonestReadout":592},[985,989,993],{"nctId":531,"briefTitle":532,"status":108,"phases":986,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":987,"interventions":988},[91],[21],[539,507,540,539],{"nctId":589,"briefTitle":590,"status":147,"phases":990,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":991,"interventions":992},[90,91],[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],[72,318,617,618,619,620,621],{"nctId":994,"briefTitle":995,"status":108,"phases":996,"primaryCompletion":218,"completion":997,"start":998,"enrollment":245,"conditions":999,"interventions":1000},"NCT00087035","Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer",[91],"2008-03","2004-05",[15],[540,1001],"erlotinib hydrochloride",{"trials":1003,"activeCount":102},[1004],{"nctId":663,"briefTitle":664,"status":108,"phases":1005,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":1006,"interventions":1007},[92],[21],[539,507,540,672,318],{"trials":1009,"activeCount":102},[],{"trials":1011,"activeCount":102},[],{"intervention":1013,"totalTrials":484,"cells":1014},"fludarabine phosphate",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1078,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1016,"activeCount":102},[],{"trials":1018,"activeCount":245,"soonestReadout":324},[1019,1030,1046,1055],{"nctId":1020,"briefTitle":1021,"status":282,"phases":1022,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":228,"conditions":1025,"interventions":1026},"NCT02070406","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",[90],"2018-12-18","2014-07-17",[33],[659,1013,1027,1028,1029],"NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL","dendritic cell vaccine therapy","aldesleukin",{"nctId":1031,"briefTitle":1032,"status":108,"phases":1033,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":245,"conditions":1036,"interventions":1040},"NCT02775292","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",[90],"2019-04-08","2017-01-03",[1037,1038,1039],"Adult Solid Neoplasm","Childhood Solid Neoplasm","Metastatic Neoplasm",[1041,1042,1043,789,1044,1045],"Aldesleukin","Cyclophosphamide","Fludarabine Phosphate","NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL","NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine",{"nctId":1047,"briefTitle":1048,"status":134,"phases":1049,"enrollment":102,"conditions":1050,"interventions":1052},"NCT00004114","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer",[90],[27,18,1051],"Myelodysplastic Syndromes",[1053,659,1054,1013],"filgrastim","cytarabine",{"nctId":1056,"briefTitle":1057,"status":147,"phases":1058,"primaryCompletion":324,"completion":325,"start":1059,"enrollment":19,"conditions":1060,"interventions":1075},"NCT04007029","Modified Immune Cells (CD19\u002FCD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",[90],"2019-10-04",[1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],"CD19 Positive","CD20 Positive","Recurrent Chronic Lymphocytic Leukemia","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Refractory Small Lymphocytic Lymphoma",[1076,1042,1043,1077],"Chimeric Antigen Receptor T-Cell Therapy","Tocilizumab",{"trials":1079,"activeCount":245,"soonestReadout":1084},[1080,1090,1109,1116,1126],{"nctId":1081,"briefTitle":1082,"status":147,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":962,"conditions":1087,"interventions":1089},"NCT01697527","Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies",[91],"2026-11-02","2027-11-02","2012-11-02",[1088],"Malignant Neoplasm",[1029,1013,659,1027,1028],{"nctId":1091,"briefTitle":1092,"status":282,"phases":1093,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1105},"NCT04205838","Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma",[91],"2026-02-19","2020-03-04",23,[1098,1099,1100,1064,1101,1067,1102,1070,1103,1073,1104],"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma","Progressive Disease","Recurrent High Grade B-Cell Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[1106,1107,1042,1108,1043],"Anakinra","Axicabtagene Ciloleucel","Fludarabine",{"nctId":1110,"briefTitle":1111,"status":625,"phases":1112,"conditions":1113,"interventions":1115},"NCT00004194","Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease",[90,91],[1114],"Graft Versus Host Disease",[1013],{"nctId":1117,"briefTitle":1118,"status":134,"phases":1119,"enrollment":102,"conditions":1120,"interventions":1121},"NCT00004878","Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia",[91],[1114,27],[1122,1054,1013,1123,1124,1125],"therapeutic allogeneic lymphocytes","idarubicin","methotrexate","tacrolimus",{"nctId":1127,"briefTitle":1128,"status":108,"phases":1129,"primaryCompletion":1130,"start":1131,"enrollment":638,"conditions":1132,"interventions":1133},"NCT00020800","Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia",[91],"2003-04","2001-09",[18],[1134,1013],"rituximab",{"trials":1136,"activeCount":102},[],{"trials":1138,"activeCount":102},[],{"trials":1140,"activeCount":102},[],{"intervention":1142,"totalTrials":340,"cells":1143},"Osimertinib",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":102},[],{"trials":1149,"activeCount":231,"soonestReadout":1165},[1150,1161,1174],{"nctId":1151,"briefTitle":1152,"status":108,"phases":1153,"primaryCompletion":46,"completion":46,"start":1154,"enrollment":36,"conditions":1155,"interventions":1160},"NCT03732352","18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma",[91],"2018-11-28",[1156,1157,175,329,1158,1159],"EGFR Gene Amplification","EGFR Gene Mutation","Supratentorial Glioblastoma","TP53 Wt Allele",[1142],{"nctId":1162,"briefTitle":1163,"status":147,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":16,"conditions":1168,"interventions":1172},"NCT04285671","Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer",[90,91],"2026-12-02","2027-12-02","2021-01-29",[1169,1170,1171,160,161],"Metastatic Lung Non-Small Cell Carcinoma","Refractory Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8",[1173,1142,620],"Necitumumab",{"nctId":1175,"briefTitle":1176,"status":264,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1094,"enrollment":242,"conditions":1180,"interventions":1181},"NCT07323641","Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer",[91],"2027-02-01","2028-02-01",[338],[1142,1182],"Telisotuzumab Vedotin",{"trials":1184,"activeCount":102},[],{"trials":1186,"activeCount":102},[],{"trials":1188,"activeCount":102},[],{"intervention":471,"totalTrials":340,"cells":1190},{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1192,"activeCount":102},[],{"trials":1194,"activeCount":102},[],{"trials":1196,"activeCount":231,"soonestReadout":61},[1197,1201,1205],{"nctId":455,"briefTitle":456,"status":282,"phases":1198,"primaryCompletion":458,"completion":458,"start":459,"enrollment":9,"conditions":1199,"interventions":1200},[90,91],[461,462,463,464,465,466,467,468,469],[62,471],{"nctId":59,"briefTitle":60,"status":147,"phases":1202,"primaryCompletion":61,"completion":241,"start":483,"enrollment":484,"conditions":1203,"interventions":1204},[91],[486,487,488,489],[62,471],{"nctId":492,"briefTitle":493,"status":147,"phases":1206,"primaryCompletion":380,"completion":381,"start":495,"enrollment":496,"conditions":1207,"interventions":1208},[91],[498,309,312,313],[62,471],{"trials":1210,"activeCount":102},[],{"trials":1212,"activeCount":102},[],{"trials":1214,"activeCount":102},[],{"intervention":447,"totalTrials":340,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1223,"PHASE2":1229,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1218,"activeCount":102},[1219],{"nctId":777,"briefTitle":778,"status":108,"phases":1220,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1221,"interventions":1222},[89],[784,785],[445,447,787,448,788,789,450],{"trials":1224,"activeCount":245,"soonestReadout":431},[1225],{"nctId":428,"briefTitle":429,"status":237,"phases":1226,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":1227,"interventions":1228},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":1230,"activeCount":245,"soonestReadout":241},[1231],{"nctId":818,"briefTitle":819,"status":264,"phases":1232,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":1233,"interventions":1234},[90,91],[784,825],[445,447,448,788,450,827,451],{"trials":1236,"activeCount":102},[],{"trials":1238,"activeCount":102},[],{"trials":1240,"activeCount":102},[],{"intervention":1242,"totalTrials":231,"cells":1243},"Abemaciclib",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1245,"activeCount":102},[],{"trials":1247,"activeCount":102},[],{"trials":1249,"activeCount":231,"soonestReadout":1254},[1250,1263],{"nctId":1251,"briefTitle":1252,"status":264,"phases":1253,"primaryCompletion":1254,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1260},"NCT04469764","Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer",[91],"2026-07-01","2027-07-01","2020-10-16",32,[1259,361,362,363],"Recurrent Endometrial Carcinoma",[1242,1261,1262],"Anastrozole","Letrozole",{"nctId":1264,"briefTitle":1265,"status":237,"phases":1266,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1275},"NCT07191717","Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial",[91],"2030-04-30","2031-04-30","2026-04-30",42,[1272,596,599,604,1273,1274],"Anatomic Stage I Breast Cancer AJCC v8","Localized Estrogen Receptor-Positive Breast Carcinoma","Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma",[1242,1276],"Imlunestrant",{"trials":1278,"activeCount":102},[],{"trials":1280,"activeCount":102},[],{"trials":1282,"activeCount":102},[],{"intervention":1261,"totalTrials":231,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1286,"activeCount":102},[],{"trials":1288,"activeCount":102},[],{"trials":1290,"activeCount":231,"soonestReadout":1254},[1291,1295],{"nctId":1251,"briefTitle":1252,"status":264,"phases":1292,"primaryCompletion":1254,"completion":1255,"start":1256,"enrollment":1257,"conditions":1293,"interventions":1294},[91],[1259,361,362,363],[1242,1261,1262],{"nctId":1296,"briefTitle":1297,"status":264,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":1301,"conditions":1302,"interventions":1310},"NCT04553770","Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",[91],"2026-12-31","2020-10-09",88,[1303,1304,1305,1306,1307,1308,1309],"Early-stage Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Invasive Breast Cancer","Stage II Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer",[1261,1311],"Trastuzumab Deruxtecan",{"trials":1313,"activeCount":102},[],{"trials":1315,"activeCount":102},[],{"trials":1317,"activeCount":102},[],{"intervention":47,"totalTrials":231,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1321,"activeCount":102},[],{"trials":1323,"activeCount":102},[],{"trials":1325,"activeCount":231,"soonestReadout":46},[1326,1337],{"nctId":44,"briefTitle":45,"status":147,"phases":1327,"primaryCompletion":46,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1336},[91],"2025-01-31","2018-01-30",14,[1332,1333,1334,1335],"Hormone-Resistant Prostate Cancer","Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer",[47],{"nctId":54,"briefTitle":55,"status":147,"phases":1338,"primaryCompletion":56,"completion":1339,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1343},[91],"2026-09-30","2014-09-23",45,[15],[57,1344,1345,1346],"enzalutamide","trametinib","dasatinib",{"trials":1348,"activeCount":102},[],{"trials":1350,"activeCount":102},[],{"trials":1352,"activeCount":102},[],{"intervention":1354,"totalTrials":231,"cells":1355},"Apalutamide",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1357,"activeCount":102},[],{"trials":1359,"activeCount":102},[],{"trials":1361,"activeCount":231,"soonestReadout":241},[1362,1375],{"nctId":1363,"briefTitle":1364,"status":147,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":782,"conditions":1369,"interventions":1372},"NCT03902951","Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer",[91],"2027-01-01","2028-01-01","2021-03-17",[1370,1371,1334,953],"Metastatic Prostate Adenocarcinoma","Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation",[1373,1354,1374],"Abiraterone Acetate","Leuprolide Acetate",{"nctId":1376,"briefTitle":1377,"status":264,"phases":1378,"primaryCompletion":241,"completion":393,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1385},"NCT06067269","Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial",[91],"2024-03-28",95,[35,1382,1383,1384],"Stage II Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8",[1354],{"trials":1387,"activeCount":102},[],{"trials":1389,"activeCount":102},[],{"trials":1391,"activeCount":102},[],{"intervention":451,"totalTrials":231,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1402,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1395,"activeCount":102},[],{"trials":1397,"activeCount":245,"soonestReadout":431},[1398],{"nctId":428,"briefTitle":429,"status":237,"phases":1399,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":1400,"interventions":1401},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":1403,"activeCount":245,"soonestReadout":241},[1404],{"nctId":818,"briefTitle":819,"status":264,"phases":1405,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":1406,"interventions":1407},[90,91],[784,825],[445,447,448,788,450,827,451],{"trials":1409,"activeCount":102},[],{"trials":1411,"activeCount":102},[],{"trials":1413,"activeCount":102},[],{"intervention":1415,"totalTrials":231,"cells":1416},"Fisetin",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1418,"activeCount":102},[],{"trials":1420,"activeCount":102},[],{"trials":1422,"activeCount":231,"soonestReadout":433},[1423,1430],{"nctId":1424,"briefTitle":1425,"status":264,"phases":1426,"primaryCompletion":433,"completion":433,"start":1427,"enrollment":1301,"conditions":1428,"interventions":1429},"NCT05595499","Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors",[91],"2023-03-27",[1272,596,599],[1415],{"nctId":1431,"briefTitle":1432,"status":264,"phases":1433,"primaryCompletion":1434,"completion":1435,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1441},"NCT06113016","Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors",[91],"2028-06-30","2028-12-30","2024-07-23",164,[1439,596,599,1440],"Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8","Early Stage Breast Carcinoma",[1415],{"trials":1443,"activeCount":102},[],{"trials":1445,"activeCount":102},[],{"trials":1447,"activeCount":102},[],{"intervention":659,"totalTrials":98,"cells":1449},{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1480,"PHASE3":1504,"PHASE4":1510,"NA":1512},{"trials":1451,"activeCount":102},[],{"trials":1453,"activeCount":245,"soonestReadout":324},[1454,1458,1468,1472,1476],{"nctId":1020,"briefTitle":1021,"status":282,"phases":1455,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":228,"conditions":1456,"interventions":1457},[90],[33],[659,1013,1027,1028,1029],{"nctId":1459,"briefTitle":1460,"status":134,"phases":1461,"primaryCompletion":1462,"completion":1463,"start":1379,"enrollment":102,"conditions":1464,"interventions":1467},"NCT05950113","CART-BCMA\u002FCS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90],"2027-03-28","2028-03-28",[1465,1466],"Recurrent Multiple Myeloma","Refractory Multiple Myeloma",[1042,1108],{"nctId":1031,"briefTitle":1032,"status":108,"phases":1469,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":245,"conditions":1470,"interventions":1471},[90],[1037,1038,1039],[1041,1042,1043,789,1044,1045],{"nctId":1047,"briefTitle":1048,"status":134,"phases":1473,"enrollment":102,"conditions":1474,"interventions":1475},[90],[27,18,1051],[1053,659,1054,1013],{"nctId":1056,"briefTitle":1057,"status":147,"phases":1477,"primaryCompletion":324,"completion":325,"start":1059,"enrollment":19,"conditions":1478,"interventions":1479},[90],[1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],[1076,1042,1043,1077],{"trials":1481,"activeCount":245,"soonestReadout":1084},[1482,1486,1490],{"nctId":1081,"briefTitle":1082,"status":147,"phases":1483,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":962,"conditions":1484,"interventions":1485},[91],[1088],[1029,1013,659,1027,1028],{"nctId":1091,"briefTitle":1092,"status":282,"phases":1487,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":1488,"interventions":1489},[91],[1098,1099,1100,1064,1101,1067,1102,1070,1103,1073,1104],[1106,1107,1042,1108,1043],{"nctId":1491,"briefTitle":1492,"status":108,"phases":1493,"completion":998,"start":1494,"conditions":1495,"interventions":1500},"NCT00004132","Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer",[91],"2000-01",[1496,27,18,1497,1498,1499],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Multiple Myeloma and Plasma Cell Neoplasm","Oral Complications","Radiation Toxicity",[1053,1501,659,1502,1503],"palifermin","etoposide","ifosfamide",{"trials":1505,"activeCount":102},[1506],{"nctId":654,"briefTitle":655,"status":625,"phases":1507,"conditions":1508,"interventions":1509},[92],[33],[507,659,660,661],{"trials":1511,"activeCount":102},[],{"trials":1513,"activeCount":102},[1514],{"nctId":1515,"briefTitle":1516,"status":625,"phases":1517,"start":1518,"conditions":1519,"interventions":1520},"NCT00093587","Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia",[94],"2004-08",[1114,27],[1521,1522,659,1523],"anti-thymocyte globulin","busulfan","cyclosporine",{"intervention":565,"totalTrials":484,"cells":1525},{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1537,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1527,"activeCount":102},[],{"trials":1529,"activeCount":102},[1530],{"nctId":1531,"briefTitle":1532,"status":625,"phases":1533,"start":1131,"conditions":1534,"interventions":1535},"NCT00024310","Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[90],[1496,33],[1536,565],"lometrexol",{"trials":1538,"activeCount":245,"soonestReadout":404},[1539,1543,1551,1555,1559,1568,1572],{"nctId":542,"briefTitle":543,"status":108,"phases":1540,"primaryCompletion":545,"completion":545,"start":546,"enrollment":370,"conditions":1541,"interventions":1542},[91],[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563],[565,507],{"nctId":1544,"briefTitle":1545,"status":108,"phases":1546,"completion":1547,"conditions":1548,"interventions":1549},"NCT00004979","Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors",[90,91],"2000-09",[33],[565,1550],"topotecan hydrochloride",{"nctId":633,"briefTitle":634,"status":108,"phases":1552,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":1553,"interventions":1554},[91],[24],[507,641,565],{"nctId":643,"briefTitle":644,"status":108,"phases":1556,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":1557,"interventions":1558},[91],[15],[507,565],{"nctId":1560,"briefTitle":1561,"status":108,"phases":1562,"primaryCompletion":761,"completion":1563,"start":1564,"enrollment":1565,"conditions":1566,"interventions":1567},"NCT00020761","Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach",[91],"2005-08","2000-04",51,[764,765],[118,565],{"nctId":741,"briefTitle":742,"status":108,"phases":1569,"primaryCompletion":744,"start":745,"conditions":1570,"interventions":1571},[91],[747],[749,695,750,565],{"nctId":401,"briefTitle":402,"status":264,"phases":1573,"primaryCompletion":404,"completion":405,"start":406,"enrollment":206,"conditions":1574,"interventions":1575},[90,91],[408,409,410,411],[413,317,414,42],{"trials":1577,"activeCount":102},[],{"trials":1579,"activeCount":102},[],{"trials":1581,"activeCount":245,"soonestReadout":380},[1582],{"nctId":678,"briefTitle":679,"status":147,"phases":1583,"primaryCompletion":380,"completion":381,"start":681,"enrollment":682,"conditions":1584,"interventions":1585},[94],[684,685,686,687,688,689,690,691,692],[507,565],{"intervention":539,"totalTrials":522,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1602,"PHASE3":1634,"PHASE4":1640,"NA":1642},{"trials":1589,"activeCount":102},[],{"trials":1591,"activeCount":102},[1592],{"nctId":1593,"briefTitle":1594,"status":108,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":496,"conditions":1599,"interventions":1600},"NCT00085020","GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2\u002FNeu",[90],"2004-12","2005-02","2004-03",[21],[539,1601],"lapatinib ditosylate",{"trials":1603,"activeCount":231,"soonestReadout":1165},[1604,1608,1617,1621,1630],{"nctId":531,"briefTitle":532,"status":108,"phases":1605,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":1606,"interventions":1607},[91],[21],[539,507,540,539],{"nctId":1609,"briefTitle":1610,"status":282,"phases":1611,"completion":1612,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1616},"NCT00427427","Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer",[91],"2007-10","2007-01",75,[21],[620],{"nctId":589,"briefTitle":590,"status":147,"phases":1618,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":1619,"interventions":1620},[90,91],[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],[72,318,617,618,619,620,621],{"nctId":1622,"briefTitle":1623,"status":108,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1629},"NCT00033514","Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2\u002FNeu Overexpression",[90,91],"2011-12","2001-08",27,[21],[539,1001],{"nctId":1162,"briefTitle":1163,"status":147,"phases":1631,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":16,"conditions":1632,"interventions":1633},[90,91],[1169,1170,1171,160,161],[1173,1142,620],{"trials":1635,"activeCount":102},[1636],{"nctId":663,"briefTitle":664,"status":108,"phases":1637,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":1638,"interventions":1639},[92],[21],[539,507,540,672,318],{"trials":1641,"activeCount":102},[],{"trials":1643,"activeCount":102},[1644],{"nctId":1645,"briefTitle":1646,"status":108,"phases":1647,"primaryCompletion":1648,"start":1563,"enrollment":36,"conditions":1649,"interventions":1651},"NCT00433407","T-Cell Response in Patients Receiving Trastuzumab and\u002For Chemotherapy for HER2-Positive Solid Tumors",[94],"2006-02",[21,24,629,15,1650,33],"Sarcoma",[539],{"intervention":788,"totalTrials":340,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1660,"PHASE2":1662,"PHASE3":1668,"PHASE4":1674,"NA":1676},{"trials":1655,"activeCount":102},[1656],{"nctId":777,"briefTitle":778,"status":108,"phases":1657,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1658,"interventions":1659},[89],[784,785],[445,447,787,448,788,789,450],{"trials":1661,"activeCount":102},[],{"trials":1663,"activeCount":245,"soonestReadout":241},[1664],{"nctId":818,"briefTitle":819,"status":264,"phases":1665,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":1666,"interventions":1667},[90,91],[784,825],[445,447,448,788,450,827,451],{"trials":1669,"activeCount":102},[1670],{"nctId":835,"briefTitle":836,"status":625,"phases":1671,"start":838,"conditions":1672,"interventions":1673},[92],[840],[842,750,118,843,708],{"trials":1675,"activeCount":102},[],{"trials":1677,"activeCount":102},[],{"intervention":1041,"totalTrials":962,"cells":1679},{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1721,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1681,"activeCount":102},[],{"trials":1683,"activeCount":102},[1684,1700,1713,1717],{"nctId":1685,"briefTitle":1686,"status":282,"phases":1687,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":359,"conditions":1690,"interventions":1695},"NCT03240861","Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer",[90],"2023-10-19","2017-07-26",[1691,1692,1693,1694,1650],"HLA-A*0201 Positive Cells Present","Locally Advanced Malignant Neoplasm","NY-ESO-1 Positive","Unresectable Malignant Neoplasm",[1041,1696,1697,1698,1108,1699],"Busulfan","Cellular Therapy","Filgrastim","Plerixafor",{"nctId":1701,"briefTitle":1702,"status":134,"phases":1703,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":102,"conditions":1706,"interventions":1710},"NCT03506802","TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma",[90],"2019-06-25","2018-07-10",[1691,1707,1708,1709],"NY-ESO-1 Positive Tumor Cells Present","Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[1041,1697,1698,1711,1712,1699],"Lenalidomide","Melphalan",{"nctId":1020,"briefTitle":1021,"status":282,"phases":1714,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":228,"conditions":1715,"interventions":1716},[90],[33],[659,1013,1027,1028,1029],{"nctId":1031,"briefTitle":1032,"status":108,"phases":1718,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":245,"conditions":1719,"interventions":1720},[90],[1037,1038,1039],[1041,1042,1043,789,1044,1045],{"trials":1722,"activeCount":245,"soonestReadout":1084},[1723,1727],{"nctId":1081,"briefTitle":1082,"status":147,"phases":1724,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":962,"conditions":1725,"interventions":1726},[91],[1088],[1029,1013,659,1027,1028],{"nctId":1728,"briefTitle":1729,"status":625,"phases":1730,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT00301990","Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer",[91],"2005-09",65,[1734],"Kidney Cancer",[1029,178],{"trials":1737,"activeCount":102},[],{"trials":1739,"activeCount":102},[],{"trials":1741,"activeCount":102},[],{"intervention":178,"totalTrials":359,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1774,"PHASE4":1776,"NA":1778},{"trials":1745,"activeCount":102},[],{"trials":1747,"activeCount":102},[],{"trials":1749,"activeCount":245,"soonestReadout":404},[1750,1758,1762,1766,1770],{"nctId":1751,"briefTitle":1752,"status":108,"phases":1753,"primaryCompletion":1754,"completion":1754,"start":736,"enrollment":16,"conditions":1755,"interventions":1757},"NCT00049322","Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery",[91],"2012-02",[1756],"Liver Cancer",[178],{"nctId":1728,"briefTitle":1729,"status":625,"phases":1759,"start":1731,"enrollment":1732,"conditions":1760,"interventions":1761},[91],[1734],[1029,178],{"nctId":167,"briefTitle":168,"status":108,"phases":1763,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":1764,"interventions":1765},[91],[174,175,176],[178,97,141,140],{"nctId":213,"briefTitle":214,"status":108,"phases":1767,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":1768,"interventions":1769},[91],[30],[178,97],{"nctId":401,"briefTitle":402,"status":264,"phases":1771,"primaryCompletion":404,"completion":405,"start":406,"enrollment":206,"conditions":1772,"interventions":1773},[90,91],[408,409,410,411],[413,317,414,42],{"trials":1775,"activeCount":102},[],{"trials":1777,"activeCount":102},[],{"trials":1779,"activeCount":102},[],{"intervention":1346,"totalTrials":228,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1802,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1783,"activeCount":102},[],{"trials":1785,"activeCount":102},[1786,1794],{"nctId":1787,"briefTitle":1788,"status":108,"phases":1789,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1270,"conditions":1792,"interventions":1793},"NCT00064233","BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate",[90],"2006-10","2003-11",[27],[1346],{"nctId":1795,"briefTitle":1796,"status":108,"phases":1797,"primaryCompletion":1798,"start":1799,"enrollment":9,"conditions":1800,"interventions":1801},"NCT00345826","Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",[90],"2010-07","2005-11",[27],[1346],{"trials":1803,"activeCount":245,"soonestReadout":56},[1804,1811],{"nctId":1805,"briefTitle":1806,"status":625,"phases":1807,"start":735,"conditions":1808,"interventions":1809},"NCT00112775","BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate",[91],[27],[1346,1810],"imatinib mesylate",{"nctId":54,"briefTitle":55,"status":147,"phases":1812,"primaryCompletion":56,"completion":1339,"start":1340,"enrollment":1341,"conditions":1813,"interventions":1814},[91],[15],[57,1344,1345,1346],{"trials":1816,"activeCount":102},[],{"trials":1818,"activeCount":102},[],{"trials":1820,"activeCount":102},[],{"intervention":1027,"totalTrials":340,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1835,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1824,"activeCount":102},[],{"trials":1826,"activeCount":102},[1827,1831],{"nctId":1020,"briefTitle":1021,"status":282,"phases":1828,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":228,"conditions":1829,"interventions":1830},[90],[33],[659,1013,1027,1028,1029],{"nctId":1031,"briefTitle":1032,"status":108,"phases":1832,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":245,"conditions":1833,"interventions":1834},[90],[1037,1038,1039],[1041,1042,1043,789,1044,1045],{"trials":1836,"activeCount":245,"soonestReadout":1084},[1837],{"nctId":1081,"briefTitle":1082,"status":147,"phases":1838,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":962,"conditions":1839,"interventions":1840},[91],[1088],[1029,1013,659,1027,1028],{"trials":1842,"activeCount":102},[],{"trials":1844,"activeCount":102},[],{"trials":1846,"activeCount":102},[],{"intervention":1028,"totalTrials":340,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1865,"PHASE3":1871,"PHASE4":1873,"NA":1875},{"trials":1850,"activeCount":102},[],{"trials":1852,"activeCount":102},[1853,1857],{"nctId":1020,"briefTitle":1021,"status":282,"phases":1854,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":228,"conditions":1855,"interventions":1856},[90],[33],[659,1013,1027,1028,1029],{"nctId":1858,"briefTitle":1859,"status":108,"phases":1860,"primaryCompletion":1861,"start":1862,"enrollment":1330,"conditions":1863,"interventions":1864},"NCT00004880","Vaccine Therapy in Treating Patients With Advanced Kidney Cancer",[90],"2001-04","1997-06",[1734],[1028],{"trials":1866,"activeCount":245,"soonestReadout":1084},[1867],{"nctId":1081,"briefTitle":1082,"status":147,"phases":1868,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":962,"conditions":1869,"interventions":1870},[91],[1088],[1029,1013,659,1027,1028],{"trials":1872,"activeCount":102},[],{"trials":1874,"activeCount":102},[],{"trials":1876,"activeCount":102},[],{"intervention":1262,"totalTrials":231,"cells":1878},{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1905,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1880,"activeCount":102},[],{"trials":1882,"activeCount":102},[1883],{"nctId":1884,"briefTitle":1885,"status":282,"phases":1886,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":98,"conditions":1889,"interventions":1902},"NCT03128619","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",[90],"2022-03-31","2017-08-02",[1890,1891,604,1892,1893,1894,1895,1896,1897,1306,1307,1308,1309,1898,1899,1900,1901],"Estrogen Receptor Positive","HER2\u002FNeu Negative","Multifocal Breast Carcinoma","Postmenopausal","Progesterone Receptor Positive","Stage I Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer",[1903,1262,1904],"Copanlisib","Palbociclib",{"trials":1906,"activeCount":245,"soonestReadout":1254},[1907],{"nctId":1251,"briefTitle":1252,"status":264,"phases":1908,"primaryCompletion":1254,"completion":1255,"start":1256,"enrollment":1257,"conditions":1909,"interventions":1910},[91],[1259,361,362,363],[1242,1261,1262],{"trials":1912,"activeCount":102},[],{"trials":1914,"activeCount":102},[],{"trials":1916,"activeCount":102},[],{"intervention":1918,"totalTrials":231,"cells":1919},"Liposome-encapsulated Daunorubicin-Cytarabine",{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1934,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1921,"activeCount":102},[],{"trials":1923,"activeCount":102},[1924],{"nctId":1925,"briefTitle":1926,"status":282,"phases":1927,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":496,"conditions":1930,"interventions":1932},"NCT03904251","CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia",[90],"2023-10-25","2019-07-18",[1931],"Acute Myelogenous Leukemia",[1933,1918],"Gemtuzumab Ozogamicin",{"trials":1935,"activeCount":245,"soonestReadout":51},[1936],{"nctId":49,"briefTitle":50,"status":147,"phases":1937,"primaryCompletion":51,"completion":51,"start":1938,"enrollment":231,"conditions":1939,"interventions":1941},[91],"2019-04-12",[1940],"Recurrent Acute Myeloid Leukemia",[52,1918],{"trials":1943,"activeCount":102},[],{"trials":1945,"activeCount":102},[],{"trials":1947,"activeCount":102},[],{"intervention":1949,"totalTrials":245,"cells":1950},"Antiandrogen Therapy",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1952,"activeCount":102},[],{"trials":1954,"activeCount":102},[],{"trials":1956,"activeCount":245,"soonestReadout":1961},[1957],{"nctId":1958,"briefTitle":1959,"status":147,"phases":1960,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1971},"NCT03541850","Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery",[91],"2026-11-01","2027-11-01","2019-01-29",92,[1966,1967,1968,1969,1970],"PSA Level Greater Than 0.03","PSA Progression","Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7","Stage II Prostate Adenocarcinoma AJCC v7","Stage III Prostate Adenocarcinoma AJCC v7",[1949],{"trials":1973,"activeCount":102},[],{"trials":1975,"activeCount":102},[],{"trials":1977,"activeCount":102},[],{"intervention":933,"totalTrials":245,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1981,"activeCount":102},[],{"trials":1983,"activeCount":102},[],{"trials":1985,"activeCount":245,"soonestReadout":925},[1986],{"nctId":922,"briefTitle":923,"status":264,"phases":1987,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":1988,"interventions":1989},[91],[930,931],[933,913],{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[],{"trials":1995,"activeCount":102},[],{"intervention":1373,"totalTrials":245,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1999,"activeCount":102},[],{"trials":2001,"activeCount":102},[],{"trials":2003,"activeCount":245,"soonestReadout":1366},[2004],{"nctId":1363,"briefTitle":1364,"status":147,"phases":2005,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":782,"conditions":2006,"interventions":2007},[91],[1370,1371,1334,953],[1373,1354,1374],{"trials":2009,"activeCount":102},[],{"trials":2011,"activeCount":102},[],{"trials":2013,"activeCount":102},[],{"intervention":1374,"totalTrials":245,"cells":2015},{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2017,"activeCount":102},[],{"trials":2019,"activeCount":102},[],{"trials":2021,"activeCount":245,"soonestReadout":1366},[2022],{"nctId":1363,"briefTitle":1364,"status":147,"phases":2023,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":782,"conditions":2024,"interventions":2025},[91],[1370,1371,1334,953],[1373,1354,1374],{"trials":2027,"activeCount":102},[],{"trials":2029,"activeCount":102},[],{"trials":2031,"activeCount":102},[],{"intervention":1311,"totalTrials":245,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":102},[],{"trials":2039,"activeCount":245,"soonestReadout":1299},[2040],{"nctId":1296,"briefTitle":1297,"status":264,"phases":2041,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":1301,"conditions":2042,"interventions":2043},[91],[1303,1304,1305,1306,1307,1308,1309],[1261,1311],{"trials":2045,"activeCount":102},[],{"trials":2047,"activeCount":102},[],{"trials":2049,"activeCount":102},[],{"intervention":827,"totalTrials":245,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":102},[],{"trials":2055,"activeCount":102},[],{"trials":2057,"activeCount":245,"soonestReadout":241},[2058],{"nctId":818,"briefTitle":819,"status":264,"phases":2059,"primaryCompletion":241,"completion":821,"start":822,"enrollment":823,"conditions":2060,"interventions":2061},[90,91],[784,825],[445,447,448,788,450,827,451],{"trials":2063,"activeCount":102},[],{"trials":2065,"activeCount":102},[],{"trials":2067,"activeCount":102},[],{"intervention":163,"totalTrials":245,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":102},[],{"trials":2073,"activeCount":102},[],{"trials":2075,"activeCount":245,"soonestReadout":149},[2076],{"nctId":145,"briefTitle":146,"status":147,"phases":2077,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":2078,"interventions":2079},[90,91],[153,154,155,156,157,158,159,160,161],[163,164,165],{"trials":2081,"activeCount":102},[],{"trials":2083,"activeCount":102},[],{"trials":2085,"activeCount":102},[],{"intervention":164,"totalTrials":245,"cells":2087},{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2089,"activeCount":102},[],{"trials":2091,"activeCount":102},[],{"trials":2093,"activeCount":245,"soonestReadout":149},[2094],{"nctId":145,"briefTitle":146,"status":147,"phases":2095,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":2096,"interventions":2097},[90,91],[153,154,155,156,157,158,159,160,161],[163,164,165],{"trials":2099,"activeCount":102},[],{"trials":2101,"activeCount":102},[],{"trials":2103,"activeCount":102},[],{"intervention":2105,"totalTrials":245,"cells":2106},"Ropeginterferon Alfa-2B",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2108,"activeCount":102},[],{"trials":2110,"activeCount":102},[],{"trials":2112,"activeCount":245,"soonestReadout":2117},[2113],{"nctId":2114,"briefTitle":2115,"status":237,"phases":2116,"primaryCompletion":2117,"completion":2118,"start":2119,"enrollment":206,"conditions":2120,"interventions":2126},"NCT07468916","Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",[91],"2031-09-30","2032-09-30","2026-09-29",[2121,2122,2123,2124,2125],"Atypical Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","Myelodysplastic\u002FMyeloproliferative Neoplasm, Not Otherwise Specified",[2105],{"trials":2128,"activeCount":102},[],{"trials":2130,"activeCount":102},[],{"trials":2132,"activeCount":102},[],{"intervention":2134,"totalTrials":245,"cells":2135},"Duvelisib",{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2137,"activeCount":102},[],{"trials":2139,"activeCount":102},[],{"trials":2141,"activeCount":245,"soonestReadout":240},[2142],{"nctId":2143,"briefTitle":2144,"status":264,"phases":2145,"primaryCompletion":240,"completion":2146,"start":2147,"enrollment":36,"conditions":2148,"interventions":2151},"NCT06810778","Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",[90,91],"2031-06-01","2025-05-02",[2149,2150],"T-cell-prolymphocytic Leukemia","Cutaneous T-Cell Lymphoma Refractory",[2134,2152],"Venetoclax",{"trials":2154,"activeCount":102},[],{"trials":2156,"activeCount":102},[],{"trials":2158,"activeCount":102},[],{"intervention":2152,"totalTrials":245,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2162,"activeCount":102},[],{"trials":2164,"activeCount":102},[],{"trials":2166,"activeCount":245,"soonestReadout":240},[2167],{"nctId":2143,"briefTitle":2144,"status":264,"phases":2168,"primaryCompletion":240,"completion":2146,"start":2147,"enrollment":36,"conditions":2169,"interventions":2170},[90,91],[2149,2150],[2134,2152],{"trials":2172,"activeCount":102},[],{"trials":2174,"activeCount":102},[],{"trials":2176,"activeCount":102},[],{"intervention":2178,"totalTrials":245,"cells":2179},"Acalabrutinib",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2197,"PHASE4":2199,"NA":2201},{"trials":2181,"activeCount":102},[],{"trials":2183,"activeCount":102},[],{"trials":2185,"activeCount":245,"soonestReadout":380},[2186],{"nctId":2187,"briefTitle":2188,"status":264,"phases":2189,"primaryCompletion":380,"completion":381,"start":2190,"enrollment":19,"conditions":2191,"interventions":2196},"NCT05256641","Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma",[90,91],"2023-01-23",[2192,2193,2194,2195],"Diffuse Large B-Cell Lymphoma","High-grade B-cell Lymphoma","Transformed Lymphoma","Secondary Central Nervous System Lymphoma",[2178],{"trials":2198,"activeCount":102},[],{"trials":2200,"activeCount":102},[],{"trials":2202,"activeCount":102},[],{"intervention":573,"totalTrials":245,"cells":2204},{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2215,"PHASE4":2217,"NA":2219},{"trials":2206,"activeCount":102},[],{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":245,"soonestReadout":239},[2211],{"nctId":567,"briefTitle":568,"status":237,"phases":2212,"primaryCompletion":239,"completion":240,"start":431,"enrollment":31,"conditions":2213,"interventions":2214},[91],[571],[72,573,574],{"trials":2216,"activeCount":102},[],{"trials":2218,"activeCount":102},[],{"trials":2220,"activeCount":102},[],{"intervention":574,"totalTrials":245,"cells":2222},{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2224,"activeCount":102},[],{"trials":2226,"activeCount":102},[],{"trials":2228,"activeCount":245,"soonestReadout":239},[2229],{"nctId":567,"briefTitle":568,"status":237,"phases":2230,"primaryCompletion":239,"completion":240,"start":431,"enrollment":31,"conditions":2231,"interventions":2232},[91],[571],[72,573,574],{"trials":2234,"activeCount":102},[],{"trials":2236,"activeCount":102},[],{"trials":2238,"activeCount":102},[],{"intervention":2240,"totalTrials":245,"cells":2241},"Ivonescimab",{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2243,"activeCount":102},[],{"trials":2245,"activeCount":102},[],{"trials":2247,"activeCount":245,"soonestReadout":2252},[2248],{"nctId":2249,"briefTitle":2250,"status":264,"phases":2251,"primaryCompletion":2252,"completion":2253,"start":2254,"enrollment":383,"conditions":2255,"interventions":2257},"NCT06980077","Ivonescimab for the Treatment of Thymic Cancer",[91],"2027-06-17","2028-06-17","2025-07-15",[2256],"Thymus Carcinoma",[2240],{"trials":2259,"activeCount":102},[],{"trials":2261,"activeCount":102},[],{"trials":2263,"activeCount":102},[],{"intervention":2265,"totalTrials":245,"cells":2266},"Lutetium Lu-177 PNT2002",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2284,"PHASE4":2286,"NA":2288},{"trials":2268,"activeCount":102},[],{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":245,"soonestReadout":2277},[2273],{"nctId":2274,"briefTitle":2275,"status":147,"phases":2276,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2283},"NCT05496959","177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study",[91],"2032-09-01","2033-09-01","2022-09-02",93,[2282,35,931,953],"Oligometastatic Prostate Carcinoma",[2265],{"trials":2285,"activeCount":102},[],{"trials":2287,"activeCount":102},[],{"trials":2289,"activeCount":102},[],{"intervention":617,"totalTrials":245,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2293,"activeCount":102},[],{"trials":2295,"activeCount":102},[],{"trials":2297,"activeCount":245,"soonestReadout":592},[2298],{"nctId":589,"briefTitle":590,"status":147,"phases":2299,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":2300,"interventions":2301},[90,91],[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],[72,318,617,618,619,620,621],{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":102},[],{"trials":2307,"activeCount":102},[],{"intervention":618,"totalTrials":245,"cells":2309},{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2311,"activeCount":102},[],{"trials":2313,"activeCount":102},[],{"trials":2315,"activeCount":245,"soonestReadout":592},[2316],{"nctId":589,"briefTitle":590,"status":147,"phases":2317,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":2318,"interventions":2319},[90,91],[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],[72,318,617,618,619,620,621],{"trials":2321,"activeCount":102},[],{"trials":2323,"activeCount":102},[],{"trials":2325,"activeCount":102},[],{"intervention":619,"totalTrials":245,"cells":2327},{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2338,"PHASE4":2340,"NA":2342},{"trials":2329,"activeCount":102},[],{"trials":2331,"activeCount":102},[],{"trials":2333,"activeCount":245,"soonestReadout":592},[2334],{"nctId":589,"briefTitle":590,"status":147,"phases":2335,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":2336,"interventions":2337},[90,91],[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],[72,318,617,618,619,620,621],{"trials":2339,"activeCount":102},[],{"trials":2341,"activeCount":102},[],{"trials":2343,"activeCount":102},[],{"intervention":621,"totalTrials":245,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2356,"PHASE4":2358,"NA":2360},{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":245,"soonestReadout":592},[2352],{"nctId":589,"briefTitle":590,"status":147,"phases":2353,"primaryCompletion":592,"completion":593,"start":594,"enrollment":477,"conditions":2354,"interventions":2355},[90,91],[596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615],[72,318,617,618,619,620,621],{"trials":2357,"activeCount":102},[],{"trials":2359,"activeCount":102},[],{"trials":2361,"activeCount":102},[],{"intervention":57,"totalTrials":245,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2365,"activeCount":102},[],{"trials":2367,"activeCount":102},[],{"trials":2369,"activeCount":245,"soonestReadout":56},[2370],{"nctId":54,"briefTitle":55,"status":147,"phases":2371,"primaryCompletion":56,"completion":1339,"start":1340,"enrollment":1341,"conditions":2372,"interventions":2373},[91],[15],[57,1344,1345,1346],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":102},[],{"intervention":1344,"totalTrials":245,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":102},[],{"trials":2385,"activeCount":102},[],{"trials":2387,"activeCount":245,"soonestReadout":56},[2388],{"nctId":54,"briefTitle":55,"status":147,"phases":2389,"primaryCompletion":56,"completion":1339,"start":1340,"enrollment":1341,"conditions":2390,"interventions":2391},[91],[15],[57,1344,1345,1346],{"trials":2393,"activeCount":102},[],{"trials":2395,"activeCount":102},[],{"trials":2397,"activeCount":102},[],{"intervention":211,"totalTrials":245,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":102},[],{"trials":2403,"activeCount":102},[],{"trials":2405,"activeCount":245,"soonestReadout":203},[2406],{"nctId":200,"briefTitle":201,"status":147,"phases":2407,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":2408,"interventions":2409},[91],[208,209],[211,165],{"trials":2411,"activeCount":102},[],{"trials":2413,"activeCount":102},[],{"trials":2415,"activeCount":102},[],{"intervention":2417,"totalTrials":245,"cells":2418},"Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2420,"activeCount":102},[],{"trials":2422,"activeCount":102},[],{"trials":2424,"activeCount":245,"soonestReadout":203},[2425],{"nctId":2426,"briefTitle":2427,"status":264,"phases":2428,"primaryCompletion":203,"completion":204,"start":2429,"enrollment":242,"conditions":2430,"interventions":2432},"NCT05558904","An Investigational Scan (Me-4FDG PET\u002FCT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer",[90,91],"2023-01-19",[2431],"Lung Adenocarcinoma",[2417],{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":102},[],{"trials":2438,"activeCount":102},[],{"intervention":1173,"totalTrials":245,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[],{"trials":2446,"activeCount":245,"soonestReadout":1165},[2447],{"nctId":1162,"briefTitle":1163,"status":147,"phases":2448,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":16,"conditions":2449,"interventions":2450},[90,91],[1169,1170,1171,160,161],[1173,1142,620],{"trials":2452,"activeCount":102},[],{"trials":2454,"activeCount":102},[],{"trials":2456,"activeCount":102},[],{"intervention":2458,"totalTrials":245,"cells":2459},"Tarlatamab treatment",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2477,"PHASE4":2479,"NA":2481},{"trials":2461,"activeCount":102},[],{"trials":2463,"activeCount":102},[],{"trials":2465,"activeCount":245,"soonestReadout":2470},[2466],{"nctId":2467,"briefTitle":2468,"status":264,"phases":2469,"primaryCompletion":2470,"completion":2471,"start":2472,"enrollment":682,"conditions":2473,"interventions":2476},"NCT06788938","Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms",[91],"2028-04-24","2029-04-24","2025-03-21",[2474,2475],"DLL3-expressing Tumors","Advanced Tumors",[2458],{"trials":2478,"activeCount":102},[],{"trials":2480,"activeCount":102},[],{"trials":2482,"activeCount":102},[],{"intervention":2484,"totalTrials":245,"cells":2485},"Zirconium Zr 89 Girentuximab",{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2507,"PHASE4":2509,"NA":2511},{"trials":2487,"activeCount":102},[],{"trials":2489,"activeCount":102},[],{"trials":2491,"activeCount":245,"soonestReadout":2496},[2492],{"nctId":2493,"briefTitle":2494,"status":264,"phases":2495,"primaryCompletion":2496,"completion":2497,"start":2498,"enrollment":2499,"conditions":2500,"interventions":2506},"NCT06447103","An Investigational Scan (89Zr-DFO-GmAb PET\u002FCT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer",[91],"2029-12-01","2030-12-01","2024-08-06",91,[2501,2502,2503,2504,2505],"Clear Cell Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage II Renal Cell Cancer","Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer",[2484],{"trials":2508,"activeCount":102},[],{"trials":2510,"activeCount":102},[],{"trials":2512,"activeCount":102},[],{"intervention":2514,"totalTrials":245,"cells":2515},"Hormone Therapy",{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2517,"activeCount":102},[],{"trials":2519,"activeCount":102},[],{"trials":2521,"activeCount":245,"soonestReadout":324},[2522],{"nctId":2523,"briefTitle":2524,"status":264,"phases":2525,"primaryCompletion":324,"completion":325,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2532},"NCT04915508","Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy",[91],"2021-06-23",102,[35,2529,2530,310,2531,953],"Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage IIIC Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8",[2514],{"trials":2534,"activeCount":102},[],{"trials":2536,"activeCount":102},[],{"trials":2538,"activeCount":102},[],{"intervention":1182,"totalTrials":245,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2551,"PHASE4":2553,"NA":2555},{"trials":2542,"activeCount":102},[],{"trials":2544,"activeCount":102},[],{"trials":2546,"activeCount":245,"soonestReadout":1178},[2547],{"nctId":1175,"briefTitle":1176,"status":264,"phases":2548,"primaryCompletion":1178,"completion":1179,"start":1094,"enrollment":242,"conditions":2549,"interventions":2550},[91],[338],[1142,1182],{"trials":2552,"activeCount":102},[],{"trials":2554,"activeCount":102},[],{"trials":2556,"activeCount":102},[],{"intervention":1276,"totalTrials":245,"cells":2558},{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2560,"activeCount":102},[],{"trials":2562,"activeCount":102},[],{"trials":2564,"activeCount":245,"soonestReadout":1267},[2565],{"nctId":1264,"briefTitle":1265,"status":237,"phases":2566,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1270,"conditions":2567,"interventions":2568},[91],[1272,596,599,604,1273,1274],[1242,1276],{"trials":2570,"activeCount":102},[],{"trials":2572,"activeCount":102},[],{"trials":2574,"activeCount":102},[],{"intervention":52,"totalTrials":245,"cells":2576},{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2587,"PHASE4":2589,"NA":2591},{"trials":2578,"activeCount":102},[],{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":245,"soonestReadout":51},[2583],{"nctId":49,"briefTitle":50,"status":147,"phases":2584,"primaryCompletion":51,"completion":51,"start":1938,"enrollment":231,"conditions":2585,"interventions":2586},[91],[1940],[52,1918],{"trials":2588,"activeCount":102},[],{"trials":2590,"activeCount":102},[],{"trials":2592,"activeCount":102},[],{"intervention":399,"totalTrials":245,"cells":2594},{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2596,"activeCount":102},[],{"trials":2598,"activeCount":102},[],{"trials":2600,"activeCount":245,"soonestReadout":393},[2601],{"nctId":390,"briefTitle":391,"status":264,"phases":2602,"primaryCompletion":393,"completion":394,"start":395,"enrollment":25,"conditions":2603,"interventions":2604},[91],[397],[399,42],{"trials":2606,"activeCount":102},[],{"trials":2608,"activeCount":102},[],{"trials":2610,"activeCount":102},[],{"intervention":2612,"totalTrials":245,"cells":2613},"Fluorine F 18 Flotufolastat",{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2615,"activeCount":102},[],{"trials":2617,"activeCount":102},[],{"trials":2619,"activeCount":245,"soonestReadout":2624},[2620],{"nctId":2621,"briefTitle":2622,"status":264,"phases":2623,"primaryCompletion":2624,"completion":2625,"start":2626,"enrollment":2627,"conditions":2628,"interventions":2629},"NCT07185165","An Investigational Scan (Flotufolastat F 18 PET\u002FCT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.",[91],"2035-10-25","2036-10-25","2025-10-09",81,[943],[2612],{"trials":2631,"activeCount":102},[],{"trials":2633,"activeCount":102},[],{"trials":2635,"activeCount":102},[],{"intervention":332,"totalTrials":340,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2666,"PHASE3":2668,"PHASE4":2670,"NA":2672},{"trials":2639,"activeCount":102},[],{"trials":2641,"activeCount":231,"soonestReadout":324},[2642,2652,2656],{"nctId":2643,"briefTitle":2644,"status":134,"phases":2645,"primaryCompletion":2496,"completion":2497,"start":2646,"enrollment":102,"conditions":2647,"interventions":2649},"NCT05457959","Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and\u002For Progressive Diffuse Hemispheric Glioma, H3 G34-mutant",[90],"2024-12-01",[2648],"Diffuse Hemispheric Glioma, H3 G34-Mutant",[2650,2651,789,332],"Dendritic Cell Tumor Peptide Vaccine","Ipilimumab",{"nctId":321,"briefTitle":322,"status":147,"phases":2653,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":2654,"interventions":2655},[90],[329],[331,42,332],{"nctId":2657,"briefTitle":2658,"status":147,"phases":2659,"primaryCompletion":2660,"completion":2661,"start":2662,"enrollment":962,"conditions":2663,"interventions":2664},"NCT06342908","A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma",[90],"2027-03-08","2028-01-09","2024-06-14",[2648],[2665,332],"Dendritic Cell Therapy",{"trials":2667,"activeCount":102},[],{"trials":2669,"activeCount":102},[],{"trials":2671,"activeCount":102},[],{"trials":2673,"activeCount":102},[],{"intervention":67,"totalTrials":231,"cells":2675},{"EARLY_PHASE1":2676,"PHASE1":2688,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2677,"activeCount":245,"soonestReadout":1254},[2678],{"nctId":2679,"briefTitle":2680,"status":147,"phases":2681,"primaryCompletion":1254,"completion":2682,"start":2683,"enrollment":477,"conditions":2684,"interventions":2687},"NCT04457258","68Ga-FAPi-46 PET\u002FCT Scan in Imaging Patients With Sarcoma",[89],"2027-07-21","2020-09-08",[2685,2686,1650],"Metastatic Sarcoma","Recurrent Sarcoma",[67],{"trials":2689,"activeCount":245,"soonestReadout":66},[2690],{"nctId":64,"briefTitle":65,"status":147,"phases":2691,"primaryCompletion":66,"completion":1255,"start":2692,"enrollment":370,"conditions":2693,"interventions":2709},[90],"2020-08-27",[2694,2695,2696,2697,2698,2699,2700,2701,2702,2703,2704,2705,2706,2707,315,2708],"Bladder Carcinoma","Cervical Carcinoma","Cholangiocarcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Hepatocellular Carcinoma","Malignant Adrenal Gland Neoplasm","Malignant Brain Neoplasm","Malignant Pleural Neoplasm","Malignant Skin Neoplasm","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Malignant Thymus Neoplasm","Neuroendocrine Neoplasm","Thyroid Gland Carcinoma","Cancer of Unknown Primary Site",[67],{"trials":2711,"activeCount":102},[],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":102},[],{"intervention":789,"totalTrials":98,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2726,"PHASE2":2805,"PHASE3":2861,"PHASE4":2863,"NA":2865},{"trials":2721,"activeCount":102},[2722],{"nctId":777,"briefTitle":778,"status":108,"phases":2723,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":2724,"interventions":2725},[89],[784,785],[445,447,787,448,788,789,450],{"trials":2727,"activeCount":245,"soonestReadout":380},[2728,2765,2783,2787,2791],{"nctId":2729,"briefTitle":2730,"status":147,"phases":2731,"primaryCompletion":380,"completion":381,"start":2732,"enrollment":1330,"conditions":2733,"interventions":2764},"NCT04420975","Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma",[90],"2020-10-14",[2734,2735,2736,2737,2738,2739,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763],"Leiomyosarcoma","Malignant Peripheral Nerve Sheath Tumor","Myxofibrosarcoma","Pleomorphic Rhabdomyosarcoma","Resectable Dedifferentiated Liposarcoma","Resectable Soft Tissue Sarcoma","Resectable Undifferentiated Pleomorphic Sarcoma","Soft Tissue Fibrosarcoma","Spindle Cell Sarcoma","Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8","Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IA Retroperitoneal Sarcoma AJCC v8","Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IB Retroperitoneal Sarcoma AJCC v8","Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage II Retroperitoneal Sarcoma AJCC v8","Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage III Retroperitoneal Sarcoma AJCC v8","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IIIA Retroperitoneal Sarcoma AJCC v8","Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IIIB Retroperitoneal Sarcoma AJCC v8","Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Storiform-Pleomorphic Malignant Fibrous Histiocytoma","Synovial Sarcoma","Undifferentiated High Grade Pleomorphic Sarcoma of Bone","Undifferentiated Pleomorphic Sarcoma","Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells","Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant","Undifferentiated Spindle Cell Sarcoma",[292,789],{"nctId":2766,"briefTitle":2767,"status":282,"phases":2768,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":962,"conditions":2771,"interventions":2781},"NCT04185311","Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",[90],"2023-05-17","2019-07-10",[2772,1272,2773,2774,596,597,598,600,601,1891,2775,2776,2777,2778,2779,607,608,609,610,612,613,2780],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Invasive Ductal Carcinoma, Not Otherwise Specified","Progesterone Receptor Negative","Prognostic Stage 0 Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma",[2651,789,2782],"Talimogene Laherparepvec",{"nctId":2643,"briefTitle":2644,"status":134,"phases":2784,"primaryCompletion":2496,"completion":2497,"start":2646,"enrollment":102,"conditions":2785,"interventions":2786},[90],[2648],[2650,2651,789,332],{"nctId":1031,"briefTitle":1032,"status":108,"phases":2788,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":245,"conditions":2789,"interventions":2790},[90],[1037,1038,1039],[1041,1042,1043,789,1044,1045],{"nctId":2792,"briefTitle":2793,"status":282,"phases":2794,"primaryCompletion":2795,"completion":2795,"start":2796,"enrollment":962,"conditions":2797,"interventions":2803},"NCT03425461","Anti-SEMA4D Monoclonal Antibody VX15\u002F2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma",[90],"2021-03-04","2018-06-14",[126,2798,2799,2800,2801,2802],"Stage III Cutaneous Melanoma AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7",[2804,2651,789],"Anti-SEMA4D Monoclonal Antibody VX15\u002F2503",{"trials":2806,"activeCount":102},[2807,2819,2829,2842],{"nctId":2808,"briefTitle":2809,"status":134,"phases":2810,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":102,"conditions":2814,"interventions":2817},"NCT03014804","Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma",[91],"2020-12-01","2022-12-01","2019-12-01",[174,176,2815,329,2816],"Oligodendroglioma","Small Cell Glioblastoma",[2818,789],"autologous dendritic cells pulsed with tumor lysate antigen Vaccine",{"nctId":2820,"briefTitle":2821,"status":108,"phases":2822,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":2825,"conditions":2826,"interventions":2828},"NCT02880020","Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery",[91],"2022-08-09","2016-12-14",36,[2827],"Gastrointestinal Stromal Tumor",[2651,789],{"nctId":2830,"briefTitle":2831,"status":108,"phases":2832,"primaryCompletion":2833,"completion":2833,"start":2834,"enrollment":98,"conditions":2835,"interventions":2840},"NCT03623854","Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma",[91],"2023-09-28","2019-04-03",[2836,2837,2838,2839],"Chordoma","Locally Advanced Chordoma","Metastatic Chordoma","Unresectable Chordoma",[789,2841],"Relatlimab",{"nctId":2843,"briefTitle":2844,"status":282,"phases":2845,"primaryCompletion":2846,"completion":2846,"start":2847,"enrollment":340,"conditions":2848,"interventions":2860},"NCT04375527","Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma",[91],"2024-11-22","2020-12-03",[2849,2850,2851,2852,2853,2854,2855,2856,2857,2858,2859],"Clinical Stage III Cutaneous Melanoma AJCC V8","Clinical Stage IV Cutaneous Melanoma AJCC V8","Locally Advanced Cutaneous Melanoma","Metastatic Cutaneous Melanoma","Pathologic Stage III Cutaneous Melanoma AJCC V8","Pathologic Stage IIIA Cutaneous Melanoma AJCC V8","Pathologic Stage IIIB Cutaneous Melanoma AJCC V8","Pathologic Stage IIIC Cutaneous Melanoma AJCC V8","Pathologic Stage IIID Cutaneous Melanoma AJCC V8","Pathologic Stage IV Cutaneous Melanoma AJCC V8","Unresectable Cutaneous Melanoma",[982,789],{"trials":2862,"activeCount":102},[],{"trials":2864,"activeCount":102},[],{"trials":2866,"activeCount":102},[],{"intervention":2868,"totalTrials":340,"cells":2869},"capecitabine",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2889,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2871,"activeCount":102},[],{"trials":2873,"activeCount":245,"soonestReadout":203},[2874,2885],{"nctId":2875,"briefTitle":2876,"status":108,"phases":2877,"primaryCompletion":2878,"completion":2879,"start":761,"enrollment":31,"conditions":2880,"interventions":2883},"NCT00052273","LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors",[90],"2004-11","2005-10",[2881,2882],"Adult","Solid Tumor",[2868,2884],"enzastaurin hydrochloride",{"nctId":793,"briefTitle":794,"status":264,"phases":2886,"primaryCompletion":203,"completion":796,"start":797,"enrollment":383,"conditions":2887,"interventions":2888},[90],[799,800,801,802,803,804,805,806,807,808],[810,445,448,450],{"trials":2890,"activeCount":102},[2891],{"nctId":2892,"briefTitle":2893,"status":108,"phases":2894,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":484,"conditions":2897,"interventions":2902},"NCT01783756","Phase 1b\u002F2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",[90,91],"2019-05-10","2013-06-26",[2898,2899,2900,2901,1901],"Central Nervous System Metastases","HER2-positive Breast Cancer","Male Breast Cancer","Recurrent Breast Cancer",[1601,2903,2868],"everolimus",{"trials":2905,"activeCount":102},[],{"trials":2907,"activeCount":102},[],{"trials":2909,"activeCount":102},[],{"intervention":319,"totalTrials":231,"cells":2911},{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2920,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2913,"activeCount":102},[],{"trials":2915,"activeCount":245,"soonestReadout":71},[2916],{"nctId":69,"briefTitle":70,"status":147,"phases":2917,"primaryCompletion":71,"completion":241,"start":297,"enrollment":268,"conditions":2918,"interventions":2919},[90],[299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315],[72,317,318,319,42],{"trials":2921,"activeCount":102},[2922],{"nctId":1491,"briefTitle":1492,"status":108,"phases":2923,"completion":998,"start":1494,"conditions":2924,"interventions":2925},[91],[1496,27,18,1497,1498,1499],[1053,1501,659,1502,1503],{"trials":2927,"activeCount":102},[],{"trials":2929,"activeCount":102},[],{"trials":2931,"activeCount":102},[],{"intervention":292,"totalTrials":231,"cells":2933},{"EARLY_PHASE1":2934,"PHASE1":2940,"PHASE2":2946,"PHASE3":2948,"PHASE4":2950,"NA":2952},{"trials":2935,"activeCount":102},[2936],{"nctId":280,"briefTitle":281,"status":282,"phases":2937,"primaryCompletion":284,"completion":284,"start":285,"enrollment":245,"conditions":2938,"interventions":2939},[89],[287,288,289,290],[292,42],{"trials":2941,"activeCount":245,"soonestReadout":380},[2942],{"nctId":2729,"briefTitle":2730,"status":147,"phases":2943,"primaryCompletion":380,"completion":381,"start":2732,"enrollment":1330,"conditions":2944,"interventions":2945},[90],[2734,2735,2736,2737,2738,2739,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763],[292,789],{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[],{"trials":2953,"activeCount":102},[],{"intervention":2955,"totalTrials":231,"cells":2956},"autologous dendritic cell-adenovirus CCL21 vaccine",{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2973,"PHASE3":2975,"PHASE4":2977,"NA":2979},{"trials":2958,"activeCount":102},[],{"trials":2960,"activeCount":245,"soonestReadout":76},[2961,2969],{"nctId":2962,"briefTitle":2963,"status":108,"phases":2964,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":28,"conditions":2967,"interventions":2968},"NCT00601094","Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[90],"2017-05-23","2009-02-26",[24],[2955],{"nctId":74,"briefTitle":75,"status":147,"phases":2970,"primaryCompletion":76,"completion":335,"start":336,"enrollment":19,"conditions":2971,"interventions":2972},[90],[338,159,160,161],[77,42],{"trials":2974,"activeCount":102},[],{"trials":2976,"activeCount":102},[],{"trials":2978,"activeCount":102},[],{"trials":2980,"activeCount":102},[],{"intervention":2982,"totalTrials":245,"cells":2983},"EGFR Inhibitor ERAS-801",{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":3002,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2985,"activeCount":102},[],{"trials":2987,"activeCount":245,"soonestReadout":2992},[2988],{"nctId":2989,"briefTitle":2990,"status":264,"phases":2991,"primaryCompletion":2992,"completion":2993,"start":2994,"enrollment":98,"conditions":2995,"interventions":3001},"NCT07089641","ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial",[90],"2027-07-30","2028-07-30","2025-07-28",[2996,2997,2998,2999,3000],"IDH Wildtype Glioblastoma","Recurrent Astrocytoma","IDH Wildtype Recurrent Glioblastoma","Resectable Astrocytoma","Resectable Glioblastoma",[2982],{"trials":3003,"activeCount":102},[],{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":102},[],{"intervention":87,"totalTrials":245,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3025,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":3013,"activeCount":102},[],{"trials":3015,"activeCount":245,"soonestReadout":86},[3016],{"nctId":84,"briefTitle":85,"status":147,"phases":3017,"primaryCompletion":86,"completion":3018,"start":3019,"enrollment":3020,"conditions":3021,"interventions":3023},[90],"2027-05-22","2020-05-14",38,[3022],"Rhabdomyosarcoma",[87,3024],"Mocetinostat",{"trials":3026,"activeCount":102},[],{"trials":3028,"activeCount":102},[],{"trials":3030,"activeCount":102},[],{"trials":3032,"activeCount":102},[],{"intervention":3024,"totalTrials":245,"cells":3034},{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3049},{"trials":3036,"activeCount":102},[],{"trials":3038,"activeCount":245,"soonestReadout":86},[3039],{"nctId":84,"briefTitle":85,"status":147,"phases":3040,"primaryCompletion":86,"completion":3018,"start":3019,"enrollment":3020,"conditions":3041,"interventions":3042},[90],[3022],[87,3024],{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":102},[],{"trials":3050,"activeCount":102},[],{"intervention":331,"totalTrials":245,"cells":3052},{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3061,"PHASE3":3063,"PHASE4":3065,"NA":3067},{"trials":3054,"activeCount":102},[],{"trials":3056,"activeCount":245,"soonestReadout":324},[3057],{"nctId":321,"briefTitle":322,"status":147,"phases":3058,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":3059,"interventions":3060},[90],[329],[331,42,332],{"trials":3062,"activeCount":102},[],{"trials":3064,"activeCount":102},[],{"trials":3066,"activeCount":102},[],{"trials":3068,"activeCount":102},[],{"intervention":2665,"totalTrials":245,"cells":3070},{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3079,"PHASE3":3081,"PHASE4":3083,"NA":3085},{"trials":3072,"activeCount":102},[],{"trials":3074,"activeCount":245,"soonestReadout":2660},[3075],{"nctId":2657,"briefTitle":2658,"status":147,"phases":3076,"primaryCompletion":2660,"completion":2661,"start":2662,"enrollment":962,"conditions":3077,"interventions":3078},[90],[2648],[2665,332],{"trials":3080,"activeCount":102},[],{"trials":3082,"activeCount":102},[],{"trials":3084,"activeCount":102},[],{"trials":3086,"activeCount":102},[],{"intervention":3088,"totalTrials":245,"cells":3089},"Fluoxetine",{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3102,"PHASE3":3104,"PHASE4":3106,"NA":3108},{"trials":3091,"activeCount":102},[],{"trials":3093,"activeCount":245,"soonestReadout":1254},[3094],{"nctId":3095,"briefTitle":3096,"status":264,"phases":3097,"primaryCompletion":1254,"completion":1255,"start":3098,"enrollment":98,"conditions":3099,"interventions":3101},"NCT06225011","Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer",[90],"2025-03-20",[3100],"Colorectal Adenocarcinoma",[3088],{"trials":3103,"activeCount":102},[],{"trials":3105,"activeCount":102},[],{"trials":3107,"activeCount":102},[],{"trials":3109,"activeCount":102},[],{"intervention":446,"totalTrials":245,"cells":3111},{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3120,"PHASE3":3122,"PHASE4":3124,"NA":3126},{"trials":3113,"activeCount":102},[],{"trials":3115,"activeCount":245,"soonestReadout":431},[3116],{"nctId":428,"briefTitle":429,"status":237,"phases":3117,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":3118,"interventions":3119},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":3121,"activeCount":102},[],{"trials":3123,"activeCount":102},[],{"trials":3125,"activeCount":102},[],{"trials":3127,"activeCount":102},[],{"intervention":449,"totalTrials":245,"cells":3129},{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3138,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3131,"activeCount":102},[],{"trials":3133,"activeCount":245,"soonestReadout":431},[3134],{"nctId":428,"briefTitle":429,"status":237,"phases":3135,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":3136,"interventions":3137},[90],[436,437,438,439,440,441,442,443],[317,62,445,446,447,448,449,450,451],{"trials":3139,"activeCount":102},[],{"trials":3141,"activeCount":102},[],{"trials":3143,"activeCount":102},[],{"trials":3145,"activeCount":102},[],{"intervention":1076,"totalTrials":245,"cells":3147},{"EARLY_PHASE1":3148,"PHASE1":3150,"PHASE2":3156,"PHASE3":3158,"PHASE4":3160,"NA":3162},{"trials":3149,"activeCount":102},[],{"trials":3151,"activeCount":245,"soonestReadout":324},[3152],{"nctId":1056,"briefTitle":1057,"status":147,"phases":3153,"primaryCompletion":324,"completion":325,"start":1059,"enrollment":19,"conditions":3154,"interventions":3155},[90],[1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],[1076,1042,1043,1077],{"trials":3157,"activeCount":102},[],{"trials":3159,"activeCount":102},[],{"trials":3161,"activeCount":102},[],{"trials":3163,"activeCount":102},[],{"intervention":1077,"totalTrials":245,"cells":3165},{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3174,"PHASE3":3176,"PHASE4":3178,"NA":3180},{"trials":3167,"activeCount":102},[],{"trials":3169,"activeCount":245,"soonestReadout":324},[3170],{"nctId":1056,"briefTitle":1057,"status":147,"phases":3171,"primaryCompletion":324,"completion":325,"start":1059,"enrollment":19,"conditions":3172,"interventions":3173},[90],[1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074],[1076,1042,1043,1077],{"trials":3175,"activeCount":102},[],{"trials":3177,"activeCount":102},[],{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":102},[],{"intervention":3183,"totalTrials":245,"cells":3184},"Dapagliflozin Propanediol",{"EARLY_PHASE1":3185,"PHASE1":3200,"PHASE2":3202,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3186,"activeCount":245,"soonestReadout":3191},[3187],{"nctId":3188,"briefTitle":3189,"status":264,"phases":3190,"primaryCompletion":3191,"completion":3192,"start":3193,"enrollment":3194,"conditions":3195,"interventions":3199},"NCT07235280","Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma",[89],"2028-06-29","2029-06-29","2025-12-02",48,[2431,3196,3197,3198,24],"Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8",[3183],{"trials":3201,"activeCount":102},[],{"trials":3203,"activeCount":102},[],{"trials":3205,"activeCount":102},[],{"trials":3207,"activeCount":102},[],{"trials":3209,"activeCount":102},[],{"intervention":3211,"totalTrials":245,"cells":3212},"99mTc-based PSMA Imaging and Surgery Agent",{"EARLY_PHASE1":3213,"PHASE1":3222,"PHASE2":3224,"PHASE3":3226,"PHASE4":3228,"NA":3230},{"trials":3214,"activeCount":245,"soonestReadout":433},[3215],{"nctId":3216,"briefTitle":3217,"status":264,"phases":3218,"primaryCompletion":433,"completion":431,"start":3219,"enrollment":16,"conditions":3220,"interventions":3221},"NCT04857502","99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer",[89],"2021-04-27",[943,1334],[3211],{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[],{"trials":3227,"activeCount":102},[],{"trials":3229,"activeCount":102},[],{"trials":3231,"activeCount":102},[],{"intervention":82,"totalTrials":245,"cells":3233},{"EARLY_PHASE1":3234,"PHASE1":3236,"PHASE2":3238,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3235,"activeCount":102},[],{"trials":3237,"activeCount":102},[],{"trials":3239,"activeCount":102},[],{"trials":3241,"activeCount":102},[],{"trials":3243,"activeCount":102},[],{"trials":3245,"activeCount":245,"soonestReadout":81},[3246],{"nctId":79,"briefTitle":80,"status":147,"phases":3247,"primaryCompletion":81,"completion":950,"start":3248,"enrollment":3249,"conditions":3250,"interventions":3253},[94],"2014-01-27",220,[3251,3252],"Adenocarcinoma of the Prostate","Stage III Prostate Cancer",[82],{"intervention":3255,"totalTrials":340,"cells":3256},"epoetin alfa",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3274,"PHASE4":3285,"NA":3295},{"trials":3258,"activeCount":102},[],{"trials":3260,"activeCount":102},[],{"trials":3262,"activeCount":102},[3263],{"nctId":3264,"briefTitle":3265,"status":108,"phases":3266,"primaryCompletion":3267,"start":1563,"enrollment":3268,"conditions":3269,"interventions":3273},"NCT00255749","Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer",[91],"2007-04",89,[3270,27,18,3271,1497,3272,33],"Anemia","Lymphoproliferative Disorder","Precancerous Condition",[3255],{"trials":3275,"activeCount":102},[3276],{"nctId":3277,"briefTitle":3278,"status":108,"phases":3279,"primaryCompletion":1791,"start":3280,"enrollment":1330,"conditions":3281,"interventions":3283},"NCT00070382","Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer",[92],"2003-08",[3270,27,18,3271,1497,3282,33],"Precancerous\u002FNonmalignant Condition",[3284,3255],"darbepoetin alfa",{"trials":3286,"activeCount":102},[3287],{"nctId":3288,"briefTitle":3289,"status":108,"phases":3290,"completion":3291,"conditions":3292,"interventions":3294},"NCT00022386","Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer",[93],"2004-04",[3270,21,3293],"Fatigue",[3255],{"trials":3296,"activeCount":102},[],{"intervention":118,"totalTrials":962,"cells":3298},{"EARLY_PHASE1":3299,"PHASE1":3305,"PHASE2":3311,"PHASE3":3336,"PHASE4":3342,"NA":3344},{"trials":3300,"activeCount":102},[3301],{"nctId":777,"briefTitle":778,"status":108,"phases":3302,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":3303,"interventions":3304},[89],[784,785],[445,447,787,448,788,789,450],{"trials":3306,"activeCount":102},[3307],{"nctId":106,"briefTitle":107,"status":108,"phases":3308,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":3309,"interventions":3310},[90],[114,115],[117,97,118],{"trials":3312,"activeCount":102},[3313,3323,3327],{"nctId":3314,"briefTitle":3315,"status":108,"phases":3316,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":1096,"conditions":3320,"interventions":3321},"NCT00003225","Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer",[90,91],"2000-03","2001-06","1997-07",[840],[3322,118],"amifostine trihydrate",{"nctId":1560,"briefTitle":1561,"status":108,"phases":3324,"primaryCompletion":761,"completion":1563,"start":1564,"enrollment":1565,"conditions":3325,"interventions":3326},[91],[764,765],[118,565],{"nctId":3328,"briefTitle":3329,"status":108,"phases":3330,"primaryCompletion":3331,"completion":3332,"start":3333,"enrollment":327,"conditions":3334,"interventions":3335},"NCT00003748","Irinotecan in Treating Patients With Esophageal or Stomach Cancer",[91],"2000-06","2005-01","1998-08",[764,765],[118],{"trials":3337,"activeCount":102},[3338],{"nctId":835,"briefTitle":836,"status":625,"phases":3339,"start":838,"conditions":3340,"interventions":3341},[92],[840],[842,750,118,843,708],{"trials":3343,"activeCount":102},[],{"trials":3345,"activeCount":102},[],{"intervention":708,"totalTrials":231,"cells":3347},{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3356,"PHASE3":3358,"PHASE4":3364,"NA":3366},{"trials":3349,"activeCount":102},[],{"trials":3351,"activeCount":102},[3352],{"nctId":702,"briefTitle":703,"status":625,"phases":3353,"conditions":3354,"interventions":3355},[90],[33],[695,707,708],{"trials":3357,"activeCount":102},[],{"trials":3359,"activeCount":102},[3360],{"nctId":835,"briefTitle":836,"status":625,"phases":3361,"start":838,"conditions":3362,"interventions":3363},[92],[840],[842,750,118,843,708],{"trials":3365,"activeCount":102},[],{"trials":3367,"activeCount":102},[],{"intervention":3369,"totalTrials":231,"cells":3370},"epratuzumab",{"EARLY_PHASE1":3371,"PHASE1":3373,"PHASE2":3375,"PHASE3":3383,"PHASE4":3390,"NA":3392},{"trials":3372,"activeCount":102},[],{"trials":3374,"activeCount":102},[],{"trials":3376,"activeCount":102},[3377],{"nctId":3378,"briefTitle":3379,"status":625,"phases":3380,"start":668,"conditions":3381,"interventions":3382},"NCT00042913","Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma",[91],[18],[3369],{"trials":3384,"activeCount":102},[3385],{"nctId":3386,"briefTitle":3379,"status":625,"phases":3387,"start":1131,"conditions":3388,"interventions":3389},"NCT00022685",[92],[18],[3369],{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":102},[],{"intervention":842,"totalTrials":245,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":102},[],{"trials":3399,"activeCount":102},[],{"trials":3401,"activeCount":102},[],{"trials":3403,"activeCount":102},[3404],{"nctId":835,"briefTitle":836,"status":625,"phases":3405,"start":838,"conditions":3406,"interventions":3407},[92],[840],[842,750,118,843,708],{"trials":3409,"activeCount":102},[],{"trials":3411,"activeCount":102},[],{"intervention":3413,"totalTrials":245,"cells":3414},"cefepime hydrochloride",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3421,"PHASE4":3433,"NA":3435},{"trials":3416,"activeCount":102},[],{"trials":3418,"activeCount":102},[],{"trials":3420,"activeCount":102},[],{"trials":3422,"activeCount":102},[3423],{"nctId":3424,"briefTitle":3425,"status":625,"phases":3426,"start":1131,"conditions":3427,"interventions":3431},"NCT00020865","Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia",[92],[3428,3429,27,18,3430,33],"Fever, Sweats, and Hot Flashes","Infection","Neutropenia",[3413,3432],"levofloxacin",{"trials":3434,"activeCount":102},[],{"trials":3436,"activeCount":102},[],{"intervention":3432,"totalTrials":245,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3451,"NA":3453},{"trials":3440,"activeCount":102},[],{"trials":3442,"activeCount":102},[],{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[3447],{"nctId":3424,"briefTitle":3425,"status":625,"phases":3448,"start":1131,"conditions":3449,"interventions":3450},[92],[3428,3429,27,18,3430,33],[3413,3432],{"trials":3452,"activeCount":102},[],{"trials":3454,"activeCount":102},[],{"intervention":660,"totalTrials":245,"cells":3456},{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3463,"PHASE4":3469,"NA":3471},{"trials":3458,"activeCount":102},[],{"trials":3460,"activeCount":102},[],{"trials":3462,"activeCount":102},[],{"trials":3464,"activeCount":102},[3465],{"nctId":654,"briefTitle":655,"status":625,"phases":3466,"conditions":3467,"interventions":3468},[92],[33],[507,659,660,661],{"trials":3470,"activeCount":102},[],{"trials":3472,"activeCount":102},[],{"intervention":661,"totalTrials":245,"cells":3474},{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3479,"PHASE3":3481,"PHASE4":3487,"NA":3489},{"trials":3476,"activeCount":102},[],{"trials":3478,"activeCount":102},[],{"trials":3480,"activeCount":102},[],{"trials":3482,"activeCount":102},[3483],{"nctId":654,"briefTitle":655,"status":625,"phases":3484,"conditions":3485,"interventions":3486},[92],[33],[507,659,660,661],{"trials":3488,"activeCount":102},[],{"trials":3490,"activeCount":102},[],{"intervention":3492,"totalTrials":245,"cells":3493},"eculizumab",{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3500,"PHASE4":3509,"NA":3511},{"trials":3495,"activeCount":102},[],{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[],{"trials":3501,"activeCount":102},[3502],{"nctId":3503,"briefTitle":3504,"status":108,"phases":3505,"completion":3506,"start":2878,"conditions":3507,"interventions":3508},"NCT00112983","Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria",[92],"2005-06",[27],[3492],{"trials":3510,"activeCount":102},[],{"trials":3512,"activeCount":102},[],{"intervention":3284,"totalTrials":245,"cells":3514},{"EARLY_PHASE1":3515,"PHASE1":3517,"PHASE2":3519,"PHASE3":3521,"PHASE4":3527,"NA":3529},{"trials":3516,"activeCount":102},[],{"trials":3518,"activeCount":102},[],{"trials":3520,"activeCount":102},[],{"trials":3522,"activeCount":102},[3523],{"nctId":3277,"briefTitle":3278,"status":108,"phases":3524,"primaryCompletion":1791,"start":3280,"enrollment":1330,"conditions":3525,"interventions":3526},[92],[3270,27,18,3271,1497,3282,33],[3284,3255],{"trials":3528,"activeCount":102},[],{"trials":3530,"activeCount":102},[],{"intervention":672,"totalTrials":245,"cells":3532},{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3539,"PHASE4":3545,"NA":3547},{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[],{"trials":3538,"activeCount":102},[],{"trials":3540,"activeCount":102},[3541],{"nctId":663,"briefTitle":664,"status":108,"phases":3542,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":3543,"interventions":3544},[92],[21],[539,507,540,672,318],{"trials":3546,"activeCount":102},[],{"trials":3548,"activeCount":102},[],{"intervention":3550,"totalTrials":245,"cells":3551},"porfimer sodium",{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3558,"PHASE4":3572,"NA":3574},{"trials":3553,"activeCount":102},[],{"trials":3555,"activeCount":102},[],{"trials":3557,"activeCount":102},[],{"trials":3559,"activeCount":102},[3560],{"nctId":3561,"briefTitle":3562,"status":134,"phases":3563,"enrollment":102,"conditions":3564,"interventions":3571},"NCT00253617","Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery",[92],[3565,3566,3567,3568,3569,3570],"Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma of the Gallbladder","Unresectable Extrahepatic Bile Duct Cancer","Unresectable Gallbladder Cancer","Recurrent Extrahepatic Bile Duct Cancer","Recurrent Gallbladder Cancer",[3550],{"trials":3573,"activeCount":102},[],{"trials":3575,"activeCount":102},[],{"intervention":3577,"totalTrials":245,"cells":3578},"Fragmin",{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3583,"PHASE3":3585,"PHASE4":3597,"NA":3599},{"trials":3580,"activeCount":102},[],{"trials":3582,"activeCount":102},[],{"trials":3584,"activeCount":102},[],{"trials":3586,"activeCount":102},[3587],{"nctId":3588,"briefTitle":3589,"status":108,"phases":3590,"primaryCompletion":3591,"completion":3591,"start":1564,"conditions":3592,"interventions":3596},"NCT00006083","Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter",[92],"2000-11",[3593,3594,27,18,1497,1051,3282,33,3595],"Cervical Cancer","Chronic Myeloproliferative Disorders","Veno-occlusive Disease",[3577],{"trials":3598,"activeCount":102},[],{"trials":3600,"activeCount":102},[],{"intervention":3602,"totalTrials":245,"cells":3603},"sargramostim",{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3610,"PHASE4":3624,"NA":3626},{"trials":3605,"activeCount":102},[],{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[3612],{"nctId":3613,"briefTitle":3614,"status":134,"phases":3615,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":102,"conditions":3618,"interventions":3623},"NCT01826864","Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma",[92],"2017-08-08","2011-08-05",[3619,3620,3621,3622],"Stage IB Melanoma","Stage IIA Melanoma","Stage IIB Melanoma","Stage IIC Melanoma",[3602],{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"intervention":767,"totalTrials":245,"cells":3629},{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3636,"PHASE4":3642,"NA":3644},{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"trials":3635,"activeCount":102},[],{"trials":3637,"activeCount":102},[3638],{"nctId":758,"briefTitle":759,"status":108,"phases":3639,"primaryCompletion":744,"completion":761,"start":762,"enrollment":522,"conditions":3640,"interventions":3641},[92],[764,765],[767,695,750],{"trials":3643,"activeCount":102},[],{"trials":3645,"activeCount":102},[],{"intervention":1053,"totalTrials":359,"cells":3647},{"EARLY_PHASE1":3648,"PHASE1":3650,"PHASE2":3664,"PHASE3":3678,"PHASE4":3680,"NA":3682},{"trials":3649,"activeCount":102},[],{"trials":3651,"activeCount":102},[3652,3656,3660],{"nctId":1685,"briefTitle":1686,"status":282,"phases":3653,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":359,"conditions":3654,"interventions":3655},[90],[1691,1692,1693,1694,1650],[1041,1696,1697,1698,1108,1699],{"nctId":1701,"briefTitle":1702,"status":134,"phases":3657,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":102,"conditions":3658,"interventions":3659},[90],[1691,1707,1708,1709],[1041,1697,1698,1711,1712,1699],{"nctId":1047,"briefTitle":1048,"status":134,"phases":3661,"enrollment":102,"conditions":3662,"interventions":3663},[90],[27,18,1051],[1053,659,1054,1013],{"trials":3665,"activeCount":102},[3666,3674],{"nctId":3667,"briefTitle":3668,"status":108,"phases":3669,"primaryCompletion":3670,"start":1547,"enrollment":228,"conditions":3671,"interventions":3672},"NCT00006968","Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer",[90,91],"2004-09",[1734],[1053,1523,3673],"pentostatin",{"nctId":1491,"briefTitle":1492,"status":108,"phases":3675,"completion":998,"start":1494,"conditions":3676,"interventions":3677},[91],[1496,27,18,1497,1498,1499],[1053,1501,659,1502,1503],{"trials":3679,"activeCount":102},[],{"trials":3681,"activeCount":102},[],{"trials":3683,"activeCount":102},[],{"intervention":1134,"totalTrials":359,"cells":3685},{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3705,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3687,"activeCount":102},[],{"trials":3689,"activeCount":102},[3690,3698],{"nctId":3691,"briefTitle":3692,"status":108,"phases":3693,"completion":1612,"start":3694,"conditions":3695,"interventions":3696},"NCT00040950","Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2002-03",[18],[1134,3697],"agatolimod sodium",{"nctId":3699,"briefTitle":3700,"status":282,"phases":3701,"primaryCompletion":3702,"start":1130,"conditions":3703,"interventions":3704},"NCT00060294","Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia",[90],"2004-06",[18],[1134],{"trials":3706,"activeCount":102},[3707,3716,3724],{"nctId":3708,"briefTitle":3709,"status":108,"phases":3710,"primaryCompletion":3711,"completion":1597,"start":3712,"enrollment":1330,"conditions":3713,"interventions":3714},"NCT00003963","Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",[91],"2003-09","1999-05",[18],[1134,3715],"vinorelbine ditartrate",{"nctId":3717,"briefTitle":3718,"status":108,"phases":3719,"primaryCompletion":744,"completion":3720,"start":3721,"enrollment":522,"conditions":3722,"interventions":3723},"NCT00004889","Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia",[91],"2005-07","1999-12",[18],[1134],{"nctId":1127,"briefTitle":1128,"status":108,"phases":3725,"primaryCompletion":1130,"start":1131,"enrollment":638,"conditions":3726,"interventions":3727},[91],[18],[1134,1013],{"trials":3729,"activeCount":102},[],{"trials":3731,"activeCount":102},[],{"trials":3733,"activeCount":102},[],{"intervention":1001,"totalTrials":359,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3746,"PHASE3":3771,"PHASE4":3773,"NA":3775},{"trials":3737,"activeCount":102},[],{"trials":3739,"activeCount":102},[3740],{"nctId":3741,"briefTitle":3742,"status":108,"phases":3743,"completion":666,"start":3280,"conditions":3744,"interventions":3745},"NCT00072072","Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],[24],[641,1001],{"trials":3747,"activeCount":102},[3748,3755,3759,3763],{"nctId":3749,"briefTitle":3750,"status":625,"phases":3751,"start":3720,"conditions":3752,"interventions":3753},"NCT00278187","Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[91],[24],[3754,1001],"volociximab",{"nctId":1622,"briefTitle":1623,"status":108,"phases":3756,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":3757,"interventions":3758},[90,91],[21],[539,1001],{"nctId":994,"briefTitle":995,"status":108,"phases":3760,"primaryCompletion":218,"completion":997,"start":998,"enrollment":245,"conditions":3761,"interventions":3762},[91],[15],[540,1001],{"nctId":3764,"briefTitle":3765,"status":108,"phases":3766,"primaryCompletion":3767,"completion":3767,"start":998,"enrollment":28,"conditions":3768,"interventions":3770},"NCT00088946","Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer",[91],"2006-07",[3769],"Bladder Cancer",[1001],{"trials":3772,"activeCount":102},[],{"trials":3774,"activeCount":102},[],{"trials":3776,"activeCount":102},[],{"intervention":3778,"totalTrials":228,"cells":3779},"bortezomib",{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":102},[],{"trials":3785,"activeCount":102},[3786,3793,3801,3808],{"nctId":3787,"briefTitle":3788,"status":108,"phases":3789,"primaryCompletion":3720,"start":3790,"enrollment":638,"conditions":3791,"interventions":3792},"NCT00066508","Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy",[91],"2003-05",[18],[3778],{"nctId":3794,"briefTitle":3795,"status":108,"phases":3796,"primaryCompletion":3797,"completion":3797,"start":3798,"enrollment":228,"conditions":3799,"interventions":3800},"NCT00276614","Bortezomib in Treating Patients With Metastatic Kidney Cancer",[91],"2009-07","2006-04",[1734],[3778],{"nctId":3802,"briefTitle":3803,"status":108,"phases":3804,"primaryCompletion":3805,"completion":3805,"start":3702,"enrollment":16,"conditions":3806,"interventions":3807},"NCT00084747","Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma",[90,91],"2013-01",[1497],[3778],{"nctId":3809,"briefTitle":3810,"status":108,"phases":3811,"primaryCompletion":3812,"completion":3812,"start":3813,"enrollment":359,"conditions":3814,"interventions":3815},"NCT00182637","Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma",[91],"2010-09","2004-07",[18],[3778],{"trials":3817,"activeCount":102},[],{"trials":3819,"activeCount":102},[],{"trials":3821,"activeCount":102},[],{"intervention":707,"totalTrials":228,"cells":3823},{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3839,"PHASE3":3854,"PHASE4":3856,"NA":3858},{"trials":3825,"activeCount":102},[],{"trials":3827,"activeCount":102},[3828,3832],{"nctId":702,"briefTitle":703,"status":625,"phases":3829,"conditions":3830,"interventions":3831},[90],[33],[695,707,708],{"nctId":3833,"briefTitle":3834,"status":625,"phases":3835,"start":2879,"enrollment":477,"conditions":3836,"interventions":3837},"NCT00324597","AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma",[90],[24,18,3271,33],[707,3838],"motesanib diphosphate",{"trials":3840,"activeCount":102},[3841,3850],{"nctId":3842,"briefTitle":3843,"status":134,"phases":3844,"primaryCompletion":3845,"start":3846,"enrollment":102,"conditions":3847,"interventions":3848},"NCT00020774","SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer",[91],"2003-01","1998-10",[1756],[707,3849],"lonafarnib",{"nctId":732,"briefTitle":733,"status":108,"phases":3851,"primaryCompletion":735,"start":736,"enrollment":245,"conditions":3852,"interventions":3853},[91],[18],[695,739,707],{"trials":3855,"activeCount":102},[],{"trials":3857,"activeCount":102},[],{"trials":3859,"activeCount":102},[],{"intervention":641,"totalTrials":228,"cells":3861},{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3879,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3863,"activeCount":102},[],{"trials":3865,"activeCount":102},[3866,3870],{"nctId":3741,"briefTitle":3742,"status":108,"phases":3867,"completion":666,"start":3280,"conditions":3868,"interventions":3869},[90],[24],[641,1001],{"nctId":3871,"briefTitle":3872,"status":108,"phases":3873,"primaryCompletion":3874,"completion":3875,"start":3876,"enrollment":638,"conditions":3877,"interventions":3878},"NCT00104767","Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],"2014-10","2015-10","2009-01",[24],[641],{"trials":3880,"activeCount":102},[3881,3890],{"nctId":3882,"briefTitle":3883,"status":108,"phases":3884,"primaryCompletion":3885,"completion":3886,"start":3887,"enrollment":25,"conditions":3888,"interventions":3889},"NCT00020878","Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers",[91],"2002-11","2009-05","2001-03",[24],[641],{"nctId":633,"briefTitle":634,"status":108,"phases":3891,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":3892,"interventions":3893},[91],[24],[507,641,565],{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[],{"trials":3899,"activeCount":102},[],{"intervention":2651,"totalTrials":228,"cells":3901},{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3918,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[3906,3910,3914],{"nctId":2766,"briefTitle":2767,"status":282,"phases":3907,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":962,"conditions":3908,"interventions":3909},[90],[2772,1272,2773,2774,596,597,598,600,601,1891,2775,2776,2777,2778,2779,607,608,609,610,612,613,2780],[2651,789,2782],{"nctId":2643,"briefTitle":2644,"status":134,"phases":3911,"primaryCompletion":2496,"completion":2497,"start":2646,"enrollment":102,"conditions":3912,"interventions":3913},[90],[2648],[2650,2651,789,332],{"nctId":2792,"briefTitle":2793,"status":282,"phases":3915,"primaryCompletion":2795,"completion":2795,"start":2796,"enrollment":962,"conditions":3916,"interventions":3917},[90],[126,2798,2799,2800,2801,2802],[2804,2651,789],{"trials":3919,"activeCount":102},[3920],{"nctId":2820,"briefTitle":2821,"status":108,"phases":3921,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":2825,"conditions":3922,"interventions":3923},[91],[2827],[2651,789],{"trials":3925,"activeCount":102},[],{"trials":3927,"activeCount":102},[],{"trials":3929,"activeCount":102},[],{"intervention":1108,"totalTrials":340,"cells":3931},{"EARLY_PHASE1":3932,"PHASE1":3934,"PHASE2":3944,"PHASE3":3950,"PHASE4":3952,"NA":3954},{"trials":3933,"activeCount":102},[],{"trials":3935,"activeCount":102},[3936,3940],{"nctId":1685,"briefTitle":1686,"status":282,"phases":3937,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":359,"conditions":3938,"interventions":3939},[90],[1691,1692,1693,1694,1650],[1041,1696,1697,1698,1108,1699],{"nctId":1459,"briefTitle":1460,"status":134,"phases":3941,"primaryCompletion":1462,"completion":1463,"start":1379,"enrollment":102,"conditions":3942,"interventions":3943},[90],[1465,1466],[1042,1108],{"trials":3945,"activeCount":102},[3946],{"nctId":1091,"briefTitle":1092,"status":282,"phases":3947,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":3948,"interventions":3949},[91],[1098,1099,1100,1064,1101,1067,1102,1070,1103,1073,1104],[1106,1107,1042,1108,1043],{"trials":3951,"activeCount":102},[],{"trials":3953,"activeCount":102},[],{"trials":3955,"activeCount":102},[],{"intervention":3957,"totalTrials":340,"cells":3958},"panitumumab",{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3970,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3960,"activeCount":102},[],{"trials":3962,"activeCount":102},[3963],{"nctId":3964,"briefTitle":3965,"status":108,"phases":3966,"primaryCompletion":3720,"start":1564,"conditions":3967,"interventions":3969},"NCT00004879","Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer",[90],[840,764,1734,24,3968,15],"Pancreatic Cancer",[3957],{"trials":3971,"activeCount":102},[3972,3979],{"nctId":3973,"briefTitle":3974,"status":108,"phases":3975,"primaryCompletion":3790,"start":3976,"enrollment":112,"conditions":3977,"interventions":3978},"NCT00039273","Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer",[91],"2002-07",[840],[3957],{"nctId":3980,"briefTitle":3981,"status":108,"phases":3982,"primaryCompletion":3711,"completion":3983,"start":3885,"conditions":3984,"interventions":3985},"NCT00054574","Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer",[91],"2004-02",[15],[3957],{"trials":3987,"activeCount":102},[],{"trials":3989,"activeCount":102},[],{"trials":3991,"activeCount":102},[],{"intervention":982,"totalTrials":340,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":4002,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":3995,"activeCount":102},[],{"trials":3997,"activeCount":102},[3998],{"nctId":973,"briefTitle":974,"status":134,"phases":3999,"primaryCompletion":976,"completion":977,"start":978,"enrollment":102,"conditions":4000,"interventions":4001},[90],[980,354],[982,318],{"trials":4003,"activeCount":102},[4004,4017],{"nctId":4005,"briefTitle":4006,"status":134,"phases":4007,"primaryCompletion":4008,"completion":4009,"start":4010,"enrollment":102,"conditions":4011,"interventions":4014},"NCT02263898","Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations",[91],"2019-12","2020-12","2015-01",[4012,4013],"Recurrent Melanoma","Stage IV Melanoma",[4015,4016],"Raf kinase inhibitor LGX818","binimetinib",{"nctId":2843,"briefTitle":2844,"status":282,"phases":4018,"primaryCompletion":2846,"completion":2846,"start":2847,"enrollment":340,"conditions":4019,"interventions":4020},[91],[2849,2850,2851,2852,2853,2854,2855,2856,2857,2858,2859],[982,789],{"trials":4022,"activeCount":102},[],{"trials":4024,"activeCount":102},[],{"trials":4026,"activeCount":102},[],{"intervention":4028,"totalTrials":340,"cells":4029},"Gallium Ga 68-labeled PSMA-11",{"EARLY_PHASE1":4030,"PHASE1":4040,"PHASE2":4042,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4031,"activeCount":102},[4032],{"nctId":4033,"briefTitle":4034,"status":108,"phases":4035,"primaryCompletion":4036,"completion":4036,"start":4037,"enrollment":1330,"conditions":4038,"interventions":4039},"NCT04282824","Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer",[89],"2020-05-06","2019-06-05",[943],[4028],{"trials":4041,"activeCount":102},[],{"trials":4043,"activeCount":102},[4044,4055],{"nctId":4045,"briefTitle":4046,"status":108,"phases":4047,"primaryCompletion":4048,"completion":4048,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4054},"NCT04050215","68GA-PSMA-11 PET\u002FCT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer",[91],"2021-09-27","2018-04-02",937,[4052,1333,35,943,4053,1967,310,2531,953],"Biochemically Recurrent Prostate Carcinoma","PSA Level Greater Than Fifty",[4028],{"nctId":4056,"briefTitle":4057,"status":108,"phases":4058,"primaryCompletion":4059,"completion":4059,"start":1938,"enrollment":172,"conditions":4060,"interventions":4061},"NCT03515577","Gallium Ga 68-labeled PSMA-11 PET\u002FCT and Fluciclovine F18 PET\u002FCT in Imaging Participants With Recurrent Prostate Cancer After Surgery",[91],"2019-04-25",[1334],[4062,4028],"Fluciclovine F18",{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[],{"trials":4068,"activeCount":102},[],{"intervention":1601,"totalTrials":231,"cells":4070},{"EARLY_PHASE1":4071,"PHASE1":4073,"PHASE2":4079,"PHASE3":4085,"PHASE4":4087,"NA":4089},{"trials":4072,"activeCount":102},[],{"trials":4074,"activeCount":102},[4075],{"nctId":1593,"briefTitle":1594,"status":108,"phases":4076,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":496,"conditions":4077,"interventions":4078},[90],[21],[539,1601],{"trials":4080,"activeCount":102},[4081],{"nctId":2892,"briefTitle":2893,"status":108,"phases":4082,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":484,"conditions":4083,"interventions":4084},[90,91],[2898,2899,2900,2901,1901],[1601,2903,2868],{"trials":4086,"activeCount":102},[],{"trials":4088,"activeCount":102},[],{"trials":4090,"activeCount":102},[],{"intervention":1933,"totalTrials":231,"cells":4092},{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4101,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4094,"activeCount":102},[],{"trials":4096,"activeCount":102},[4097],{"nctId":1925,"briefTitle":1926,"status":282,"phases":4098,"primaryCompletion":1928,"completion":1928,"start":1929,"enrollment":496,"conditions":4099,"interventions":4100},[90],[1931],[1933,1918],{"trials":4102,"activeCount":102},[4103],{"nctId":4104,"briefTitle":4105,"status":625,"phases":4106,"start":1131,"conditions":4107,"interventions":4108},"NCT00022321","Gemtuzumab in Treating Patients With Myelodysplastic Syndrome",[91],[1051],[4109],"gemtuzumab ozogamicin",{"trials":4111,"activeCount":102},[],{"trials":4113,"activeCount":102},[],{"trials":4115,"activeCount":102},[],{"intervention":730,"totalTrials":231,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4119,"activeCount":102},[],{"trials":4121,"activeCount":102},[],{"trials":4123,"activeCount":102},[4124,4128],{"nctId":720,"briefTitle":721,"status":282,"phases":4125,"primaryCompletion":723,"completion":723,"start":724,"enrollment":245,"conditions":4126,"interventions":4127},[91],[463,726,727,469,728],[730,317],{"nctId":741,"briefTitle":742,"status":108,"phases":4129,"primaryCompletion":744,"start":745,"conditions":4130,"interventions":4131},[91],[747],[749,695,750,565],{"trials":4133,"activeCount":102},[],{"trials":4135,"activeCount":102},[],{"trials":4137,"activeCount":102},[],{"intervention":1810,"totalTrials":231,"cells":4139},{"EARLY_PHASE1":4140,"PHASE1":4142,"PHASE2":4144,"PHASE3":4160,"PHASE4":4162,"NA":4164},{"trials":4141,"activeCount":102},[],{"trials":4143,"activeCount":102},[],{"trials":4145,"activeCount":102},[4146,4150],{"nctId":1805,"briefTitle":1806,"status":625,"phases":4147,"start":735,"conditions":4148,"interventions":4149},[91],[27],[1346,1810],{"nctId":4151,"briefTitle":4152,"status":108,"phases":4153,"completion":4154,"start":627,"conditions":4155,"interventions":4156},"NCT00015860","STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia",[90,91],"2003-10",[27],[4157,1810,4158,4159],"daunorubicin hydrochloride","prednisone","vincristine sulfate",{"trials":4161,"activeCount":102},[],{"trials":4163,"activeCount":102},[],{"trials":4165,"activeCount":102},[],{"intervention":4167,"totalTrials":231,"cells":4168},"temsirolimus",{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4188,"PHASE4":4190,"NA":4192},{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[],{"trials":4174,"activeCount":102},[4175,4182],{"nctId":4176,"briefTitle":4177,"status":108,"phases":4178,"primaryCompletion":4179,"start":3280,"enrollment":268,"conditions":4180,"interventions":4181},"NCT00071968","Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse",[91],"2006-05",[15],[4167],{"nctId":4183,"briefTitle":4184,"status":108,"phases":4185,"completion":1598,"start":1547,"conditions":4186,"interventions":4187},"NCT00012142","CCI-779 in Treating Patients With Prostate Cancer",[91],[15],[4167],{"trials":4189,"activeCount":102},[],{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[],{"intervention":140,"totalTrials":231,"cells":4195},{"EARLY_PHASE1":4196,"PHASE1":4198,"PHASE2":4200,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4197,"activeCount":102},[],{"trials":4199,"activeCount":102},[],{"trials":4201,"activeCount":102},[4202,4206],{"nctId":132,"briefTitle":133,"status":134,"phases":4203,"primaryCompletion":136,"start":137,"enrollment":102,"conditions":4204,"interventions":4205},[91],[30],[97,140,141,142,143],{"nctId":167,"briefTitle":168,"status":108,"phases":4207,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":4208,"interventions":4209},[91],[174,175,176],[178,97,141,140],{"trials":4211,"activeCount":102},[],{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"intervention":141,"totalTrials":231,"cells":4217},{"EARLY_PHASE1":4218,"PHASE1":4220,"PHASE2":4222,"PHASE3":4232,"PHASE4":4234,"NA":4236},{"trials":4219,"activeCount":102},[],{"trials":4221,"activeCount":102},[],{"trials":4223,"activeCount":102},[4224,4228],{"nctId":132,"briefTitle":133,"status":134,"phases":4225,"primaryCompletion":136,"start":137,"enrollment":102,"conditions":4226,"interventions":4227},[91],[30],[97,140,141,142,143],{"nctId":167,"briefTitle":168,"status":108,"phases":4229,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":4230,"interventions":4231},[91],[174,175,176],[178,97,141,140],{"trials":4233,"activeCount":102},[],{"trials":4235,"activeCount":102},[],{"trials":4237,"activeCount":102},[],{"intervention":4239,"totalTrials":231,"cells":4240},"dendritic cell-MART-1 peptide vaccine",{"EARLY_PHASE1":4241,"PHASE1":4243,"PHASE2":4253,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[4245],{"nctId":4246,"briefTitle":4247,"status":108,"phases":4248,"primaryCompletion":4249,"start":3319,"conditions":4250,"interventions":4252},"NCT00005617","Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma",[90],"2002-06",[4251],"Melanoma",[4239],{"trials":4254,"activeCount":102},[4255],{"nctId":4256,"briefTitle":4257,"status":108,"phases":4258,"primaryCompletion":1731,"completion":4259,"start":3694,"enrollment":782,"conditions":4260,"interventions":4262},"NCT00039325","Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma",[90,91],"2009-06",[4261],"Melanoma (Skin)",[4239],{"trials":4264,"activeCount":102},[],{"trials":4266,"activeCount":102},[],{"trials":4268,"activeCount":102},[],{"intervention":4270,"totalTrials":231,"cells":4271},"rosiglitazone maleate",{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4292,"PHASE4":4294,"NA":4296},{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[],{"trials":4277,"activeCount":102},[4278,4286],{"nctId":4279,"briefTitle":4280,"status":282,"phases":4281,"primaryCompletion":4282,"completion":4282,"start":3267,"enrollment":231,"conditions":4283,"interventions":4285},"NCT00612066","Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)",[91],"2010-11",[4284],"Cushing's Disease",[4270],{"nctId":4287,"briefTitle":4288,"status":282,"phases":4289,"primaryCompletion":4282,"completion":4282,"start":1790,"enrollment":245,"conditions":4290,"interventions":4291},"NCT00616642","Rosiglitazone in Treating Patients With Pituitary Tumors",[91],[30],[4270],{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[],{"intervention":4299,"totalTrials":231,"cells":4300},"monoclonal antibody HuHMFG1",{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4312,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4302,"activeCount":102},[],{"trials":4304,"activeCount":102},[4305],{"nctId":4306,"briefTitle":4307,"status":108,"phases":4308,"completion":4309,"start":998,"enrollment":19,"conditions":4310,"interventions":4311},"NCT00096057","Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer",[90],"2007-12",[21],[4299],{"trials":4313,"activeCount":102},[4314],{"nctId":4315,"briefTitle":4316,"status":625,"phases":4317,"start":3790,"conditions":4318,"interventions":4319},"NCT00066547","Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy",[90,91],[21],[4299],{"trials":4321,"activeCount":102},[],{"trials":4323,"activeCount":102},[],{"trials":4325,"activeCount":102},[],{"intervention":1054,"totalTrials":231,"cells":4327},{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4336,"PHASE3":4342,"PHASE4":4344,"NA":4346},{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[4332],{"nctId":1047,"briefTitle":1048,"status":134,"phases":4333,"enrollment":102,"conditions":4334,"interventions":4335},[90],[27,18,1051],[1053,659,1054,1013],{"trials":4337,"activeCount":102},[4338],{"nctId":1117,"briefTitle":1118,"status":134,"phases":4339,"enrollment":102,"conditions":4340,"interventions":4341},[91],[1114,27],[1122,1054,1013,1123,1124,1125],{"trials":4343,"activeCount":102},[],{"trials":4345,"activeCount":102},[],{"trials":4347,"activeCount":102},[],{"intervention":4349,"totalTrials":231,"cells":4350},"Ifosfamide",{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4352,"activeCount":102},[],{"trials":4354,"activeCount":102},[],{"trials":4356,"activeCount":102},[4357,4365],{"nctId":4358,"briefTitle":4359,"status":282,"phases":4360,"primaryCompletion":4282,"start":4361,"enrollment":638,"conditions":4362,"interventions":4363},"NCT00880542","Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery",[91],"2008-08",[1650],[4364,4349],"sorafenib",{"nctId":1491,"briefTitle":1492,"status":108,"phases":4366,"completion":998,"start":1494,"conditions":4367,"interventions":4368},[91],[1496,27,18,1497,1498,1499],[1053,1501,659,1502,1503],{"trials":4370,"activeCount":102},[],{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":102},[],{"intervention":4376,"totalTrials":245,"cells":4377},"infliximab",{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4379,"activeCount":102},[],{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[4384],{"nctId":4385,"briefTitle":4386,"status":282,"phases":4387,"primaryCompletion":1613,"completion":4388,"start":1597,"enrollment":638,"conditions":4389,"interventions":4390},"NCT00112749","Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer",[91],"2012-11",[21,3293],[4376],{"trials":4392,"activeCount":102},[],{"trials":4394,"activeCount":102},[],{"trials":4396,"activeCount":102},[],{"intervention":4398,"totalTrials":245,"cells":4399},"Dichloroacetate",{"EARLY_PHASE1":4400,"PHASE1":4402,"PHASE2":4404,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4401,"activeCount":102},[],{"trials":4403,"activeCount":102},[],{"trials":4405,"activeCount":102},[4406],{"nctId":4407,"briefTitle":4408,"status":282,"phases":4409,"primaryCompletion":4410,"completion":4411,"start":137,"enrollment":638,"conditions":4412,"interventions":4414},"NCT01029925","Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)",[91],"2011-08","2011-11",[4413,24],"Metastatic Breast Cancer",[4398],{"trials":4416,"activeCount":102},[],{"trials":4418,"activeCount":102},[],{"trials":4420,"activeCount":102},[],{"intervention":2818,"totalTrials":245,"cells":4422},{"EARLY_PHASE1":4423,"PHASE1":4425,"PHASE2":4427,"PHASE3":4433,"PHASE4":4435,"NA":4437},{"trials":4424,"activeCount":102},[],{"trials":4426,"activeCount":102},[],{"trials":4428,"activeCount":102},[4429],{"nctId":2808,"briefTitle":2809,"status":134,"phases":4430,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":102,"conditions":4431,"interventions":4432},[91],[174,176,2815,329,2816],[2818,789],{"trials":4434,"activeCount":102},[],{"trials":4436,"activeCount":102},[],{"trials":4438,"activeCount":102},[],{"intervention":4440,"totalTrials":245,"cells":4441},"gimatecan",{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4446,"PHASE3":4454,"PHASE4":4456,"NA":4458},{"trials":4443,"activeCount":102},[],{"trials":4445,"activeCount":102},[],{"trials":4447,"activeCount":102},[4448],{"nctId":4449,"briefTitle":4450,"status":108,"phases":4451,"completion":3506,"start":998,"conditions":4452,"interventions":4453},"NCT00087061","Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma",[90,91],[30],[4440],{"trials":4455,"activeCount":102},[],{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[],{"intervention":4157,"totalTrials":245,"cells":4461},{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4463,"activeCount":102},[],{"trials":4465,"activeCount":102},[],{"trials":4467,"activeCount":102},[4468],{"nctId":4151,"briefTitle":4152,"status":108,"phases":4469,"completion":4154,"start":627,"conditions":4470,"interventions":4471},[90,91],[27],[4157,1810,4158,4159],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[],{"trials":4477,"activeCount":102},[],{"intervention":4158,"totalTrials":245,"cells":4479},{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4484,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4481,"activeCount":102},[],{"trials":4483,"activeCount":102},[],{"trials":4485,"activeCount":102},[4486],{"nctId":4151,"briefTitle":4152,"status":108,"phases":4487,"completion":4154,"start":627,"conditions":4488,"interventions":4489},[90,91],[27],[4157,1810,4158,4159],{"trials":4491,"activeCount":102},[],{"trials":4493,"activeCount":102},[],{"trials":4495,"activeCount":102},[],{"intervention":4159,"totalTrials":245,"cells":4497},{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[],{"trials":4503,"activeCount":102},[4504],{"nctId":4151,"briefTitle":4152,"status":108,"phases":4505,"completion":4154,"start":627,"conditions":4506,"interventions":4507},[90,91],[27],[4157,1810,4158,4159],{"trials":4509,"activeCount":102},[],{"trials":4511,"activeCount":102},[],{"trials":4513,"activeCount":102},[],{"intervention":4015,"totalTrials":245,"cells":4515},{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4517,"activeCount":102},[],{"trials":4519,"activeCount":102},[],{"trials":4521,"activeCount":102},[4522],{"nctId":4005,"briefTitle":4006,"status":134,"phases":4523,"primaryCompletion":4008,"completion":4009,"start":4010,"enrollment":102,"conditions":4524,"interventions":4525},[91],[4012,4013],[4015,4016],{"trials":4527,"activeCount":102},[],{"trials":4529,"activeCount":102},[],{"trials":4531,"activeCount":102},[],{"intervention":142,"totalTrials":245,"cells":4533},{"EARLY_PHASE1":4534,"PHASE1":4536,"PHASE2":4538,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4535,"activeCount":102},[],{"trials":4537,"activeCount":102},[],{"trials":4539,"activeCount":102},[4540],{"nctId":132,"briefTitle":133,"status":134,"phases":4541,"primaryCompletion":136,"start":137,"enrollment":102,"conditions":4542,"interventions":4543},[91],[30],[97,140,141,142,143],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[],{"trials":4549,"activeCount":102},[],{"intervention":143,"totalTrials":245,"cells":4551},{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4556,"PHASE3":4562,"PHASE4":4564,"NA":4566},{"trials":4553,"activeCount":102},[],{"trials":4555,"activeCount":102},[],{"trials":4557,"activeCount":102},[4558],{"nctId":132,"briefTitle":133,"status":134,"phases":4559,"primaryCompletion":136,"start":137,"enrollment":102,"conditions":4560,"interventions":4561},[91],[30],[97,140,141,142,143],{"trials":4563,"activeCount":102},[],{"trials":4565,"activeCount":102},[],{"trials":4567,"activeCount":102},[],{"intervention":3715,"totalTrials":245,"cells":4569},{"EARLY_PHASE1":4570,"PHASE1":4572,"PHASE2":4574,"PHASE3":4580,"PHASE4":4582,"NA":4584},{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[],{"trials":4575,"activeCount":102},[4576],{"nctId":3708,"briefTitle":3709,"status":108,"phases":4577,"primaryCompletion":3711,"completion":1597,"start":3712,"enrollment":1330,"conditions":4578,"interventions":4579},[91],[18],[1134,3715],{"trials":4581,"activeCount":102},[],{"trials":4583,"activeCount":102},[],{"trials":4585,"activeCount":102},[],{"intervention":4587,"totalTrials":245,"cells":4588},"alpha fetoprotein adenoviral vector vaccine",{"EARLY_PHASE1":4589,"PHASE1":4591,"PHASE2":4593,"PHASE3":4603,"PHASE4":4605,"NA":4607},{"trials":4590,"activeCount":102},[],{"trials":4592,"activeCount":102},[],{"trials":4594,"activeCount":102},[4595],{"nctId":4596,"briefTitle":4597,"status":134,"phases":4598,"enrollment":102,"conditions":4599,"interventions":4600},"NCT00093548","Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer",[90,91],[1756],[4587,4601,4602],"alpha fetoprotein plasmid DNA vaccine","sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant",{"trials":4604,"activeCount":102},[],{"trials":4606,"activeCount":102},[],{"trials":4608,"activeCount":102},[],{"intervention":4601,"totalTrials":245,"cells":4610},{"EARLY_PHASE1":4611,"PHASE1":4613,"PHASE2":4615,"PHASE3":4621,"PHASE4":4623,"NA":4625},{"trials":4612,"activeCount":102},[],{"trials":4614,"activeCount":102},[],{"trials":4616,"activeCount":102},[4617],{"nctId":4596,"briefTitle":4597,"status":134,"phases":4618,"enrollment":102,"conditions":4619,"interventions":4620},[90,91],[1756],[4587,4601,4602],{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"trials":4626,"activeCount":102},[],{"intervention":4602,"totalTrials":245,"cells":4628},{"EARLY_PHASE1":4629,"PHASE1":4631,"PHASE2":4633,"PHASE3":4639,"PHASE4":4641,"NA":4643},{"trials":4630,"activeCount":102},[],{"trials":4632,"activeCount":102},[],{"trials":4634,"activeCount":102},[4635],{"nctId":4596,"briefTitle":4597,"status":134,"phases":4636,"enrollment":102,"conditions":4637,"interventions":4638},[90,91],[1756],[4587,4601,4602],{"trials":4640,"activeCount":102},[],{"trials":4642,"activeCount":102},[],{"trials":4644,"activeCount":102},[],{"intervention":3754,"totalTrials":245,"cells":4646},{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4651,"PHASE3":4657,"PHASE4":4659,"NA":4661},{"trials":4648,"activeCount":102},[],{"trials":4650,"activeCount":102},[],{"trials":4652,"activeCount":102},[4653],{"nctId":3749,"briefTitle":3750,"status":625,"phases":4654,"start":3720,"conditions":4655,"interventions":4656},[91],[24],[3754,1001],{"trials":4658,"activeCount":102},[],{"trials":4660,"activeCount":102},[],{"trials":4662,"activeCount":102},[],{"intervention":4664,"totalTrials":245,"cells":4665},"autologous tumor lysate-pulsed DC vaccination",{"EARLY_PHASE1":4666,"PHASE1":4668,"PHASE2":4670,"PHASE3":4685,"PHASE4":4687,"NA":4689},{"trials":4667,"activeCount":102},[],{"trials":4669,"activeCount":102},[],{"trials":4671,"activeCount":102},[4672],{"nctId":4673,"briefTitle":4674,"status":108,"phases":4675,"primaryCompletion":4676,"completion":4676,"start":4677,"enrollment":19,"conditions":4678,"interventions":4682},"NCT01204684","Dendritic Cell Vaccine for Patients With Brain Tumors",[91],"2024-08-21","2010-10-08",[4679,4680,4681,175],"Glioma","Anaplastic Astrocytoma","Anaplastic Astro-oligodendroglioma",[4664,4683,4684],"Tumor lysate-pulsed DC vaccination+0.2% resiquimod","Tumor-lysate pulsed DC vaccination +adjuvant polyICLC",{"trials":4686,"activeCount":102},[],{"trials":4688,"activeCount":102},[],{"trials":4690,"activeCount":102},[],{"intervention":4683,"totalTrials":245,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4697,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":102},[],{"trials":4698,"activeCount":102},[4699],{"nctId":4673,"briefTitle":4674,"status":108,"phases":4700,"primaryCompletion":4676,"completion":4676,"start":4677,"enrollment":19,"conditions":4701,"interventions":4702},[91],[4679,4680,4681,175],[4664,4683,4684],{"trials":4704,"activeCount":102},[],{"trials":4706,"activeCount":102},[],{"trials":4708,"activeCount":102},[],{"intervention":4684,"totalTrials":245,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4712,"activeCount":102},[],{"trials":4714,"activeCount":102},[],{"trials":4716,"activeCount":102},[4717],{"nctId":4673,"briefTitle":4674,"status":108,"phases":4718,"primaryCompletion":4676,"completion":4676,"start":4677,"enrollment":19,"conditions":4719,"interventions":4720},[91],[4679,4680,4681,175],[4664,4683,4684],{"trials":4722,"activeCount":102},[],{"trials":4724,"activeCount":102},[],{"trials":4726,"activeCount":102},[],{"intervention":2903,"totalTrials":245,"cells":4728},{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4730,"activeCount":102},[],{"trials":4732,"activeCount":102},[],{"trials":4734,"activeCount":102},[4735],{"nctId":2892,"briefTitle":2893,"status":108,"phases":4736,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":484,"conditions":4737,"interventions":4738},[90,91],[2898,2899,2900,2901,1901],[1601,2903,2868],{"trials":4740,"activeCount":102},[],{"trials":4742,"activeCount":102},[],{"trials":4744,"activeCount":102},[],{"intervention":4746,"totalTrials":245,"cells":4747},"alemtuzumab",{"EARLY_PHASE1":4748,"PHASE1":4750,"PHASE2":4752,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4749,"activeCount":102},[],{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[4754],{"nctId":4755,"briefTitle":4756,"status":134,"phases":4757,"start":4758,"enrollment":102,"conditions":4759,"interventions":4760},"NCT00081068","Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia",[91],"2004-01",[18],[4746],{"trials":4762,"activeCount":102},[],{"trials":4764,"activeCount":102},[],{"trials":4766,"activeCount":102},[],{"intervention":4768,"totalTrials":245,"cells":4769},"sorafenib tosylate",{"EARLY_PHASE1":4770,"PHASE1":4772,"PHASE2":4774,"PHASE3":4789,"PHASE4":4791,"NA":4793},{"trials":4771,"activeCount":102},[],{"trials":4773,"activeCount":102},[],{"trials":4775,"activeCount":102},[4776],{"nctId":4777,"briefTitle":4778,"status":108,"phases":4779,"primaryCompletion":4780,"completion":4780,"start":4781,"enrollment":4782,"conditions":4783,"interventions":4788},"NCT01624285","Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer",[91],"2023-02","2012-07-16",20,[4784,4785,4786,4787],"Adult Primary Hepatocellular Carcinoma","Localized Resectable Adult Primary Liver Cancer","Localized Unresectable Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer",[4768],{"trials":4790,"activeCount":102},[],{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[],{"intervention":4062,"totalTrials":245,"cells":4796},{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4801,"PHASE3":4807,"PHASE4":4809,"NA":4811},{"trials":4798,"activeCount":102},[],{"trials":4800,"activeCount":102},[],{"trials":4802,"activeCount":102},[4803],{"nctId":4056,"briefTitle":4057,"status":108,"phases":4804,"primaryCompletion":4059,"completion":4059,"start":1938,"enrollment":172,"conditions":4805,"interventions":4806},[91],[1334],[4062,4028],{"trials":4808,"activeCount":102},[],{"trials":4810,"activeCount":102},[],{"trials":4812,"activeCount":102},[],{"intervention":3849,"totalTrials":245,"cells":4814},{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4825,"PHASE4":4827,"NA":4829},{"trials":4816,"activeCount":102},[],{"trials":4818,"activeCount":102},[],{"trials":4820,"activeCount":102},[4821],{"nctId":3842,"briefTitle":3843,"status":134,"phases":4822,"primaryCompletion":3845,"start":3846,"enrollment":102,"conditions":4823,"interventions":4824},[91],[1756],[707,3849],{"trials":4826,"activeCount":102},[],{"trials":4828,"activeCount":102},[],{"trials":4830,"activeCount":102},[],{"intervention":4832,"totalTrials":245,"cells":4833},"danusertib",{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4847,"PHASE4":4849,"NA":4851},{"trials":4835,"activeCount":102},[],{"trials":4837,"activeCount":102},[],{"trials":4839,"activeCount":102},[4840],{"nctId":4841,"briefTitle":4842,"status":625,"phases":4843,"primaryCompletion":137,"start":4844,"enrollment":31,"conditions":4845,"interventions":4846},"NCT00335868","PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy",[91],"2007-03",[27],[4832],{"trials":4848,"activeCount":102},[],{"trials":4850,"activeCount":102},[],{"trials":4852,"activeCount":102},[],{"intervention":3673,"totalTrials":245,"cells":4854},{"EARLY_PHASE1":4855,"PHASE1":4857,"PHASE2":4859,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4856,"activeCount":102},[],{"trials":4858,"activeCount":102},[],{"trials":4860,"activeCount":102},[4861],{"nctId":3667,"briefTitle":3668,"status":108,"phases":4862,"primaryCompletion":3670,"start":1547,"enrollment":228,"conditions":4863,"interventions":4864},[90,91],[1734],[1053,1523,3673],{"trials":4866,"activeCount":102},[],{"trials":4868,"activeCount":102},[],{"trials":4870,"activeCount":102},[],{"intervention":4872,"totalTrials":245,"cells":4873},"CP-675,206",{"EARLY_PHASE1":4874,"PHASE1":4876,"PHASE2":4878,"PHASE3":4888,"PHASE4":4890,"NA":4892},{"trials":4875,"activeCount":102},[],{"trials":4877,"activeCount":102},[],{"trials":4879,"activeCount":102},[4880],{"nctId":4881,"briefTitle":4882,"status":108,"phases":4883,"primaryCompletion":4884,"completion":4885,"start":1613,"enrollment":1257,"conditions":4886,"interventions":4887},"NCT00471887","Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",[91],"2011-07","2015-03",[4261],[4872],{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[],{"trials":4893,"activeCount":102},[],{"intervention":4895,"totalTrials":245,"cells":4896},"methoxy polyethylene glycol epoetin beta",{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4909,"PHASE4":4911,"NA":4913},{"trials":4898,"activeCount":102},[],{"trials":4900,"activeCount":102},[],{"trials":4902,"activeCount":102},[4903],{"nctId":4904,"briefTitle":4905,"status":108,"phases":4906,"completion":1597,"start":535,"conditions":4907,"interventions":4908},"NCT00072059","Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],[3270,24],[4895],{"trials":4910,"activeCount":102},[],{"trials":4912,"activeCount":102},[],{"trials":4914,"activeCount":102},[],{"intervention":4916,"totalTrials":245,"cells":4917},"Rapamycin",{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4922,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4919,"activeCount":102},[],{"trials":4921,"activeCount":102},[],{"trials":4923,"activeCount":102},[4924],{"nctId":4925,"briefTitle":4926,"status":108,"phases":4927,"primaryCompletion":3506,"completion":1612,"start":3976,"enrollment":496,"conditions":4928,"interventions":4929},"NCT00047073","Sirolimus in Treating Patients With Glioblastoma Multiforme",[90,91],[30],[4916],{"trials":4931,"activeCount":102},[],{"trials":4933,"activeCount":102},[],{"trials":4935,"activeCount":102},[],{"intervention":587,"totalTrials":245,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4948,"PHASE4":4950,"NA":4952},{"trials":4939,"activeCount":102},[],{"trials":4941,"activeCount":102},[],{"trials":4943,"activeCount":102},[4944],{"nctId":576,"briefTitle":577,"status":134,"phases":4945,"primaryCompletion":579,"completion":580,"start":581,"enrollment":102,"conditions":4946,"interventions":4947},[90,91],[583,584,585,361,362,363],[587,72],{"trials":4949,"activeCount":102},[],{"trials":4951,"activeCount":102},[],{"trials":4953,"activeCount":102},[],{"intervention":1106,"totalTrials":245,"cells":4955},{"EARLY_PHASE1":4956,"PHASE1":4958,"PHASE2":4960,"PHASE3":4966,"PHASE4":4968,"NA":4970},{"trials":4957,"activeCount":102},[],{"trials":4959,"activeCount":102},[],{"trials":4961,"activeCount":102},[4962],{"nctId":1091,"briefTitle":1092,"status":282,"phases":4963,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":4964,"interventions":4965},[91],[1098,1099,1100,1064,1101,1067,1102,1070,1103,1073,1104],[1106,1107,1042,1108,1043],{"trials":4967,"activeCount":102},[],{"trials":4969,"activeCount":102},[],{"trials":4971,"activeCount":102},[],{"intervention":1107,"totalTrials":245,"cells":4973},{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4978,"PHASE3":4984,"PHASE4":4986,"NA":4988},{"trials":4975,"activeCount":102},[],{"trials":4977,"activeCount":102},[],{"trials":4979,"activeCount":102},[4980],{"nctId":1091,"briefTitle":1092,"status":282,"phases":4981,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":4982,"interventions":4983},[91],[1098,1099,1100,1064,1101,1067,1102,1070,1103,1073,1104],[1106,1107,1042,1108,1043],{"trials":4985,"activeCount":102},[],{"trials":4987,"activeCount":102},[],{"trials":4989,"activeCount":102},[],{"intervention":739,"totalTrials":245,"cells":4991},{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":5002,"PHASE4":5004,"NA":5006},{"trials":4993,"activeCount":102},[],{"trials":4995,"activeCount":102},[],{"trials":4997,"activeCount":102},[4998],{"nctId":732,"briefTitle":733,"status":108,"phases":4999,"primaryCompletion":735,"start":736,"enrollment":245,"conditions":5000,"interventions":5001},[91],[18],[695,739,707],{"trials":5003,"activeCount":102},[],{"trials":5005,"activeCount":102},[],{"trials":5007,"activeCount":102},[],{"intervention":5009,"totalTrials":245,"cells":5010},"denileukin diftitox",{"EARLY_PHASE1":5011,"PHASE1":5013,"PHASE2":5015,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5012,"activeCount":102},[],{"trials":5014,"activeCount":102},[],{"trials":5016,"activeCount":102},[5017],{"nctId":5018,"briefTitle":5019,"status":108,"phases":5020,"primaryCompletion":1648,"completion":5021,"start":1596,"enrollment":172,"conditions":5022,"interventions":5023},"NCT00138164","Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[91],"2008-11",[18],[5009],{"trials":5025,"activeCount":102},[],{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":102},[],{"intervention":1550,"totalTrials":245,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5033,"activeCount":102},[],{"trials":5035,"activeCount":102},[],{"trials":5037,"activeCount":102},[5038],{"nctId":1544,"briefTitle":1545,"status":108,"phases":5039,"completion":1547,"conditions":5040,"interventions":5041},[90,91],[33],[565,1550],{"trials":5043,"activeCount":102},[],{"trials":5045,"activeCount":102},[],{"trials":5047,"activeCount":102},[],{"intervention":5049,"totalTrials":245,"cells":5050},"Amifostine",{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5065,"PHASE4":5067,"NA":5069},{"trials":5052,"activeCount":102},[],{"trials":5054,"activeCount":102},[],{"trials":5056,"activeCount":102},[5057],{"nctId":5058,"briefTitle":5059,"status":108,"phases":5060,"primaryCompletion":838,"start":5061,"enrollment":4782,"conditions":5062,"interventions":5063},"NCT00003143","Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation",[91],"1997-11",[18],[5049,5064],"DHAP",{"trials":5066,"activeCount":102},[],{"trials":5068,"activeCount":102},[],{"trials":5070,"activeCount":102},[],{"intervention":5064,"totalTrials":245,"cells":5072},{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5083,"PHASE4":5085,"NA":5087},{"trials":5074,"activeCount":102},[],{"trials":5076,"activeCount":102},[],{"trials":5078,"activeCount":102},[5079],{"nctId":5058,"briefTitle":5059,"status":108,"phases":5080,"primaryCompletion":838,"start":5061,"enrollment":4782,"conditions":5081,"interventions":5082},[91],[18],[5049,5064],{"trials":5084,"activeCount":102},[],{"trials":5086,"activeCount":102},[],{"trials":5088,"activeCount":102},[],{"intervention":5090,"totalTrials":245,"cells":5091},"gefitinib",{"EARLY_PHASE1":5092,"PHASE1":5094,"PHASE2":5096,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5093,"activeCount":102},[],{"trials":5095,"activeCount":102},[],{"trials":5097,"activeCount":102},[5098],{"nctId":5099,"briefTitle":5100,"status":134,"phases":5101,"start":5102,"enrollment":102,"conditions":5103,"interventions":5104},"NCT00098462","Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90,91],"2004-10",[24],[5090,5105],"sirolimus",{"trials":5107,"activeCount":102},[],{"trials":5109,"activeCount":102},[],{"trials":5111,"activeCount":102},[],{"intervention":5105,"totalTrials":245,"cells":5113},{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5118,"PHASE3":5124,"PHASE4":5126,"NA":5128},{"trials":5115,"activeCount":102},[],{"trials":5117,"activeCount":102},[],{"trials":5119,"activeCount":102},[5120],{"nctId":5099,"briefTitle":5100,"status":134,"phases":5121,"start":5102,"enrollment":102,"conditions":5122,"interventions":5123},[90,91],[24],[5090,5105],{"trials":5125,"activeCount":102},[],{"trials":5127,"activeCount":102},[],{"trials":5129,"activeCount":102},[],{"intervention":5131,"totalTrials":245,"cells":5132},"F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells",{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5137,"PHASE3":5148,"PHASE4":5150,"NA":5152},{"trials":5134,"activeCount":102},[],{"trials":5136,"activeCount":102},[],{"trials":5138,"activeCount":102},[5139],{"nctId":5140,"briefTitle":5141,"status":108,"phases":5142,"primaryCompletion":5143,"completion":5143,"start":5144,"enrollment":1330,"conditions":5145,"interventions":5146},"NCT00910650","Study of Gene Modified Immune Cells in Patients With Advanced Melanoma",[91],"2019-05-30","2009-10-13",[126],[5131,5147],"non-myeloablative conditioning chemotherapy",{"trials":5149,"activeCount":102},[],{"trials":5151,"activeCount":102},[],{"trials":5153,"activeCount":102},[],{"intervention":5147,"totalTrials":245,"cells":5155},{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5160,"PHASE3":5166,"PHASE4":5168,"NA":5170},{"trials":5157,"activeCount":102},[],{"trials":5159,"activeCount":102},[],{"trials":5161,"activeCount":102},[5162],{"nctId":5140,"briefTitle":5141,"status":108,"phases":5163,"primaryCompletion":5143,"completion":5143,"start":5144,"enrollment":1330,"conditions":5164,"interventions":5165},[91],[126],[5131,5147],{"trials":5167,"activeCount":102},[],{"trials":5169,"activeCount":102},[],{"trials":5171,"activeCount":102},[],{"intervention":631,"totalTrials":245,"cells":5173},{"EARLY_PHASE1":5174,"PHASE1":5176,"PHASE2":5178,"PHASE3":5184,"PHASE4":5186,"NA":5188},{"trials":5175,"activeCount":102},[],{"trials":5177,"activeCount":102},[],{"trials":5179,"activeCount":102},[5180],{"nctId":623,"briefTitle":624,"status":625,"phases":5181,"start":627,"conditions":5182,"interventions":5183},[91],[629],[507,631],{"trials":5185,"activeCount":102},[],{"trials":5187,"activeCount":102},[],{"trials":5189,"activeCount":102},[],{"intervention":198,"totalTrials":245,"cells":5191},{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5202,"PHASE4":5204,"NA":5206},{"trials":5193,"activeCount":102},[],{"trials":5195,"activeCount":102},[],{"trials":5197,"activeCount":102},[5198],{"nctId":180,"briefTitle":181,"status":134,"phases":5199,"primaryCompletion":183,"completion":183,"start":184,"enrollment":102,"conditions":5200,"interventions":5201},[91],[186,187,188,189,190,191,192,193,194,195,196],[198,165],{"trials":5203,"activeCount":102},[],{"trials":5205,"activeCount":102},[],{"trials":5207,"activeCount":102},[],{"intervention":5209,"totalTrials":245,"cells":5210},"bortezomib + rituximab",{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5215,"PHASE3":5223,"PHASE4":5225,"NA":5227},{"trials":5212,"activeCount":102},[],{"trials":5214,"activeCount":102},[],{"trials":5216,"activeCount":102},[5217],{"nctId":5218,"briefTitle":5219,"status":108,"phases":5220,"primaryCompletion":1563,"start":1518,"enrollment":268,"conditions":5221,"interventions":5222},"NCT00093769","Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",[91],[18],[5209],{"trials":5224,"activeCount":102},[],{"trials":5226,"activeCount":102},[],{"trials":5228,"activeCount":102},[],{"intervention":5230,"totalTrials":245,"cells":5231},"BAY 56-3722",{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5245,"PHASE4":5247,"NA":5249},{"trials":5233,"activeCount":102},[],{"trials":5235,"activeCount":102},[],{"trials":5237,"activeCount":102},[5238],{"nctId":5239,"briefTitle":5240,"status":134,"phases":5241,"enrollment":102,"conditions":5242,"interventions":5244},"NCT00040989","BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer",[91],[2505,5243],"Recurrent Renal Cell Cancer",[5230],{"trials":5246,"activeCount":102},[],{"trials":5248,"activeCount":102},[],{"trials":5250,"activeCount":102},[],{"intervention":5252,"totalTrials":245,"cells":5253},"Sunitinib",{"EARLY_PHASE1":5254,"PHASE1":5256,"PHASE2":5258,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5255,"activeCount":102},[],{"trials":5257,"activeCount":102},[],{"trials":5259,"activeCount":102},[5260],{"nctId":5261,"briefTitle":5262,"status":134,"phases":5263,"start":136,"enrollment":102,"conditions":5264,"interventions":5266},"NCT01070186","Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma",[91],[5265],"Renal Cell Carcinoma",[5252],{"trials":5268,"activeCount":102},[],{"trials":5270,"activeCount":102},[],{"trials":5272,"activeCount":102},[],{"intervention":5274,"totalTrials":245,"cells":5275},"CP-547,632",{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5290,"PHASE4":5292,"NA":5294},{"trials":5277,"activeCount":102},[],{"trials":5279,"activeCount":102},[],{"trials":5281,"activeCount":102},[5282],{"nctId":5283,"briefTitle":5284,"status":108,"phases":5285,"completion":1597,"start":1596,"conditions":5286,"interventions":5289},"NCT00096239","CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",[91],[5287,629,5288],"Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer",[5274],{"trials":5291,"activeCount":102},[],{"trials":5293,"activeCount":102},[],{"trials":5295,"activeCount":102},[],{"intervention":5297,"totalTrials":245,"cells":5298},"paclitaxel albumin-stabilized nanoparticle formulation",{"EARLY_PHASE1":5299,"PHASE1":5301,"PHASE2":5303,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5300,"activeCount":102},[],{"trials":5302,"activeCount":102},[],{"trials":5304,"activeCount":102},[5305],{"nctId":5306,"briefTitle":5307,"status":108,"phases":5308,"completion":5309,"start":3983,"conditions":5310,"interventions":5311},"NCT00081042","ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma",[91],"2010-01",[4261],[5297],{"trials":5313,"activeCount":102},[],{"trials":5315,"activeCount":102},[],{"trials":5317,"activeCount":102},[],{"intervention":5319,"totalTrials":245,"cells":5320},"autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5322,"activeCount":102},[],{"trials":5324,"activeCount":102},[],{"trials":5326,"activeCount":102},[5327],{"nctId":5328,"briefTitle":5329,"status":108,"phases":5330,"completion":3812,"start":3332,"enrollment":5331,"conditions":5332,"interventions":5333},"NCT00107159","Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma",[91],37,[4261],[5319],{"trials":5335,"activeCount":102},[],{"trials":5337,"activeCount":102},[],{"trials":5339,"activeCount":102},[],{"intervention":2841,"totalTrials":245,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5343,"activeCount":102},[],{"trials":5345,"activeCount":102},[],{"trials":5347,"activeCount":102},[5348],{"nctId":2830,"briefTitle":2831,"status":108,"phases":5349,"primaryCompletion":2833,"completion":2833,"start":2834,"enrollment":98,"conditions":5350,"interventions":5351},[91],[2836,2837,2838,2839],[789,2841],{"trials":5353,"activeCount":102},[],{"trials":5355,"activeCount":102},[],{"trials":5357,"activeCount":102},[],{"intervention":1122,"totalTrials":245,"cells":5359},{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5370,"PHASE4":5372,"NA":5374},{"trials":5361,"activeCount":102},[],{"trials":5363,"activeCount":102},[],{"trials":5365,"activeCount":102},[5366],{"nctId":1117,"briefTitle":1118,"status":134,"phases":5367,"enrollment":102,"conditions":5368,"interventions":5369},[91],[1114,27],[1122,1054,1013,1123,1124,1125],{"trials":5371,"activeCount":102},[],{"trials":5373,"activeCount":102},[],{"trials":5375,"activeCount":102},[],{"intervention":1123,"totalTrials":245,"cells":5377},{"EARLY_PHASE1":5378,"PHASE1":5380,"PHASE2":5382,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5379,"activeCount":102},[],{"trials":5381,"activeCount":102},[],{"trials":5383,"activeCount":102},[5384],{"nctId":1117,"briefTitle":1118,"status":134,"phases":5385,"enrollment":102,"conditions":5386,"interventions":5387},[91],[1114,27],[1122,1054,1013,1123,1124,1125],{"trials":5389,"activeCount":102},[],{"trials":5391,"activeCount":102},[],{"trials":5393,"activeCount":102},[],{"intervention":1124,"totalTrials":245,"cells":5395},{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5400,"PHASE3":5406,"PHASE4":5408,"NA":5410},{"trials":5397,"activeCount":102},[],{"trials":5399,"activeCount":102},[],{"trials":5401,"activeCount":102},[5402],{"nctId":1117,"briefTitle":1118,"status":134,"phases":5403,"enrollment":102,"conditions":5404,"interventions":5405},[91],[1114,27],[1122,1054,1013,1123,1124,1125],{"trials":5407,"activeCount":102},[],{"trials":5409,"activeCount":102},[],{"trials":5411,"activeCount":102},[],{"intervention":1125,"totalTrials":245,"cells":5413},{"EARLY_PHASE1":5414,"PHASE1":5416,"PHASE2":5418,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5415,"activeCount":102},[],{"trials":5417,"activeCount":102},[],{"trials":5419,"activeCount":102},[5420],{"nctId":1117,"briefTitle":1118,"status":134,"phases":5421,"enrollment":102,"conditions":5422,"interventions":5423},[91],[1114,27],[1122,1054,1013,1123,1124,1125],{"trials":5425,"activeCount":102},[],{"trials":5427,"activeCount":102},[],{"trials":5429,"activeCount":102},[],{"intervention":3322,"totalTrials":245,"cells":5431},{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5436,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5433,"activeCount":102},[],{"trials":5435,"activeCount":102},[],{"trials":5437,"activeCount":102},[5438],{"nctId":3314,"briefTitle":3315,"status":108,"phases":5439,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":1096,"conditions":5440,"interventions":5441},[90,91],[840],[3322,118],{"trials":5443,"activeCount":102},[],{"trials":5445,"activeCount":102},[],{"trials":5447,"activeCount":102},[],{"intervention":5449,"totalTrials":245,"cells":5450},"AFP gene hepatocellular carcinoma vaccine",{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5455,"PHASE3":5464,"PHASE4":5466,"NA":5468},{"trials":5452,"activeCount":102},[],{"trials":5454,"activeCount":102},[],{"trials":5456,"activeCount":102},[5457],{"nctId":5458,"briefTitle":5459,"status":108,"phases":5460,"primaryCompletion":668,"completion":4249,"start":5461,"enrollment":962,"conditions":5462,"interventions":5463},"NCT00005629","Vaccine Therapy in Treating Patients With Liver Cancer",[90,91],"1999-07",[1756],[5449],{"trials":5465,"activeCount":102},[],{"trials":5467,"activeCount":102},[],{"trials":5469,"activeCount":102},[],{"intervention":4364,"totalTrials":245,"cells":5471},{"EARLY_PHASE1":5472,"PHASE1":5474,"PHASE2":5476,"PHASE3":5482,"PHASE4":5484,"NA":5486},{"trials":5473,"activeCount":102},[],{"trials":5475,"activeCount":102},[],{"trials":5477,"activeCount":102},[5478],{"nctId":4358,"briefTitle":4359,"status":282,"phases":5479,"primaryCompletion":4282,"start":4361,"enrollment":638,"conditions":5480,"interventions":5481},[91],[1650],[4364,4349],{"trials":5483,"activeCount":102},[],{"trials":5485,"activeCount":102},[],{"trials":5487,"activeCount":102},[],{"intervention":5489,"totalTrials":245,"cells":5490},"bortezomib + temozolomide+ radiation therapy",{"EARLY_PHASE1":5491,"PHASE1":5493,"PHASE2":5495,"PHASE3":5506,"PHASE4":5508,"NA":5510},{"trials":5492,"activeCount":102},[],{"trials":5494,"activeCount":102},[],{"trials":5496,"activeCount":102},[5497],{"nctId":5498,"briefTitle":5499,"status":108,"phases":5500,"primaryCompletion":5501,"completion":5502,"start":5503,"enrollment":19,"conditions":5504,"interventions":5505},"NCT00998010","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",[91],"2016-03-29","2018-04-20","2011-10-03",[30],[5489],{"trials":5507,"activeCount":102},[],{"trials":5509,"activeCount":102},[],{"trials":5511,"activeCount":102},[],{"intervention":5513,"totalTrials":245,"cells":5514},"Indocyanine Green Drug",{"EARLY_PHASE1":5515,"PHASE1":5517,"PHASE2":5519,"PHASE3":5530,"PHASE4":5532,"NA":5534},{"trials":5516,"activeCount":102},[],{"trials":5518,"activeCount":102},[],{"trials":5520,"activeCount":102},[5521],{"nctId":5522,"briefTitle":5523,"status":134,"phases":5524,"primaryCompletion":5525,"completion":5525,"start":5526,"enrollment":102,"conditions":5527,"interventions":5529},"NCT03745690","Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer",[90,91],"2021-06-08","2018-12-12",[5528],"Head and Neck Carcinoma",[5513],{"trials":5531,"activeCount":102},[],{"trials":5533,"activeCount":102},[],{"trials":5535,"activeCount":102},[],{"intervention":5537,"totalTrials":245,"cells":5538},"RAD001, everolimus",{"EARLY_PHASE1":5539,"PHASE1":5541,"PHASE2":5543,"PHASE3":5555,"PHASE4":5557,"NA":5559},{"trials":5540,"activeCount":102},[],{"trials":5542,"activeCount":102},[],{"trials":5544,"activeCount":102},[5545],{"nctId":5546,"briefTitle":5547,"status":282,"phases":5548,"primaryCompletion":5549,"completion":5549,"start":5550,"enrollment":228,"conditions":5551,"interventions":5554},"NCT01345136","Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma",[91],"2024-02-06","2015-07-01",[5552,5553],"Neurofibromatosis Type 2","Neuroma, Acoustic",[5537],{"trials":5556,"activeCount":102},[],{"trials":5558,"activeCount":102},[],{"trials":5560,"activeCount":102},[],{"intervention":5562,"totalTrials":245,"cells":5563},"mucoadhesive oral wound rinse",{"EARLY_PHASE1":5564,"PHASE1":5566,"PHASE2":5568,"PHASE3":5582,"PHASE4":5584,"NA":5586},{"trials":5565,"activeCount":102},[],{"trials":5567,"activeCount":102},[],{"trials":5569,"activeCount":102},[5570],{"nctId":5571,"briefTitle":5572,"status":108,"phases":5573,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":5576,"conditions":5577,"interventions":5581},"NCT02015559","Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus",[91],"2018-11-30","2014-10-08",61,[5578,5579,1498,5580,2901,1899,1900,1901],"Estrogen Receptor-positive Breast Cancer","HER2-negative Breast Cancer","Progesterone Receptor-positive Breast Cancer",[5562],{"trials":5583,"activeCount":102},[],{"trials":5585,"activeCount":102},[],{"trials":5587,"activeCount":102},[],{"intervention":5589,"totalTrials":245,"cells":5590},"tumor lysate-pulsed autologous dendritic cell vaccine",{"EARLY_PHASE1":5591,"PHASE1":5593,"PHASE2":5595,"PHASE3":5610,"PHASE4":5612,"NA":5614},{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[],{"trials":5596,"activeCount":102},[5597],{"nctId":5598,"briefTitle":5599,"status":108,"phases":5600,"primaryCompletion":5601,"completion":5601,"start":5602,"enrollment":359,"conditions":5603,"interventions":5609},"NCT01635283","Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma",[91],"2016-05-13","2012-01-10",[5604,5605,5606,5607,5608],"Adult Diffuse Astrocytoma","Adult Mixed Glioma","Adult Oligodendroglioma","Recurrent Adult Brain Tumor","Adult Oligoastrocytoma",[5589],{"trials":5611,"activeCount":102},[],{"trials":5613,"activeCount":102},[],{"trials":5615,"activeCount":102},[],{"intervention":5617,"totalTrials":245,"cells":5618},"picoplatin",{"EARLY_PHASE1":5619,"PHASE1":5621,"PHASE2":5623,"PHASE3":5631,"PHASE4":5633,"NA":5635},{"trials":5620,"activeCount":102},[],{"trials":5622,"activeCount":102},[],{"trials":5624,"activeCount":102},[5625],{"nctId":5626,"briefTitle":5627,"status":625,"phases":5628,"conditions":5629,"interventions":5630},"NCT00021008","ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer",[91],[24],[5617],{"trials":5632,"activeCount":102},[],{"trials":5634,"activeCount":102},[],{"trials":5636,"activeCount":102},[],{"intervention":5638,"totalTrials":245,"cells":5639},"lintuzumab",{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5644,"PHASE3":5653,"PHASE4":5655,"NA":5657},{"trials":5641,"activeCount":102},[],{"trials":5643,"activeCount":102},[],{"trials":5645,"activeCount":102},[5646],{"nctId":5647,"briefTitle":5648,"status":625,"phases":5649,"start":5650,"conditions":5651,"interventions":5652},"NCT00006084","Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia",[91],"2001-02",[27],[5638],{"trials":5654,"activeCount":102},[],{"trials":5656,"activeCount":102},[],{"trials":5658,"activeCount":102},[],{"intervention":1501,"totalTrials":245,"cells":5660},{"EARLY_PHASE1":5661,"PHASE1":5663,"PHASE2":5665,"PHASE3":5671,"PHASE4":5673,"NA":5675},{"trials":5662,"activeCount":102},[],{"trials":5664,"activeCount":102},[],{"trials":5666,"activeCount":102},[5667],{"nctId":1491,"briefTitle":1492,"status":108,"phases":5668,"completion":998,"start":1494,"conditions":5669,"interventions":5670},[91],[1496,27,18,1497,1498,1499],[1053,1501,659,1502,1503],{"trials":5672,"activeCount":102},[],{"trials":5674,"activeCount":102},[],{"trials":5676,"activeCount":102},[],{"intervention":5678,"totalTrials":245,"cells":5679},"Anhydrous Enol-oxaloacetate",{"EARLY_PHASE1":5680,"PHASE1":5682,"PHASE2":5684,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5681,"activeCount":102},[],{"trials":5683,"activeCount":102},[],{"trials":5685,"activeCount":102},[5686],{"nctId":5687,"briefTitle":5688,"status":108,"phases":5689,"primaryCompletion":5690,"completion":5690,"start":5691,"enrollment":477,"conditions":5692,"interventions":5694},"NCT04290897","Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors",[91],"2024-11-12","2021-09-29",[2772,1272,2773,2774,596,597,598,600,5693,2777,2778,2779,607,608,609,610,612],"Early-Stage Breast Carcinoma",[5678],{"trials":5696,"activeCount":102},[],{"trials":5698,"activeCount":102},[],{"trials":5700,"activeCount":102},[],{"intervention":5702,"totalTrials":245,"cells":5703},"PD0332991",{"EARLY_PHASE1":5704,"PHASE1":5706,"PHASE2":5708,"PHASE3":5719,"PHASE4":5721,"NA":5723},{"trials":5705,"activeCount":102},[],{"trials":5707,"activeCount":102},[],{"trials":5709,"activeCount":102},[5710],{"nctId":5711,"briefTitle":5712,"status":108,"phases":5713,"primaryCompletion":5714,"completion":5714,"start":5715,"enrollment":370,"conditions":5716,"interventions":5718},"NCT01536743","A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression",[91],"2020-02-24","2011-12-15",[5717],"Ovarian Epithelial Carcinoma",[5702],{"trials":5720,"activeCount":102},[],{"trials":5722,"activeCount":102},[],{"trials":5724,"activeCount":102},[],{"intervention":5726,"totalTrials":245,"cells":5727},"AFP",{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5742,"PHASE4":5744,"NA":5746},{"trials":5729,"activeCount":102},[],{"trials":5731,"activeCount":102},[],{"trials":5733,"activeCount":102},[5734],{"nctId":5735,"briefTitle":5459,"status":108,"phases":5736,"primaryCompletion":1596,"completion":5737,"start":5738,"enrollment":5739,"conditions":5740,"interventions":5741},"NCT00022334",[90,91],"2008-10","2001-01",33,[1756],[5726],{"trials":5743,"activeCount":102},[],{"trials":5745,"activeCount":102},[],{"trials":5747,"activeCount":102},[],{"intervention":5749,"totalTrials":359,"cells":5750},"therapeutic autologous dendritic cells",{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5794,"PHASE3":5796,"PHASE4":5798,"NA":5800},{"trials":5752,"activeCount":102},[],{"trials":5754,"activeCount":102},[5755,5763,5770,5780,5787],{"nctId":5756,"briefTitle":5757,"status":108,"phases":5758,"primaryCompletion":5759,"completion":5760,"start":3332,"enrollment":638,"conditions":5761,"interventions":5762},"NCT00107185","Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma",[90],"2009-10","2010-03",[30],[5749],{"nctId":5764,"briefTitle":5765,"status":282,"phases":5766,"start":1597,"enrollment":268,"conditions":5767,"interventions":5768},"NCT00098917","Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer",[90],[24],[5769,5749],"autologous tumor cell vaccine",{"nctId":5771,"briefTitle":5772,"status":108,"phases":5773,"primaryCompletion":5774,"completion":5775,"start":5776,"enrollment":36,"conditions":5777,"interventions":5778},"NCT01826877","Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer",[90],"2018-07-03","2021-05-27","2013-01-14",[2501,5243,2505],[5779,5749],"AdGMCAIX-transduced autologous dendritic cells",{"nctId":5781,"briefTitle":5782,"status":108,"phases":5783,"primaryCompletion":5784,"completion":5784,"start":736,"enrollment":782,"conditions":5785,"interventions":5786},"NCT00068510","Vaccine Therapy in Treating Patients With Malignant Glioma",[90],"2012-09",[30],[5749],{"nctId":5788,"briefTitle":5789,"status":625,"phases":5790,"start":838,"conditions":5791,"interventions":5792},"NCT00005992","Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[90],[15],[5793,5749],"PSA prostate cancer vaccine",{"trials":5795,"activeCount":102},[],{"trials":5797,"activeCount":102},[],{"trials":5799,"activeCount":102},[],{"trials":5801,"activeCount":102},[],{"intervention":1697,"totalTrials":231,"cells":5803},{"EARLY_PHASE1":5804,"PHASE1":5806,"PHASE2":5816,"PHASE3":5818,"PHASE4":5820,"NA":5822},{"trials":5805,"activeCount":102},[],{"trials":5807,"activeCount":102},[5808,5812],{"nctId":1685,"briefTitle":1686,"status":282,"phases":5809,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":359,"conditions":5810,"interventions":5811},[90],[1691,1692,1693,1694,1650],[1041,1696,1697,1698,1108,1699],{"nctId":1701,"briefTitle":1702,"status":134,"phases":5813,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":102,"conditions":5814,"interventions":5815},[90],[1691,1707,1708,1709],[1041,1697,1698,1711,1712,1699],{"trials":5817,"activeCount":102},[],{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[],{"trials":5823,"activeCount":102},[],{"intervention":1699,"totalTrials":231,"cells":5825},{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5838,"PHASE3":5840,"PHASE4":5842,"NA":5844},{"trials":5827,"activeCount":102},[],{"trials":5829,"activeCount":102},[5830,5834],{"nctId":1685,"briefTitle":1686,"status":282,"phases":5831,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":359,"conditions":5832,"interventions":5833},[90],[1691,1692,1693,1694,1650],[1041,1696,1697,1698,1108,1699],{"nctId":1701,"briefTitle":1702,"status":134,"phases":5835,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":102,"conditions":5836,"interventions":5837},[90],[1691,1707,1708,1709],[1041,1697,1698,1711,1712,1699],{"trials":5839,"activeCount":102},[],{"trials":5841,"activeCount":102},[],{"trials":5843,"activeCount":102},[],{"trials":5845,"activeCount":102},[],{"intervention":527,"totalTrials":231,"cells":5847},{"EARLY_PHASE1":5848,"PHASE1":5850,"PHASE2":5865,"PHASE3":5867,"PHASE4":5869,"NA":5871},{"trials":5849,"activeCount":102},[],{"trials":5851,"activeCount":102},[5852,5856],{"nctId":518,"briefTitle":519,"status":108,"phases":5853,"primaryCompletion":297,"completion":297,"start":521,"enrollment":522,"conditions":5854,"interventions":5855},[90],[524],[526,527,507],{"nctId":5857,"briefTitle":5858,"status":108,"phases":5859,"primaryCompletion":5860,"completion":5860,"start":5861,"enrollment":496,"conditions":5862,"interventions":5863},"NCT01784640","Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer",[90],"2018-10-11","2014-01-31",[687,688,524],[5864,527],"Hsp90 inhibitor AUY922",{"trials":5866,"activeCount":102},[],{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":102},[],{"trials":5872,"activeCount":102},[],{"intervention":5874,"totalTrials":231,"cells":5875},"motexafin gadolinium",{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5893,"PHASE3":5895,"PHASE4":5897,"NA":5899},{"trials":5877,"activeCount":102},[],{"trials":5879,"activeCount":102},[5880,5887],{"nctId":5881,"briefTitle":5882,"status":108,"phases":5883,"completion":3702,"start":5884,"conditions":5885,"interventions":5886},"NCT00003410","Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas",[90],"1998-07",[30],[5874],{"nctId":5888,"briefTitle":5889,"status":108,"phases":5890,"start":5884,"conditions":5891,"interventions":5892},"NCT00003409","Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[90],[30],[5874],{"trials":5894,"activeCount":102},[],{"trials":5896,"activeCount":102},[],{"trials":5898,"activeCount":102},[],{"trials":5900,"activeCount":102},[],{"intervention":5902,"totalTrials":231,"cells":5903},"azacitidine",{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5929,"PHASE3":5931,"PHASE4":5933,"NA":5935},{"trials":5905,"activeCount":102},[],{"trials":5907,"activeCount":102},[5908,5917],{"nctId":5909,"briefTitle":5910,"status":282,"phases":5911,"primaryCompletion":5912,"start":5913,"enrollment":245,"conditions":5914,"interventions":5915},"NCT00234000","Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes",[90],"2009-02","2007-02",[27,1051],[5916,5902],"arsenic trioxide",{"nctId":5918,"briefTitle":5919,"status":134,"phases":5920,"primaryCompletion":5921,"completion":5922,"start":5923,"enrollment":102,"conditions":5924,"interventions":5926},"NCT05720988","Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia",[90],"2025-08-03","2026-08-03","2024-08-03",[5925],"Acute Myeloid Leukemia",[5927,5928],"Azacitidine","Tagraxofusp-erzs",{"trials":5930,"activeCount":102},[],{"trials":5932,"activeCount":102},[],{"trials":5934,"activeCount":102},[],{"trials":5936,"activeCount":102},[],{"intervention":1903,"totalTrials":245,"cells":5938},{"EARLY_PHASE1":5939,"PHASE1":5941,"PHASE2":5947,"PHASE3":5949,"PHASE4":5951,"NA":5953},{"trials":5940,"activeCount":102},[],{"trials":5942,"activeCount":102},[5943],{"nctId":1884,"briefTitle":1885,"status":282,"phases":5944,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":98,"conditions":5945,"interventions":5946},[90],[1890,1891,604,1892,1893,1894,1895,1896,1897,1306,1307,1308,1309,1898,1899,1900,1901],[1903,1262,1904],{"trials":5948,"activeCount":102},[],{"trials":5950,"activeCount":102},[],{"trials":5952,"activeCount":102},[],{"trials":5954,"activeCount":102},[],{"intervention":1904,"totalTrials":245,"cells":5956},{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5965,"PHASE3":5967,"PHASE4":5969,"NA":5971},{"trials":5958,"activeCount":102},[],{"trials":5960,"activeCount":102},[5961],{"nctId":1884,"briefTitle":1885,"status":282,"phases":5962,"primaryCompletion":1887,"completion":1887,"start":1888,"enrollment":98,"conditions":5963,"interventions":5964},[90],[1890,1891,604,1892,1893,1894,1895,1896,1897,1306,1307,1308,1309,1898,1899,1900,1901],[1903,1262,1904],{"trials":5966,"activeCount":102},[],{"trials":5968,"activeCount":102},[],{"trials":5970,"activeCount":102},[],{"trials":5972,"activeCount":102},[],{"intervention":2884,"totalTrials":245,"cells":5974},{"EARLY_PHASE1":5975,"PHASE1":5977,"PHASE2":5983,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5976,"activeCount":102},[],{"trials":5978,"activeCount":102},[5979],{"nctId":2875,"briefTitle":2876,"status":108,"phases":5980,"primaryCompletion":2878,"completion":2879,"start":761,"enrollment":31,"conditions":5981,"interventions":5982},[90],[2881,2882],[2868,2884],{"trials":5984,"activeCount":102},[],{"trials":5986,"activeCount":102},[],{"trials":5988,"activeCount":102},[],{"trials":5990,"activeCount":102},[],{"intervention":5992,"totalTrials":245,"cells":5993},"warfarin",{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":6005,"PHASE3":6007,"PHASE4":6009,"NA":6011},{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":102},[5998],{"nctId":5999,"briefTitle":6000,"status":108,"phases":6001,"primaryCompletion":6002,"completion":6002,"start":998,"enrollment":19,"conditions":6003,"interventions":6004},"NCT00091299","Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors",[90],"2012-08",[33],[5992],{"trials":6006,"activeCount":102},[],{"trials":6008,"activeCount":102},[],{"trials":6010,"activeCount":102},[],{"trials":6012,"activeCount":102},[],{"intervention":6014,"totalTrials":245,"cells":6015},"bortezomib + ganciclovir",{"EARLY_PHASE1":6016,"PHASE1":6018,"PHASE2":6026,"PHASE3":6028,"PHASE4":6030,"NA":6032},{"trials":6017,"activeCount":102},[],{"trials":6019,"activeCount":102},[6020],{"nctId":6021,"briefTitle":6022,"status":282,"phases":6023,"primaryCompletion":1798,"start":735,"enrollment":245,"conditions":6024,"interventions":6025},"NCT00093704","Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma",[90],[18,3271],[6014],{"trials":6027,"activeCount":102},[],{"trials":6029,"activeCount":102},[],{"trials":6031,"activeCount":102},[],{"trials":6033,"activeCount":102},[],{"intervention":6035,"totalTrials":245,"cells":6036},"Ad-sig-hMUC-1\u002FecdCD40L vaccine",{"EARLY_PHASE1":6037,"PHASE1":6039,"PHASE2":6049,"PHASE3":6051,"PHASE4":6053,"NA":6055},{"trials":6038,"activeCount":102},[],{"trials":6040,"activeCount":102},[6041],{"nctId":6042,"briefTitle":6043,"status":134,"phases":6044,"primaryCompletion":6045,"start":6046,"enrollment":102,"conditions":6047,"interventions":6048},"NCT00706615","Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer",[90],"2009-04","2008-07",[21],[6035],{"trials":6050,"activeCount":102},[],{"trials":6052,"activeCount":102},[],{"trials":6054,"activeCount":102},[],{"trials":6056,"activeCount":102},[],{"intervention":6058,"totalTrials":245,"cells":6059},"tocladesine",{"EARLY_PHASE1":6060,"PHASE1":6062,"PHASE2":6070,"PHASE3":6072,"PHASE4":6074,"NA":6076},{"trials":6061,"activeCount":102},[],{"trials":6063,"activeCount":102},[6064],{"nctId":6065,"briefTitle":6066,"status":625,"phases":6067,"start":1861,"conditions":6068,"interventions":6069},"NCT00021268","Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer",[90],[840],[6058],{"trials":6071,"activeCount":102},[],{"trials":6073,"activeCount":102},[],{"trials":6075,"activeCount":102},[],{"trials":6077,"activeCount":102},[],{"intervention":1536,"totalTrials":245,"cells":6079},{"EARLY_PHASE1":6080,"PHASE1":6082,"PHASE2":6088,"PHASE3":6090,"PHASE4":6092,"NA":6094},{"trials":6081,"activeCount":102},[],{"trials":6083,"activeCount":102},[6084],{"nctId":1531,"briefTitle":1532,"status":625,"phases":6085,"start":1131,"conditions":6086,"interventions":6087},[90],[1496,33],[1536,565],{"trials":6089,"activeCount":102},[],{"trials":6091,"activeCount":102},[],{"trials":6093,"activeCount":102},[],{"trials":6095,"activeCount":102},[],{"intervention":5769,"totalTrials":245,"cells":6097},{"EARLY_PHASE1":6098,"PHASE1":6100,"PHASE2":6106,"PHASE3":6108,"PHASE4":6110,"NA":6112},{"trials":6099,"activeCount":102},[],{"trials":6101,"activeCount":102},[6102],{"nctId":5764,"briefTitle":5765,"status":282,"phases":6103,"start":1597,"enrollment":268,"conditions":6104,"interventions":6105},[90],[24],[5769,5749],{"trials":6107,"activeCount":102},[],{"trials":6109,"activeCount":102},[],{"trials":6111,"activeCount":102},[],{"trials":6113,"activeCount":102},[],{"intervention":1711,"totalTrials":245,"cells":6115},{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6124,"PHASE3":6126,"PHASE4":6128,"NA":6130},{"trials":6117,"activeCount":102},[],{"trials":6119,"activeCount":102},[6120],{"nctId":1701,"briefTitle":1702,"status":134,"phases":6121,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":102,"conditions":6122,"interventions":6123},[90],[1691,1707,1708,1709],[1041,1697,1698,1711,1712,1699],{"trials":6125,"activeCount":102},[],{"trials":6127,"activeCount":102},[],{"trials":6129,"activeCount":102},[],{"trials":6131,"activeCount":102},[],{"intervention":1712,"totalTrials":245,"cells":6133},{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6142,"PHASE3":6144,"PHASE4":6146,"NA":6148},{"trials":6135,"activeCount":102},[],{"trials":6137,"activeCount":102},[6138],{"nctId":1701,"briefTitle":1702,"status":134,"phases":6139,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":102,"conditions":6140,"interventions":6141},[90],[1691,1707,1708,1709],[1041,1697,1698,1711,1712,1699],{"trials":6143,"activeCount":102},[],{"trials":6145,"activeCount":102},[],{"trials":6147,"activeCount":102},[],{"trials":6149,"activeCount":102},[],{"intervention":6151,"totalTrials":245,"cells":6152},"orantinib",{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6163,"PHASE3":6165,"PHASE4":6167,"NA":6169},{"trials":6154,"activeCount":102},[],{"trials":6156,"activeCount":102},[6157],{"nctId":6158,"briefTitle":6159,"status":625,"phases":6160,"conditions":6161,"interventions":6162},"NCT00024063","SU006668 in Treating Patients With Advanced Solid Tumors",[90],[21,840,765,1734,24,1497,3968,15],[6151],{"trials":6164,"activeCount":102},[],{"trials":6166,"activeCount":102},[],{"trials":6168,"activeCount":102},[],{"trials":6170,"activeCount":102},[],{"intervention":6172,"totalTrials":245,"cells":6173},"SU011248",{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6184,"PHASE3":6186,"PHASE4":6188,"NA":6190},{"trials":6175,"activeCount":102},[],{"trials":6177,"activeCount":102},[6178],{"nctId":6179,"briefTitle":6180,"status":108,"phases":6181,"primaryCompletion":3797,"start":218,"enrollment":962,"conditions":6182,"interventions":6183},"NCT00790595","Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy",[90],[15],[6172,6172,6172,6172,6172],{"trials":6185,"activeCount":102},[],{"trials":6187,"activeCount":102},[],{"trials":6189,"activeCount":102},[],{"trials":6191,"activeCount":102},[],{"intervention":6193,"totalTrials":245,"cells":6194},"therapeutic autologous lymphocytes",{"EARLY_PHASE1":6195,"PHASE1":6197,"PHASE2":6205,"PHASE3":6207,"PHASE4":6209,"NA":6211},{"trials":6196,"activeCount":102},[],{"trials":6198,"activeCount":102},[6199],{"nctId":6200,"briefTitle":6201,"status":108,"phases":6202,"completion":736,"start":3694,"conditions":6203,"interventions":6204},"NCT00039299","Biological Therapy in Treating Patients With Prostate Cancer",[90],[15],[6193],{"trials":6206,"activeCount":102},[],{"trials":6208,"activeCount":102},[],{"trials":6210,"activeCount":102},[],{"trials":6212,"activeCount":102},[],{"intervention":6214,"totalTrials":245,"cells":6215},"Gallium Ga 68 Gozetotide",{"EARLY_PHASE1":6216,"PHASE1":6218,"PHASE2":6229,"PHASE3":6231,"PHASE4":6233,"NA":6235},{"trials":6217,"activeCount":102},[],{"trials":6219,"activeCount":102},[6220],{"nctId":6221,"briefTitle":6222,"status":282,"phases":6223,"primaryCompletion":6224,"completion":6224,"start":6225,"enrollment":484,"conditions":6226,"interventions":6228},"NCT04279561","Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET\u002FCT Imaging in Patients With Castration-Resistant Prostate Cancer",[90],"2022-09-15","2020-04-16",[300,1333,6227,2531,953],"Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8",[6214],{"trials":6230,"activeCount":102},[],{"trials":6232,"activeCount":102},[],{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[],{"intervention":117,"totalTrials":245,"cells":6238},{"EARLY_PHASE1":6239,"PHASE1":6241,"PHASE2":6247,"PHASE3":6249,"PHASE4":6251,"NA":6253},{"trials":6240,"activeCount":102},[],{"trials":6242,"activeCount":102},[6243],{"nctId":106,"briefTitle":107,"status":108,"phases":6244,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":6245,"interventions":6246},[90],[114,115],[117,97,118],{"trials":6248,"activeCount":102},[],{"trials":6250,"activeCount":102},[],{"trials":6252,"activeCount":102},[],{"trials":6254,"activeCount":102},[],{"intervention":6256,"totalTrials":245,"cells":6257},"maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody",{"EARLY_PHASE1":6258,"PHASE1":6260,"PHASE2":6268,"PHASE3":6270,"PHASE4":6272,"NA":6274},{"trials":6259,"activeCount":102},[],{"trials":6261,"activeCount":102},[6262],{"nctId":6263,"briefTitle":6264,"status":108,"phases":6265,"primaryCompletion":6046,"completion":5759,"start":3291,"enrollment":477,"conditions":6266,"interventions":6267},"NCT00090896","CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",[90],[4261],[6256],{"trials":6269,"activeCount":102},[],{"trials":6271,"activeCount":102},[],{"trials":6273,"activeCount":102},[],{"trials":6275,"activeCount":102},[],{"intervention":3697,"totalTrials":245,"cells":6277},{"EARLY_PHASE1":6278,"PHASE1":6280,"PHASE2":6286,"PHASE3":6288,"PHASE4":6290,"NA":6292},{"trials":6279,"activeCount":102},[],{"trials":6281,"activeCount":102},[6282],{"nctId":3691,"briefTitle":3692,"status":108,"phases":6283,"completion":1612,"start":3694,"conditions":6284,"interventions":6285},[90],[18],[1134,3697],{"trials":6287,"activeCount":102},[],{"trials":6289,"activeCount":102},[],{"trials":6291,"activeCount":102},[],{"trials":6293,"activeCount":102},[],{"intervention":6295,"totalTrials":245,"cells":6296},"exatecan mesylate",{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6307,"PHASE3":6309,"PHASE4":6311,"NA":6313},{"trials":6298,"activeCount":102},[],{"trials":6300,"activeCount":102},[6301],{"nctId":6302,"briefTitle":6303,"status":108,"phases":6304,"completion":1612,"start":668,"conditions":6305,"interventions":6306},"NCT00045318","Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction",[90],[33],[6295],{"trials":6308,"activeCount":102},[],{"trials":6310,"activeCount":102},[],{"trials":6312,"activeCount":102},[],{"trials":6314,"activeCount":102},[],{"intervention":5779,"totalTrials":245,"cells":6316},{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6325,"PHASE3":6327,"PHASE4":6329,"NA":6331},{"trials":6318,"activeCount":102},[],{"trials":6320,"activeCount":102},[6321],{"nctId":5771,"briefTitle":5772,"status":108,"phases":6322,"primaryCompletion":5774,"completion":5775,"start":5776,"enrollment":36,"conditions":6323,"interventions":6324},[90],[2501,5243,2505],[5779,5749],{"trials":6326,"activeCount":102},[],{"trials":6328,"activeCount":102},[],{"trials":6330,"activeCount":102},[],{"trials":6332,"activeCount":102},[],{"intervention":526,"totalTrials":245,"cells":6334},{"EARLY_PHASE1":6335,"PHASE1":6337,"PHASE2":6343,"PHASE3":6345,"PHASE4":6347,"NA":6349},{"trials":6336,"activeCount":102},[],{"trials":6338,"activeCount":102},[6339],{"nctId":518,"briefTitle":519,"status":108,"phases":6340,"primaryCompletion":297,"completion":297,"start":521,"enrollment":522,"conditions":6341,"interventions":6342},[90],[524],[526,527,507],{"trials":6344,"activeCount":102},[],{"trials":6346,"activeCount":102},[],{"trials":6348,"activeCount":102},[],{"trials":6350,"activeCount":102},[],{"intervention":6352,"totalTrials":245,"cells":6353},"MVA-MUC1-IL2 vaccine",{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6364,"PHASE3":6366,"PHASE4":6368,"NA":6370},{"trials":6355,"activeCount":102},[],{"trials":6357,"activeCount":102},[6358],{"nctId":6359,"briefTitle":6360,"status":108,"phases":6361,"completion":998,"start":1564,"conditions":6362,"interventions":6363},"NCT00004881","Vaccine Therapy in Treating Patients With Advanced Cancer",[90],[33],[6352],{"trials":6365,"activeCount":102},[],{"trials":6367,"activeCount":102},[],{"trials":6369,"activeCount":102},[],{"trials":6371,"activeCount":102},[],{"intervention":2782,"totalTrials":245,"cells":6373},{"EARLY_PHASE1":6374,"PHASE1":6376,"PHASE2":6382,"PHASE3":6384,"PHASE4":6386,"NA":6388},{"trials":6375,"activeCount":102},[],{"trials":6377,"activeCount":102},[6378],{"nctId":2766,"briefTitle":2767,"status":282,"phases":6379,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":962,"conditions":6380,"interventions":6381},[90],[2772,1272,2773,2774,596,597,598,600,601,1891,2775,2776,2777,2778,2779,607,608,609,610,612,613,2780],[2651,789,2782],{"trials":6383,"activeCount":102},[],{"trials":6385,"activeCount":102},[],{"trials":6387,"activeCount":102},[],{"trials":6389,"activeCount":102},[],{"intervention":2650,"totalTrials":245,"cells":6391},{"EARLY_PHASE1":6392,"PHASE1":6394,"PHASE2":6400,"PHASE3":6402,"PHASE4":6404,"NA":6406},{"trials":6393,"activeCount":102},[],{"trials":6395,"activeCount":102},[6396],{"nctId":2643,"briefTitle":2644,"status":134,"phases":6397,"primaryCompletion":2496,"completion":2497,"start":2646,"enrollment":102,"conditions":6398,"interventions":6399},[90],[2648],[2650,2651,789,332],{"trials":6401,"activeCount":102},[],{"trials":6403,"activeCount":102},[],{"trials":6405,"activeCount":102},[],{"trials":6407,"activeCount":102},[],{"intervention":5864,"totalTrials":245,"cells":6409},{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6418,"PHASE3":6420,"PHASE4":6422,"NA":6424},{"trials":6411,"activeCount":102},[],{"trials":6413,"activeCount":102},[6414],{"nctId":5857,"briefTitle":5858,"status":108,"phases":6415,"primaryCompletion":5860,"completion":5860,"start":5861,"enrollment":496,"conditions":6416,"interventions":6417},[90],[687,688,524],[5864,527],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"trials":6423,"activeCount":102},[],{"trials":6425,"activeCount":102},[],{"intervention":6427,"totalTrials":245,"cells":6428},"tanespimycin",{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6439,"PHASE3":6441,"PHASE4":6443,"NA":6445},{"trials":6430,"activeCount":102},[],{"trials":6432,"activeCount":102},[6433],{"nctId":6434,"briefTitle":6435,"status":108,"phases":6436,"completion":1790,"start":5102,"conditions":6437,"interventions":6438},"NCT00100997","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",[90],[27],[6427],{"trials":6440,"activeCount":102},[],{"trials":6442,"activeCount":102},[],{"trials":6444,"activeCount":102},[],{"trials":6446,"activeCount":102},[],{"intervention":5916,"totalTrials":245,"cells":6448},{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6457,"PHASE3":6459,"PHASE4":6461,"NA":6463},{"trials":6450,"activeCount":102},[],{"trials":6452,"activeCount":102},[6453],{"nctId":5909,"briefTitle":5910,"status":282,"phases":6454,"primaryCompletion":5912,"start":5913,"enrollment":245,"conditions":6455,"interventions":6456},[90],[27,1051],[5916,5902],{"trials":6458,"activeCount":102},[],{"trials":6460,"activeCount":102},[],{"trials":6462,"activeCount":102},[],{"trials":6464,"activeCount":102},[],{"intervention":5928,"totalTrials":245,"cells":6466},{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6475,"PHASE3":6477,"PHASE4":6479,"NA":6481},{"trials":6468,"activeCount":102},[],{"trials":6470,"activeCount":102},[6471],{"nctId":5918,"briefTitle":5919,"status":134,"phases":6472,"primaryCompletion":5921,"completion":5922,"start":5923,"enrollment":102,"conditions":6473,"interventions":6474},[90],[5925],[5927,5928],{"trials":6476,"activeCount":102},[],{"trials":6478,"activeCount":102},[],{"trials":6480,"activeCount":102},[],{"trials":6482,"activeCount":102},[],{"intervention":6484,"totalTrials":245,"cells":6485},"BMS-59926",{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6496,"PHASE3":6498,"PHASE4":6500,"NA":6502},{"trials":6487,"activeCount":102},[],{"trials":6489,"activeCount":102},[6490],{"nctId":6491,"briefTitle":6492,"status":108,"phases":6493,"primaryCompletion":3798,"start":1518,"enrollment":484,"conditions":6494,"interventions":6495},"NCT00093730","BMS-599626 in Treating Patients With Metastatic Solid Tumors",[90],[33],[6484],{"trials":6497,"activeCount":102},[],{"trials":6499,"activeCount":102},[],{"trials":6501,"activeCount":102},[],{"trials":6503,"activeCount":102},[],{"intervention":6505,"totalTrials":245,"cells":6506},"carbendazim",{"EARLY_PHASE1":6507,"PHASE1":6509,"PHASE2":6517,"PHASE3":6519,"PHASE4":6521,"NA":6523},{"trials":6508,"activeCount":102},[],{"trials":6510,"activeCount":102},[6511],{"nctId":6512,"briefTitle":6513,"status":625,"phases":6514,"conditions":6515,"interventions":6516},"NCT00023816","Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma",[90],[18,33],[6505],{"trials":6518,"activeCount":102},[],{"trials":6520,"activeCount":102},[],{"trials":6522,"activeCount":102},[],{"trials":6524,"activeCount":102},[],{"intervention":1045,"totalTrials":245,"cells":6526},{"EARLY_PHASE1":6527,"PHASE1":6529,"PHASE2":6535,"PHASE3":6537,"PHASE4":6539,"NA":6541},{"trials":6528,"activeCount":102},[],{"trials":6530,"activeCount":102},[6531],{"nctId":1031,"briefTitle":1032,"status":108,"phases":6532,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":245,"conditions":6533,"interventions":6534},[90],[1037,1038,1039],[1041,1042,1043,789,1044,1045],{"trials":6536,"activeCount":102},[],{"trials":6538,"activeCount":102},[],{"trials":6540,"activeCount":102},[],{"trials":6542,"activeCount":102},[],{"intervention":6544,"totalTrials":245,"cells":6545},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":6546,"PHASE1":6548,"PHASE2":6562,"PHASE3":6564,"PHASE4":6566,"NA":6568},{"trials":6547,"activeCount":102},[],{"trials":6549,"activeCount":102},[6550],{"nctId":6551,"briefTitle":6552,"status":134,"phases":6553,"primaryCompletion":6554,"completion":71,"start":6555,"enrollment":102,"conditions":6556,"interventions":6561},"NCT04280471","Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease",[90],"2024-12-30","2023-09-01",[6557,6558,6559,6560],"Acute Graft Versus Host Disease","Gastrointestinal Tract Acute Graft Versus Host Disease","Severe Gastrointestinal Tract Acute Graft Versus Host Disease","Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease",[6544],{"trials":6563,"activeCount":102},[],{"trials":6565,"activeCount":102},[],{"trials":6567,"activeCount":102},[],{"trials":6569,"activeCount":102},[],{"intervention":6571,"totalTrials":245,"cells":6572},"alloreactive CTL",{"EARLY_PHASE1":6573,"PHASE1":6575,"PHASE2":6589,"PHASE3":6591,"PHASE4":6593,"NA":6595},{"trials":6574,"activeCount":102},[],{"trials":6576,"activeCount":102},[6577],{"nctId":6578,"briefTitle":6579,"status":108,"phases":6580,"primaryCompletion":6581,"completion":6581,"start":1798,"enrollment":98,"conditions":6582,"interventions":6588},"NCT01144247","Cellular Immunotherapy Study for Brain Cancer",[90],"2015-07",[6583,4680,6584,6585,6586,6587],"Gliomas","Anaplastic Oligodendroglioma","Anaplastic Mixed Glioma","Glioblastoma Multiforme","Malignant Meningioma",[6571],{"trials":6590,"activeCount":102},[],{"trials":6592,"activeCount":102},[],{"trials":6594,"activeCount":102},[],{"trials":6596,"activeCount":102},[],{"intervention":6598,"totalTrials":245,"cells":6599},"CP-724,714",{"EARLY_PHASE1":6600,"PHASE1":6602,"PHASE2":6611,"PHASE3":6613,"PHASE4":6615,"NA":6617},{"trials":6601,"activeCount":102},[],{"trials":6603,"activeCount":102},[6604],{"nctId":6605,"briefTitle":6606,"status":108,"phases":6607,"primaryCompletion":1596,"completion":6608,"start":3845,"enrollment":484,"conditions":6609,"interventions":6610},"NCT00055926","CP-724,714 in Treating Patients With Metastatic Breast Cancer",[90],"2005-05",[21],[6598],{"trials":6612,"activeCount":102},[],{"trials":6614,"activeCount":102},[],{"trials":6616,"activeCount":102},[],{"trials":6618,"activeCount":102},[],{"intervention":3838,"totalTrials":245,"cells":6620},{"EARLY_PHASE1":6621,"PHASE1":6623,"PHASE2":6629,"PHASE3":6631,"PHASE4":6633,"NA":6635},{"trials":6622,"activeCount":102},[],{"trials":6624,"activeCount":102},[6625],{"nctId":3833,"briefTitle":3834,"status":625,"phases":6626,"start":2879,"enrollment":477,"conditions":6627,"interventions":6628},[90],[24,18,3271,33],[707,3838],{"trials":6630,"activeCount":102},[],{"trials":6632,"activeCount":102},[],{"trials":6634,"activeCount":102},[],{"trials":6636,"activeCount":102},[],{"intervention":5793,"totalTrials":245,"cells":6638},{"EARLY_PHASE1":6639,"PHASE1":6641,"PHASE2":6647,"PHASE3":6649,"PHASE4":6651,"NA":6653},{"trials":6640,"activeCount":102},[],{"trials":6642,"activeCount":102},[6643],{"nctId":5788,"briefTitle":5789,"status":625,"phases":6644,"start":838,"conditions":6645,"interventions":6646},[90],[15],[5793,5749],{"trials":6648,"activeCount":102},[],{"trials":6650,"activeCount":102},[],{"trials":6652,"activeCount":102},[],{"trials":6654,"activeCount":102},[],{"intervention":6656,"totalTrials":245,"cells":6657},"Erlotinib + Sirolimus",{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6669,"PHASE3":6671,"PHASE4":6673,"NA":6675},{"trials":6659,"activeCount":102},[],{"trials":6661,"activeCount":102},[6662],{"nctId":6663,"briefTitle":6664,"status":108,"phases":6665,"primaryCompletion":1625,"completion":5784,"start":6666,"enrollment":9,"conditions":6667,"interventions":6668},"NCT00509431","Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma",[90],"2006-08",[30],[6656],{"trials":6670,"activeCount":102},[],{"trials":6672,"activeCount":102},[],{"trials":6674,"activeCount":102},[],{"trials":6676,"activeCount":102},[],{"intervention":6678,"totalTrials":245,"cells":6679},"quercetin",{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6697,"PHASE3":6699,"PHASE4":6701,"NA":6703},{"trials":6681,"activeCount":102},[],{"trials":6683,"activeCount":102},[6684],{"nctId":6685,"briefTitle":6686,"status":108,"phases":6687,"primaryCompletion":6688,"completion":6689,"start":6690,"enrollment":1257,"conditions":6691,"interventions":6696},"NCT01912820","Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery",[90],"2016-01-31","2021-06-10","2014-01-01",[3251,6692,6693,6694,6695,3252,1335],"Recurrent Prostate Cancer","Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer",[6678],{"trials":6698,"activeCount":102},[],{"trials":6700,"activeCount":102},[],{"trials":6702,"activeCount":102},[],{"trials":6704,"activeCount":102},[],{"intervention":6706,"totalTrials":245,"cells":6707},"glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine",{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6719,"PHASE3":6721,"PHASE4":6723,"NA":6725},{"trials":6709,"activeCount":102},[],{"trials":6711,"activeCount":102},[6712],{"nctId":6713,"briefTitle":5782,"status":108,"phases":6714,"primaryCompletion":6715,"completion":6716,"start":4179,"enrollment":522,"conditions":6717,"interventions":6718},"NCT00612001",[90],"2011-01","2012-10",[30],[6706],{"trials":6720,"activeCount":102},[],{"trials":6722,"activeCount":102},[],{"trials":6724,"activeCount":102},[],{"trials":6726,"activeCount":102},[],{"intervention":128,"totalTrials":245,"cells":6728},{"EARLY_PHASE1":6729,"PHASE1":6731,"PHASE2":6737,"PHASE3":6739,"PHASE4":6741,"NA":6743},{"trials":6730,"activeCount":102},[],{"trials":6732,"activeCount":102},[6733],{"nctId":120,"briefTitle":121,"status":108,"phases":6734,"primaryCompletion":123,"completion":123,"start":124,"enrollment":31,"conditions":6735,"interventions":6736},[90],[126],[128,97],{"trials":6738,"activeCount":102},[],{"trials":6740,"activeCount":102},[],{"trials":6742,"activeCount":102},[],{"trials":6744,"activeCount":102},[],{"intervention":2804,"totalTrials":245,"cells":6746},{"EARLY_PHASE1":6747,"PHASE1":6749,"PHASE2":6755,"PHASE3":6757,"PHASE4":6759,"NA":6761},{"trials":6748,"activeCount":102},[],{"trials":6750,"activeCount":102},[6751],{"nctId":2792,"briefTitle":2793,"status":282,"phases":6752,"primaryCompletion":2795,"completion":2795,"start":2796,"enrollment":962,"conditions":6753,"interventions":6754},[90],[126,2798,2799,2800,2801,2802],[2804,2651,789],{"trials":6756,"activeCount":102},[],{"trials":6758,"activeCount":102},[],{"trials":6760,"activeCount":102},[],{"trials":6762,"activeCount":102},[],{"intervention":6764,"totalTrials":245,"cells":6765},"Akt\u002FERK Inhibitor ONC201",{"EARLY_PHASE1":6766,"PHASE1":6768,"PHASE2":6781,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6767,"activeCount":102},[],{"trials":6769,"activeCount":102},[6770],{"nctId":6771,"briefTitle":6772,"status":134,"phases":6773,"primaryCompletion":6774,"completion":1254,"start":6775,"enrollment":102,"conditions":6776,"interventions":6780},"NCT04854044","ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma",[90],"2025-07-01","2021-05-01",[329,6777,6778,6779],"Recurrent Gliosarcoma","Recurrent Supratentorial Glioblastoma","Supratentorial Gliosarcoma",[6764],{"trials":6782,"activeCount":102},[],{"trials":6784,"activeCount":102},[],{"trials":6786,"activeCount":102},[],{"trials":6788,"activeCount":102},[],{"intervention":6790,"totalTrials":245,"cells":6791},"Arm I Packed Red Blood Cell Transfusion",{"EARLY_PHASE1":6792,"PHASE1":6804,"PHASE2":6806,"PHASE3":6808,"PHASE4":6810,"NA":6812},{"trials":6793,"activeCount":102},[6794],{"nctId":6795,"briefTitle":6796,"status":282,"phases":6797,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":245,"conditions":6800,"interventions":6802},"NCT05841706","Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer",[89],"2025-03-17","2023-08-10",[6801],"Resectable Pancreatic Carcinoma",[6790,6803],"Arm II Packed Red Blood Cell Transfusion",{"trials":6805,"activeCount":102},[],{"trials":6807,"activeCount":102},[],{"trials":6809,"activeCount":102},[],{"trials":6811,"activeCount":102},[],{"trials":6813,"activeCount":102},[],{"intervention":6803,"totalTrials":245,"cells":6815},{"EARLY_PHASE1":6816,"PHASE1":6822,"PHASE2":6824,"PHASE3":6826,"PHASE4":6828,"NA":6830},{"trials":6817,"activeCount":102},[6818],{"nctId":6795,"briefTitle":6796,"status":282,"phases":6819,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":245,"conditions":6820,"interventions":6821},[89],[6801],[6790,6803],{"trials":6823,"activeCount":102},[],{"trials":6825,"activeCount":102},[],{"trials":6827,"activeCount":102},[],{"trials":6829,"activeCount":102},[],{"trials":6831,"activeCount":102},[],{"intervention":6833,"totalTrials":245,"cells":6834},"68Ga-DOTATATE",{"EARLY_PHASE1":6835,"PHASE1":6847,"PHASE2":6849,"PHASE3":6851,"PHASE4":6853,"NA":6855},{"trials":6836,"activeCount":102},[6837],{"nctId":6838,"briefTitle":6839,"status":108,"phases":6840,"primaryCompletion":6841,"completion":6841,"start":6842,"enrollment":6843,"conditions":6844,"interventions":6846},"NCT01873248","Impact of 68Ga-DOTATATE PET\u002FCT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective",[89],"2017-06-16","2013-08-26",100,[6845],"Neuroendocrine Tumors",[6833],{"trials":6848,"activeCount":102},[],{"trials":6850,"activeCount":102},[],{"trials":6852,"activeCount":102},[],{"trials":6854,"activeCount":102},[],{"trials":6856,"activeCount":102},[],{"intervention":1696,"totalTrials":231,"cells":6858},{"EARLY_PHASE1":6859,"PHASE1":6861,"PHASE2":6867,"PHASE3":6869,"PHASE4":6871,"NA":6873},{"trials":6860,"activeCount":102},[],{"trials":6862,"activeCount":102},[6863],{"nctId":1685,"briefTitle":1686,"status":282,"phases":6864,"primaryCompletion":1688,"completion":1688,"start":1689,"enrollment":359,"conditions":6865,"interventions":6866},[90],[1691,1692,1693,1694,1650],[1041,1696,1697,1698,1108,1699],{"trials":6868,"activeCount":102},[],{"trials":6870,"activeCount":102},[],{"trials":6872,"activeCount":102},[],{"trials":6874,"activeCount":102},[6875],{"nctId":1515,"briefTitle":1516,"status":625,"phases":6876,"start":1518,"conditions":6877,"interventions":6878},[94],[1114,27],[1521,1522,659,1523],{"intervention":1523,"totalTrials":231,"cells":6880},{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6882,"activeCount":102},[],{"trials":6884,"activeCount":102},[],{"trials":6886,"activeCount":102},[6887],{"nctId":3667,"briefTitle":3668,"status":108,"phases":6888,"primaryCompletion":3670,"start":1547,"enrollment":228,"conditions":6889,"interventions":6890},[90,91],[1734],[1053,1523,3673],{"trials":6892,"activeCount":102},[],{"trials":6894,"activeCount":102},[],{"trials":6896,"activeCount":102},[6897],{"nctId":1515,"briefTitle":1516,"status":625,"phases":6898,"start":1518,"conditions":6899,"interventions":6900},[94],[1114,27],[1521,1522,659,1523],{"intervention":6902,"totalTrials":245,"cells":6903},"Ganitumab",{"EARLY_PHASE1":6904,"PHASE1":6906,"PHASE2":6908,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6905,"activeCount":102},[],{"trials":6907,"activeCount":102},[],{"trials":6909,"activeCount":102},[],{"trials":6911,"activeCount":102},[],{"trials":6913,"activeCount":102},[],{"trials":6915,"activeCount":102},[6916],{"nctId":6917,"briefTitle":6918,"status":6919,"phases":6920,"conditions":6921,"interventions":6923},"NCT03029481","Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma","NO_LONGER_AVAILABLE",[],[6922],"Ewing Sarcoma",[6902],{"intervention":6925,"totalTrials":245,"cells":6926},"MitoGel",{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6931,"PHASE3":6933,"PHASE4":6935,"NA":6937},{"trials":6928,"activeCount":102},[],{"trials":6930,"activeCount":102},[],{"trials":6932,"activeCount":102},[],{"trials":6934,"activeCount":102},[],{"trials":6936,"activeCount":102},[],{"trials":6938,"activeCount":102},[6939],{"nctId":6940,"briefTitle":6941,"status":6919,"phases":6942,"conditions":6943,"interventions":6945},"NCT02701023","Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma",[],[6944],"Urothelial Carcinoma Ureteral Location",[6925],{"intervention":6947,"totalTrials":245,"cells":6948},"[18F] CFA",{"EARLY_PHASE1":6949,"PHASE1":6951,"PHASE2":6953,"PHASE3":6955,"PHASE4":6957,"NA":6959},{"trials":6950,"activeCount":102},[],{"trials":6952,"activeCount":102},[],{"trials":6954,"activeCount":102},[],{"trials":6956,"activeCount":102},[],{"trials":6958,"activeCount":102},[],{"trials":6960,"activeCount":102},[6961],{"nctId":6962,"briefTitle":6963,"status":108,"phases":6964,"primaryCompletion":6965,"completion":6965,"start":6966,"enrollment":228,"conditions":6967,"interventions":6969},"NCT03409419","PET Imaging of the Immune System Using Analog Probes",[],"2020-11-10","2018-04-10",[6968],"Malignant Melanoma",[6947],{"intervention":6971,"totalTrials":245,"cells":6972},"68Ga DOTATATE",{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6979,"PHASE4":6981,"NA":6983},{"trials":6974,"activeCount":102},[],{"trials":6976,"activeCount":102},[],{"trials":6978,"activeCount":102},[],{"trials":6980,"activeCount":102},[],{"trials":6982,"activeCount":102},[],{"trials":6984,"activeCount":102},[6985],{"nctId":6986,"briefTitle":6987,"status":6919,"phases":6988,"conditions":6989,"interventions":6993},"NCT02174679","68Ga DOTATATE PET\u002FCT in Neuroendocrine Tumors (Expanded Access)",[],[6990,6845,6991,6992],"Carcinoid Cancer","Medullary Thyroid Cancer","Cancers Expressing Somatostatin Receptors",[6971],{"intervention":6995,"totalTrials":245,"cells":6996},"INS316",{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7003,"PHASE4":7005,"NA":7007},{"trials":6998,"activeCount":102},[],{"trials":7000,"activeCount":102},[],{"trials":7002,"activeCount":102},[],{"trials":7004,"activeCount":102},[],{"trials":7006,"activeCount":102},[],{"trials":7008,"activeCount":102},[7009],{"nctId":7010,"briefTitle":7011,"status":625,"phases":7012,"conditions":7013,"interventions":7014},"NCT00033527","INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer",[94],[24],[6995],{"intervention":7016,"totalTrials":245,"cells":7017},"Carbon-11 Sodium Acetate",{"EARLY_PHASE1":7018,"PHASE1":7020,"PHASE2":7022,"PHASE3":7024,"PHASE4":7026,"NA":7028},{"trials":7019,"activeCount":102},[],{"trials":7021,"activeCount":102},[],{"trials":7023,"activeCount":102},[],{"trials":7025,"activeCount":102},[],{"trials":7027,"activeCount":102},[],{"trials":7029,"activeCount":102},[7030],{"nctId":7031,"briefTitle":7032,"status":6919,"phases":7033,"conditions":7034,"interventions":7035},"NCT02826395","C11 Sodium Acetate PET\u002FCT Imaging of PCa",[],[15],[7016],{"intervention":7037,"totalTrials":245,"cells":7038},"FG-3019",{"EARLY_PHASE1":7039,"PHASE1":7041,"PHASE2":7043,"PHASE3":7045,"PHASE4":7047,"NA":7049},{"trials":7040,"activeCount":102},[],{"trials":7042,"activeCount":102},[],{"trials":7044,"activeCount":102},[],{"trials":7046,"activeCount":102},[],{"trials":7048,"activeCount":102},[],{"trials":7050,"activeCount":102},[7051],{"nctId":7052,"briefTitle":7053,"status":134,"phases":7054,"primaryCompletion":7055,"completion":7056,"start":7057,"enrollment":102,"conditions":7058,"interventions":7059},"NCT02851381","Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer",[94],"2016-09","2017-08","2016-08",[3968],[7037],{"intervention":7061,"totalTrials":245,"cells":7062},"Apricoxib",{"EARLY_PHASE1":7063,"PHASE1":7065,"PHASE2":7067,"PHASE3":7069,"PHASE4":7071,"NA":7073},{"trials":7064,"activeCount":102},[],{"trials":7066,"activeCount":102},[],{"trials":7068,"activeCount":102},[],{"trials":7070,"activeCount":102},[],{"trials":7072,"activeCount":102},[],{"trials":7074,"activeCount":102},[7075],{"nctId":7076,"briefTitle":7077,"status":282,"phases":7078,"primaryCompletion":7079,"completion":7079,"start":4411,"enrollment":245,"conditions":7080,"interventions":7082},"NCT01532362","Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer",[94],"2012-05",[7081],"Non Small Cell Lung Cancer",[7061],{"intervention":7084,"totalTrials":245,"cells":7085},"oblimersen sodium",{"EARLY_PHASE1":7086,"PHASE1":7088,"PHASE2":7090,"PHASE3":7092,"PHASE4":7094,"NA":7096},{"trials":7087,"activeCount":102},[],{"trials":7089,"activeCount":102},[],{"trials":7091,"activeCount":102},[],{"trials":7093,"activeCount":102},[],{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":102},[7098],{"nctId":7099,"briefTitle":7100,"status":625,"phases":7101,"start":3280,"conditions":7102,"interventions":7103},"NCT00070343","Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301",[94],[4261],[7084,7104],"dacarbazine",{"intervention":7104,"totalTrials":245,"cells":7106},{"EARLY_PHASE1":7107,"PHASE1":7109,"PHASE2":7111,"PHASE3":7113,"PHASE4":7115,"NA":7117},{"trials":7108,"activeCount":102},[],{"trials":7110,"activeCount":102},[],{"trials":7112,"activeCount":102},[],{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":102},[],{"trials":7118,"activeCount":102},[7119],{"nctId":7099,"briefTitle":7100,"status":625,"phases":7120,"start":3280,"conditions":7121,"interventions":7122},[94],[4261],[7084,7104],{"intervention":7124,"totalTrials":245,"cells":7125},"Idelalisib",{"EARLY_PHASE1":7126,"PHASE1":7128,"PHASE2":7130,"PHASE3":7132,"PHASE4":7134,"NA":7136},{"trials":7127,"activeCount":102},[],{"trials":7129,"activeCount":102},[],{"trials":7131,"activeCount":102},[],{"trials":7133,"activeCount":102},[],{"trials":7135,"activeCount":102},[],{"trials":7137,"activeCount":102},[7138],{"nctId":7139,"briefTitle":7140,"status":282,"phases":7141,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":245,"conditions":7144,"interventions":7151},"NCT02928510","Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma",[],"2018-06-05","2016-02-01",[7145,7146,7147,7148,7149,1063,7150,1068],"Absence of Signs or Symptoms","B-Cell Non-Hodgkin Lymphoma","Digestive System Signs and Symptoms","Indolent Adult Non-Hodgkin Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Indolent Adult Non-Hodgkin Lymphoma",[7124],{"intervention":7153,"totalTrials":245,"cells":7154},"Trametinib 2 mg",{"EARLY_PHASE1":7155,"PHASE1":7157,"PHASE2":7159,"PHASE3":7161,"PHASE4":7163,"NA":7165},{"trials":7156,"activeCount":102},[],{"trials":7158,"activeCount":102},[],{"trials":7160,"activeCount":102},[],{"trials":7162,"activeCount":102},[],{"trials":7164,"activeCount":102},[],{"trials":7166,"activeCount":102},[7167],{"nctId":7168,"briefTitle":7169,"status":6919,"phases":7170,"conditions":7171,"interventions":7173},"NCT03386071","Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib",[],[7172],"Progressive Metastatic Castrate Resistant Prostate Cancer",[7153],{"intervention":7175,"totalTrials":245,"cells":7176},"FLT",{"EARLY_PHASE1":7177,"PHASE1":7179,"PHASE2":7181,"PHASE3":7183,"PHASE4":7185,"NA":7187},{"trials":7178,"activeCount":102},[],{"trials":7180,"activeCount":102},[],{"trials":7182,"activeCount":102},[],{"trials":7184,"activeCount":102},[],{"trials":7186,"activeCount":102},[],{"trials":7188,"activeCount":102},[7189],{"nctId":7190,"briefTitle":7191,"status":108,"phases":7192,"primaryCompletion":1059,"completion":1059,"start":7193,"enrollment":7194,"conditions":7195,"interventions":7198},"NCT01410630","FLT-PET\u002FCT vs FDG-PET\u002FCT for Therapy Monitoring of Diffuse Large B-cell Lymphoma",[],"2017-09-07",66,[18,7196,7197],"Lymphoma, Non-Hodgkin","Large B Cell Diffuse Lymphoma",[7175],{"intervention":1521,"totalTrials":245,"cells":7200},{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7205,"PHASE3":7207,"PHASE4":7209,"NA":7211},{"trials":7202,"activeCount":102},[],{"trials":7204,"activeCount":102},[],{"trials":7206,"activeCount":102},[],{"trials":7208,"activeCount":102},[],{"trials":7210,"activeCount":102},[],{"trials":7212,"activeCount":102},[7213],{"nctId":1515,"briefTitle":1516,"status":625,"phases":7214,"start":1518,"conditions":7215,"interventions":7216},[94],[1114,27],[1521,1522,659,1523],{"intervention":7218,"totalTrials":245,"cells":7219},"bimatoprost ophthalmic solution",{"EARLY_PHASE1":7220,"PHASE1":7222,"PHASE2":7224,"PHASE3":7226,"PHASE4":7228,"NA":7230},{"trials":7221,"activeCount":102},[],{"trials":7223,"activeCount":102},[],{"trials":7225,"activeCount":102},[],{"trials":7227,"activeCount":102},[],{"trials":7229,"activeCount":102},[],{"trials":7231,"activeCount":102},[7232],{"nctId":7233,"briefTitle":7234,"status":134,"phases":7235,"primaryCompletion":7056,"start":7236,"enrollment":102,"conditions":7237,"interventions":7239},"NCT00999557","Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants",[94],"2016-01",[7238,21],"Alopecia",[7218],{"intervention":7241,"totalTrials":245,"cells":7242},"modafinil",{"EARLY_PHASE1":7243,"PHASE1":7245,"PHASE2":7247,"PHASE3":7249,"PHASE4":7251,"NA":7253},{"trials":7244,"activeCount":102},[],{"trials":7246,"activeCount":102},[],{"trials":7248,"activeCount":102},[],{"trials":7250,"activeCount":102},[],{"trials":7252,"activeCount":102},[],{"trials":7254,"activeCount":102},[7255],{"nctId":7256,"briefTitle":7257,"status":108,"phases":7258,"primaryCompletion":3767,"completion":7259,"start":7260,"enrollment":682,"conditions":7261,"interventions":7263},"NCT00052286","Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer",[94],"2010-08","2002-09",[30,7262,3293],"Cognitive\u002FFunctional Effects",[7241],{"intervention":7265,"totalTrials":245,"cells":7266},"polymorphism analysis",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7273,"PHASE4":7275,"NA":7277},{"trials":7268,"activeCount":102},[],{"trials":7270,"activeCount":102},[],{"trials":7272,"activeCount":102},[],{"trials":7274,"activeCount":102},[],{"trials":7276,"activeCount":102},[],{"trials":7278,"activeCount":102},[7279],{"nctId":7280,"briefTitle":7281,"status":134,"phases":7282,"start":7283,"enrollment":102,"conditions":7284,"interventions":7288},"NCT00460200","Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer",[],"2003-12",[7285,3293,629,7286,7287],"Depression","Psychosocial Effects of Cancer and Its Treatment","Sleep Disorders",[7265],{"intervention":7290,"totalTrials":245,"cells":7291},"itraconazole",{"EARLY_PHASE1":7292,"PHASE1":7294,"PHASE2":7296,"PHASE3":7298,"PHASE4":7300,"NA":7302},{"trials":7293,"activeCount":102},[],{"trials":7295,"activeCount":102},[],{"trials":7297,"activeCount":102},[],{"trials":7299,"activeCount":102},[],{"trials":7301,"activeCount":102},[],{"trials":7303,"activeCount":102},[7304],{"nctId":7305,"briefTitle":7306,"status":108,"phases":7307,"primaryCompletion":7308,"start":1791,"conditions":7309,"interventions":7311},"NCT00079222","Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",[94],"2005-04",[7310],"Cancer",[7290,7312],"voriconazole",{"intervention":7312,"totalTrials":245,"cells":7314},{"EARLY_PHASE1":7315,"PHASE1":7317,"PHASE2":7319,"PHASE3":7321,"PHASE4":7323,"NA":7325},{"trials":7316,"activeCount":102},[],{"trials":7318,"activeCount":102},[],{"trials":7320,"activeCount":102},[],{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":102},[],{"trials":7326,"activeCount":102},[7327],{"nctId":7305,"briefTitle":7306,"status":108,"phases":7328,"primaryCompletion":7308,"start":1791,"conditions":7329,"interventions":7330},[94],[7310],[7290,7312]]